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ABSTRACT OF DISSERTATION

MICROELECTRODE ARRAY STUDIES OF NORMAL AND DISEASE-ALTERED
L-GLUTAMATE REGULATION IN THE MAMMALIAN CENTRAL NERVOUS
SYSTEM

L-glutamate (Glu) is the major excitatory neurotransmitter in the
mammalian central nervous system. Monitoring extracellular Glu is critical to
understanding Glu regulation to discriminate physiological and pathological roles.
To overcome the limitations of previous in vivo extracellular Glu studies, we
developed Glu selective microelectrode arrays with better spatial and temporal
resolutions than commonly used techniques like microdialysis. We used these
microelectrode arrays to characterize basal and potassium-evoked Glu
neurotransmission in the normal rat brain. We then investigated disease-related
Glu alterations in a rat model of Parkinson’s disease and normal Glu regulation in
young and aged rhesus monkeys. In the normal anesthetized rat striatum and
frontal cortex, basal Glu was regulated by active release and uptake
mechanisms, fully TTX-dependent, and measured at ~2 micromolar levels.
Potassium-evoked Glu kinetics were fast, concentration-dependent, and rapidly
reproducible at 15-20 seconds intervals. In the unilateral 6-hydroxydopaminelesioned rat, there were significant bilateral increases in potassium-evoked Glu
release in the striatum and frontal cortex compared to hemisphere-matched nonlesioned rats. Ipsilateral striatal effects may have been related to DA loss, while
contralateral

striatal

effects

and

the

bilateral

frontal

cortical

effects may have resulted from parkinsonian neurotransmitter changes or
bilateral neuranatomical connectivity, especially in the cortex. There were also
alterations in Glu kinetics in the nucleus accumbens in both non-lesioned and
lesioned rats. With appropriate technological and methodological modifications,
we successfully recorded normal Glu signaling in anesthetized nonhuman
primates in the operating room. Fast potassium-evoked Glu signals were
recorded in the motor cortex of all monkeys, and Glu ejections showed robust
Glu uptake in the motor and frontal cortices of all monkeys. These findings are
comparable to initial rat studies. Slow evoked Glu kinetics and high basal Glu
levels with oscillatory behavior were recorded in the frontal cortex. The primary
age-related differences between monkeys were the nearly ten-fold increases in
the volumes of Glu ejected needed in the aged monkey to achieve amplitudematched signals in the motor and frontal cortices and a decreased uptake rate in
the motor cortex. Preliminary work with excised human tissue and future plans
for patient-oriented research and clinical applications are discussed.
KEYWORDS: Glutamate, Microelectrode, Voltammetry, Rat, Nonhuman primates
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Chapter One: Introduction

A Brief Introduction to Intracranial Electrode Applications

This dissertation documents continuing work towards the long-term goal of
clinically

using

implanted

microelectrode

arrays

that

detect

specific

neurochemicals to positively impact the management of human neurological
diseases. Although the concept of putting electrodes into the human brain may
sound like science fiction or at least an extreme medical approach, in fact,
neurosurgeons routinely use a wide variety of intracranial electrodes to care for
patients in the modern era. Both recording and stimulating electrode protocols
have become standards of care or good alternative approaches for patients
suffering from brain disorders such as Parkinson’s disease (PD) and epilepsy
(Starr, Vitek, and Bakay, 1998, Wyler and Abson-Kraemer, 1994). Ultimately, we
hope that microelectrodes coupled with electrochemical detection will provide
similar benefit and take their place alongside other intracranial electrodes used to
monitor, diagnose, and treat human nervous system disorders.
Both recording and stimulating electrodes are used in the surgical
treatment of PD, a progressive neurodegenerative disease which primarily
affects movement. When the symptoms are no longer well-controlled by standard
medications, advanced PD patients may elect to ablate or stimulate different
subcortical areas of their brains. These approaches attempt to alter signals
emerging from the basal ganglia or thalamus to alleviate some parkinsonian
symptoms. Targeting deep brain nuclei usually begins with an imaging study
(computed tomography (CT) and/or magnetic resonance imaging (MRI)) but is
routinely accompanied by intraoperative electrophysiological brain recordings
that use implanted electrodes. Because the patterns of spontaneous neuronal
firing predictably differ between discrete brain nuclei, electrodes can be used to
precisely locate brain areas of interest. Typically tungsten or platinum-iridium
microelectrodes are used to record single-unit, extracellular action potentials for
1

this type of mapping. In addition or as an alternative, stimulation protocols can be
followed

which

use

these

microelectrodes

(microstimulation)

and/or

macroelectrodes (macrostimulation) and rely on reported or observed changes in
visual, motor, or sensory responses to localize electrode placement. In the case
of ablation, alternating current can be passed in a monopolar fashion from the
electrode to a dispersive grounding pad on the patient’s skin to lesion the
targeted area, a technique known as radiofrequency thermocoagulation. In fact,
pallidotomies and thalamotomies (ablative surgeries which target the globus
pallidus internal segment (GPi) and motor thalamus, respectively) most often use
this technique (Krauss and Jankovic, 1996, Starr, Vitek, and Bakay, 1998, Krack
et al., 2000).
PD patients who decide with their physicians that permanent lesioning is
not the best option may elect to have a chronic indwelling stimulating electrode,
called a deep brain stimulator (DBS), implanted in one or both brain hemispheres
(Starr, Vitek, and Bakay, 1998). Again, confirming placement of the DBS
electrode may involve initial microelectrode mapping or microstimulation, and the
DBS electrode itself can be used for localizing macrostimulation prior to final
placement. Although some clinical researchers have questioned the benefit of
extensive microelectrode mapping, it is highly accepted that some form of
recording or stimulation is absolutely critical for electrode placement (Eskandar et
al., 2000, Guridi et al., 2000, Pollak et al., 2002). An extension wire is tunneled
under the patient’s skin and connected to a battery-powered pulse generator
implanted in the patient’s upper chest. A physician programs the stimulation
parameters of the pulse generator using a wireless controller, and the patient can
turn the stimulator on or off as needed. Early applications of DBS electrodes
targeted the thalamus; however, the GPi and subthalamic nucleus (STN) are
becoming increasingly popular targets (Olanow, Brin, and Obeso, 2000). Exactly
how deep brain stimulation works to alleviate PD symptoms is unknown;
functional lesioning and altering basal ganglia signaling are leading theories
(Starr, Vitek, and Bakay, 1998, Benazzouz and Hallett, 2000).

2

A wide variety of electrodes are also used in the surgical management of
patients with intractable epilepsy, a brain disorder characterized by multiple
seizures caused by abnormal cerebral electrical activity. The goal is to identify
and remove epileptogenic foci, which are local networks of hyperactive neurons
that burst-fire continuously, often at levels sufficient to initiate an epileptic
seizure. Strip, grid, and depth electrodes are all useful intra- and post-operative
tools that aid in the search for epileptogenic foci (Wyler and Abson-Kraemer,
1994). Strip and grid electrodes are both implanted in the epidural or subdural
spaces in close contact with the cortical surface and differ primarily in their
geometry. Strip electrodes have 2-16 circular contacts arranged in a linear
fashion on a flexible, flat plastic strip. Grid electrodes are two-dimensional arrays
that have 40-64 circular contacts and are basically parallel rows of strip
electrodes. Depth electrodes have 6 cylindrical contacts fabricated along flexible
tubing similar to a catheter that can be implanted into deep brain structures using
a rigid guide cannula (McCarthy, Spencer, and Riker, 1991). All three types of
electrodes are used to make electroencephalographic (EEG) recordings of brain
activity, and epileptogenic foci can be localized in relation to EEG findings from
the multiple recording sites (Olivier and Boling, Jr., 1994). Sometimes it is
necessary to determine the relationship of an epileptogenic focus to functional
cortex using a technique known as cortical mapping. This requires using an
implanted grid electrode with bipolar stimulation to determine the functional
significance of cortical regions near the area targeted for resection. In this way,
cortex that, if removed, would severely impair the patient is identified (Wyler and
Abson-Kraemer, 1994). Epileptogenic foci tend to be surgically removed not
ablated as previously discussed (Kim and Spencer, 1994).
Clearly, intracranial electrode applications such as electrophysiological
recordings and the ability to stimulate brain regions are common, valuable tools
used to monitor and manipulate the intracranial environment to benefit patient
care; however, physicians and scientists alike have been interested in
complementing

these

techniques

with

the

ability

to

monitor

specific

neurochemicals in the intact brain. Neurochemicals, such as neurotransmitters,
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are key components of the nervous system because the major communication
system between neurons is chemical signaling (Cooper, Bloom, and Roth, 1996).
Advancing the techniques employed to investigate neurochemicals will deepen
our insight and understanding of the biology, pathology, and pharmacology of the
nervous system. Currently the most widely used technique to study
neurochemicals is intracerebral microdialysis (Timmerman and Westerink, 1997).
However, the limitations of this technique (discussed later) have motivated some
scientists to develop new technologies to monitor molecules in the intracranial
environment. In the last decade, our group has developed enzyme-coated
ceramic-based

microelectrode

arrays

capable

of

recording

specific

neurochemicals and created exciting new tools for basic scientific research.
Already these high-quality devices are routinely used in animal models and may
soon record Glu from an intact human brain. This dissertation documents how we
have pushed this technology from the lab bench to the veterinary operating room
and beyond on a course to advance and diversify the ways that we study the
brain and possibly manage patients in the 21st century.

The Evolution of Enzyme-Coated Ceramic-Based Microelectrode Arrays

The idea of coupling enzyme reactions with electrodes to measure
biologically active molecules extends at least as far back as 1966 when Kajihara
and Hagihara reported measuring serum glucose levels using an oxygen
electrode coupled with glucose oxidase. Other groups were also working with the
concept; Updike and Hicks (1967) reviewed “The enzyme electrode” in Nature
the following year. By 1970, Guilbault and Hrabankova had expanded the list of
measurable chemicals to include the amino acids, but it was not until 1987 that
Korenbrot, Perry, and Copenhagen reported an enzyme electrode specifically for
the measurement of L-glutamate. Work continued, but the new technologies
suffered from slow response times, poor selectivities, inadequate sensitivities,
and limited in vivo applications. In the early 1990’s, the first reports of Glu
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recordings in the intact brain emerged (Tamiya and Karube, 1992, Hu et al.,
1994). Although it would take many more years to improve the quality and
reproducibility of electrode fabrication and performance, the technology was
beginning to move beyond the development stages and enter the exciting era of
in vivo applications.
The electrode design and performance of Hu et al. (1994), in particular,
surpassed the rest and served as one of the predecessors to our group’s
enzyme-coated ceramic-based microelectrode arrays. Their electrode consisted
of a Teflon-coated platinum-iridium wire stripped at the end and epoxyed at the
tip to create a ~700 micron long sensing cavity. Nafion™ and cellulose acetate
coatings, applied first, provided electrostatic repulsion of anionic interferents,
while subsequent application of L-glutamate oxidase and L-ascorbate oxidase in
a bovine serum albumin/glutaraldehyde protein matrix provided sensitivity to Glu
and further selectivity against ascorbic acid. Sealed in glass, starting 8-12 mm
behind the sensing cavity, the electrode was rigid enough for stereotactic
implantation into the brain of anesthetized rats. Beyond what we now recognize
as several time-tested design elements, the electrode performed exceptionally
well, using high-speed amperometry to record Glu signals not just in vitro but in
vivo. In the rat hippocampus, they investigated Glu uptake with exogenous
challenges as well as both potassium-evoked and electrically stimulated Glu
release. With average sensitivity, selectivity, limit of detection, and response
speed on par with even today’s standards, their enzyme-based electrode truly set
the bar.
However, there was room for improvement. Demonstrating reproducibility
of evoked Glu signals required a 20 minute rest interval presumed by the authors
to be necessary for neurotransmitter replenishment. This was despite the fact
that the recorded Glu signals lasted only ~1 minute, and intracellular Glu levels
were known to be sufficiently high to make a lengthy rest period for
replenishment unlikely. Furthermore, the electrode lost on average over 50%
sensitivity following brain exposure. It was a hand-made electrode that could not
easily be mass-produced for distribution or readily fabricated by other
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investigators. Despite its reported in vitro selectivity, the singular nature of the
electrode left the identity of its signal as Glu open to criticism without difficult
placement of a second, Glu-insensitive but otherwise identical, electrode within
microns of the first.
While enzyme-based techniques were advancing our ability to use
electrodes to detect specific chemicals, new electrode materials were being
developed, in parallel, to create semi-conductor based, multisite microelectrodes
as early as the 1970’s (Sreenivas et al., 1996, Burmeister, Moxon, and Gerhardt,
2000). Multisite microelectrodes had many potential advantages over single
electrodes including reproducible recording sites, spatially defined sites for
layered brain structures, and the possibility of simultaneous electrophysiological
and electrochemical recordings using the same microelectrode. They might also
offer distinctly configured recording sites for multiple analytes or monitoring
interferences. It also might be possible to supply investigators with a highly
reproducible, affordable recording device. By the mid 1990’s, micromachining,
integrated

circuit

technologies,

thin-film

deposition

techniques,

and

photolithographic patterning had advanced the field tremendously. However, the
initial silicon-based sputtered-carbon microelectrode arrays that our group
developed suffered from an undesirable electrical conductance of the silicon
substrate, which was likely the cause of a high background current and poor
signal-to-noise characteristics seen in initial studies (Sreenivas et al., 1996). To
remedy these problems, the silicon was replaced by an inert ceramic substrate
with polyimide insulation, which was also used to improve strength, diminish
cross talk, provide greater versatility, and lower production costs (Burmeister,
Moxon, and Gerhardt, 2000). Because carbon will not stick to ceramic without
extensive surface modifications, the recording site material was changed to
sputtered platinum. This also provided a better surface to detect the products of
enzyme-based chemical reactions.
In the late 1990’s and early 2000’s, our refined ceramic-based multisite
microelectrode arrays demonstrated fast and reliable Glu detection with low
detection limits (0.25 – 0.50 µM Glu), enhanced sensitivity, good selectivity
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(>100:1 versus ascorbic acid), fast response times (90% rise times = 1 second),
and superior spatial and temporal resolutions (Burmeister, Moxon, and Gerhardt,
2000, Burmeister and Gerhardt, 2001). We used procedures modified from Hu et
al. (1994) to prepare our microelectrodes (full description in Chapter Two) and
began using them routinely for in vivo studies (Burmeister et al., 2002,
Pomerleau et al., 2003). Our lab’s commitment to technology development has
continued to improve the quality and versatility of the recording capabilities. At
the same time, we have broadened our focus to explore biological applications.
Currently, our microelectrode arrays have been used to record Glu in
anesthetized mice and rats, freely-moving rats, rat brain slices, anesthetized
monkeys, and excised human brain tissue. They have also been used for
electrophysiological and electrochemical (Glu) recordings in the awake, behaving
monkey, and using other enzyme coatings, have been reconfigured to
characterize other neurotransmitters using electrochemical detection including
glucose, aspartate, choline, acetylcholine, and lactate (Burmeister and Gerhardt,
2001, Parikh et al., 2004, Burmeister, Palmer, and Gerhardt, 2005). This
dissertation documents my role in this team effort to advance how we can use
this technology to investigate normal and disease-altered biology and contribute
to both science and medicine.

Microelectrode Arrays vs. Microdialysis for Studying L-Glutamate

Microelectrode-based recording techniques are not the only approaches
used to monitor the chemical composition of the extracellular space of the brain.
In fact, the most widely used techniques are based on intracranial microdialysis,
which produces dialysate fluid samples for analysis (Khan and Shuaib, 2001).
The main advantage of microdialysis methods is the ability to couple sampling
with highly sensitive detection systems, such as high performance liquid
chromatography and electrochemical or fluorescence detection. The detection
limits of these systems for Glu are in the nanomolar to femtomolar range (Zhang
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et al., 2005, Smolders et al., 1995, Rowley, Martin, and Marsden, 1995). Another
advantage of microdialysis is the ability to measure multiple chemicals from each
sample. Often in vivo microdialysis studies will profile multiple amino acids (e.g.
Glu, γ-aminobutyric acid (GABA), glycine, aspartate, taurine) or other
neurochemicals over the time course of the experiment (Qureshi et al., 2003, Qu
et al., 1998). These capabilities certainly make this technique attractive for many
applications.
Nonetheless, there are disadvantages to microdialysis-based techniques
that limit their usefulness in certain cases. Many of these limitations stem from
the microdialysis probe and the way in which it creates samples for analysis.
Microdialysis probes basically are constructed of two steel tubes (inlet and outlet)
connected at the tip by a semipermeable dialysis membrane. Once implanted in
the brain, perfusion fluid is slowly pumped through the probe (typical flow rate: 12 µl/minute) allowing bidirectional exchange of small molecules across the
membrane (Berners, Boutelle, and Fillenz, 1994). Because molecules will move
along their concentration gradients, microdialysis probes can be used for local
drug application (reverse microdialysis) as well as for sampling from the
extracellular fluid (Khan and Shuaib, 2001). Volumes of dialysate are collected at
the end of the outlet tube outside of the brain and typically frozen for off-line
analysis. During sampling, concentrations of extracellular molecules do not
completely equilibrate with the artificial medium. In fact, in vitro recovery testing
is a routine part of most microdialysis studies. As a result, microelectrode
recordings have the distinct advantage over microdialysis-coupled detection
methods of actually measuring molecules in the extracellular fluid.
Other advantages of microelectrodes over microdialysis probes are their
size and spatial resolution. A typical cylindrical microdialysis probe (CMA/11,
CMA Microdialysis AB, North Chelmsford, MA) has a 1-4 mm long dialysis
membrane with a 0.24 mm outer diameter. Comparatively, the implantable 0.005
± 0.0005” (~130 ± 13 µm) thick ceramic portion of a microelectrode array is 10
mm long, with a triangular shape that tapers from 1 mm at the base to 2-5 µm at
the tip (Burmeister et al., 2002). The center of the array is positioned 1.0 mm
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from the tip, and the length of the array is 766 µm (length includes all four 15 x
333 µm recording sites and 100 µm front-to-back spacing). Based on these
dimensions, both the volumes of displacement and the surface areas at the
sampling/recording interfaces can be calculated and compared. A typical
microdialysis probe displaces approximately 5 to 18 times as much brain tissue
along the interface length as compared to our microelectrode arrays (0.05 - 0.18
mm3 vs. ~0.01 mm3). Furthermore, the described dialysis membrane makes
contact with about 150 – 600 times as much brain tissue as one microelectrode
recording site (0.75 – 3.02 mm2 vs. 4995 µm2). In the era of using
electrophysiological data in conjunction with neurochemical detection, the
impetus with respect to size has been to develop smaller devices and interfaces
that will potentially be less disruptive, closer to the synapse, and in contact with
fewer cells. This may be especially important for studying Glu, which is thought to
be tightly regulated perisynaptically (Danbolt, 2001). Although both techniques
measure extrasynaptic Glu, microelectrodes are smaller and have much better
spatial resolution.
Probably the single greatest advantage of using microelectrodes over
typical microdialysis is better temporal resolution (800 msec vs. typically 5-20
min). The highly sensitive detection systems used for microdialysis require
adequate sample volumes (~10-20 nl). Flow rates greater than 2 µl/minute would
create these volumes more quickly, but this approach is impractical because of
poorer relative recovery, potential for creating non-physiological conditions
around the probe, and possible tissue damage (Rossell, Gonzalez, and
Hernandez, 2003). As such, a typical off-line microdialysis study might perfuse
fluid at 1-2 µl/minute with dialysate fractions collected every 5-20 minutes.
Because it is widely recognized that small or rapid changes in neurochemicals
might be missed altogether using microdialysis as described, proponents of the
technique have pushed to improve the temporal resolution of the methods.
Primarily, investigators have reported improved temporal resolution by combining
dialysate outflow with on-line sample separation and subsequent small volume
detection methods (both on- and off-line). The best example to date would be the
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use of capillary (zone) electrophoresis separation and laser-induced fluorescence
detection (CE-LIFD) employed by several groups who report temporal resolution
of only a few seconds (Tucci et al., 1997, Lada, Vickroy, and Kennedy, 1997,
Rossell, Gonzalez, and Hernandez, 2003). The Hernandez group, in particular,
couples microdialysis on-line with derivatization reactions in a cellulose-based
capillary collection tube, which is cut into small sections, and claims 1 second
time resolution corresponding to the length of each section. Under this logic, they
could lower the temporal resolution of their method simply by cutting smaller
sections of the collection tube. However, the true temporal resolution of
microdialysis methods is limited by the number of seconds required for small
molecule diffusion and equilibration across the microdialysis membrane. As such,
temporal resolution of only a few seconds achieved by investigators such as the
Kennedy group may realistically be the lower limit of microdialysis methods. In
addition, microdialysis-based measurements are time-delayed from the actual
intracranial events by minutes to days, even with on-line detection. In contrast,
our microelectrodes sample the extracellular fluid and record Glu every 800
msec. Furthermore, Glu signals are displayed as they happen in the brain on a
second-by-second basis. In fact, we have recently developed software capable of
recording average Glu measurements forty times per second, although
recordings made at that speed are not yet routine. Clearly, our temporal
resolution is much better than typical off-line microdialysis methods and
continues to outperform the best on-line adaptations.
A commonly underreported aspect of using implanted devices for
measuring small concentrations of molecules under physiological conditions is
tissue trauma. This consideration is especially important for measuring Glu,
which is present at very high amounts inside all brain cells (10 mM, Meldrum,
Akbar, and Chapman, 1999), because traumatized cells could leak Glu into the
extracellular space and obscure experimental findings. It is widely known that
inflammation follows microdialysis probe implantation, and there is increased
glucose metabolism and decreased blood flow around the probe within the first
24 hours. Using both light and electron microscopy to observe microdialysis-
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sampled brain tissue, several ultrastructural changes were reported. Tissue
disruption was apparent up to 1.4 mm from the probe tract, there was
asymmetric (glutamatergic) synapse loss and decreased neuron density up to
400 µm from the implantation site, and swollen mitochondria and endoplasmic
reticulum were observed (Clapp-Lilly et al., 1999, Khan and Shuaib, 2001, Drew
et al., 2004). Although a full analysis of tissue damage related to implanting our
microelectrode arrays has not been conducted, initial work has revealed minimal
trauma even with microelectrodes implanted for 2 months. Strong indirect
evidence comes from recent electrophysiological recordings made with our
microelectrodes demonstrating that the neurons remain functionally intact
following implantation for up to 6 months (Deadwyler and Gerhardt, unpublished
data). Although further work is needed, these results support that our
microelectrodes may produce less tissue trauma due to their size, tapered design
with smooth edges, and means of operation.
The shortcomings of microdialysis for the measurement of Glu and GABA
have come under particular scrutiny. Glu and GABA measures in microdialysis
studies are often reported to have non-classical neurotransmitter characteristics.
In short, tetrodotoxin (TTX) applications and calcium removal, conditions which
should inhibit neuronal vesicular release of neurotransmitters, are widely
reported to have no effect on basal Glu and GABA measures (Shiraishi et al.,
1997, Timmerman and Westerink, 1997). As a result, many investigators have
concluded that basal levels of these neurochemicals originate purely from nonneuronal sources such as uptake reversal and glial metabolism. However,
Timmerman and Westerink (1997) and more recently Drew et al. (2004) have
questioned the significance of these findings. This is in light of the knowledge
that the molecules sampled by microdialysis are far removed from the synapse
and mounting evidence that some neurotransmitters, such as Glu and GABA, are
“faster” than others (i.e. more tightly regulated perisynaptically). They argue that
the non-classical nature may not be purely biological but a failure of the
microdialysis-coupled technologies to detect changes near the synapse, due to
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limitations with respect to size, spatial resolution, temporal resolution, and tissue
trauma.
In

summary,

our

ceramic-based

microelectrode

arrays

with

electrochemical detection have several advantages over microdialysis-coupled
detection techniques for the measurement of Glu. Our microelectrodes are
smaller and have better spatial resolution (15 x 333 µm vs. ~250 µm x 1-4 mm).
They have better temporal resolution (800 msec vs. typically 5-20 min) and
display the intracranial events as they happen on a second-by-second basis.
They measure Glu in the extracellular space and not an artificial medium. They
may also create less tissue trauma. Though our limit of detection (LOD: 0.25 –
0.50 µM Glu) does not rival those of the highly sensitive detection systems used
for microdialysis studies, current measures of basal and evoked Glu in the
mammalian brain are in the micromolar range, above our LOD (Hu et al., 1994,
Lada, Vickroy, and Kennedy, 1998, Kulagina, Shankar, and Michael, 1999, Baker
et al., 2002, Burmeister et al., 2002, Pomerleau et al., 2003). These advantages
are especially important for measuring fast neurotransmitters like Glu because,
unlike microdialysis probes, our microelectrode arrays are designed to be closer
to the synapse and maximize opportunities for detecting changes in
extrasynaptic Glu that may reflect synaptic events.

The Glutamatergic System in the Normal Mammalian CNS

The vast majority of synapses in the mammalian central nervous system
use Glu as a neurotransmitter to create fast neuronal excitation. Glu neuron cell
bodies can be found throughout the brain and spinal cord but are mainly
concentrated in the cerebral cortex, hippocampus, cerebellum, thalamus, and
dorsal horn of the spinal cord. Glutamatergic synapses are widely distributed
throughout the mammalian CNS with the highest density found in the
hippocampus, cortex, lateral septum, striatum, and molecular layer of the
cerebellum (Nakanishi, 1992, Hudspith, 1997, Siegel et al., 1994). While the
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neuroanatomy of Glu neurons was emerging, investigators were also exploring
the function of Glu in the brain. Today we understand that Glu plays a central role
in a wide variety of normal CNS functions including cognition, learning, memory,
sensation, and movement (Meldrum, 2000, Feldman et al., 1997, Riedel et al.,
2003).
Despite its ubiquitous nature, Glu is able to contribute to many different
CNS functions in part because of multiple Glu receptors, broadly classified as
ionotropic and metabotropic (Figure 1.1). Ionotropic Glu receptors (iGluRs) are
ligand-gated ion channels represented by N-methyl-D-aspartate (NMDA), αamino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid (AMPA), and kainate (KA)
receptors, named according to their specific agonists. In addition to being ligandgated, NMDA receptors are also voltage-gated (to relieve magnesium blockade)
and require the co-agonist glycine. The iGluRs are responsible for fast synaptic
transmission with the fast component of the excitatory post-synaptic current
(EPSC) attributed to sodium influx through AMPA receptors and the slow
component of the ESPC resulting from the slightly delayed inward movement of
both sodium and calcium through NMDA receptors. NMDA receptors have also
been shown to be important for intracellular calcium signaling responsible for
synaptic plasticity (long-term potentiation (LTP) and long-term depression (LTD)).
The role of KA receptors is less well known; however, they are densely
distributed in the CA3 region of the hippocampus and have been demonstrated
to participate in non-NMDA receptor-dependent LTP there (Bortolotto et al.
2003). IGluR subunits are encoded by different genes, have splice variants,
undergo post-transcriptional (mRNA) editing, and assemble in multiple
combinations for additional functional diversity (Siegel et al., 1994, Feldman et
al., 1997).
In addition, there are three groups of ligand-gated G-protein-coupled Glu
receptors called the metabotropic Glu receptors (mGluRs). These receptors are
not involved in fast neurotransmission but are thought to modulate the activities
of neurons and glia through intracellular second messenger signaling. Group I
mGluRs (mGluR1,5) couple with Gq11 proteins to increase phospholipase C
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Figure 1.1 The Glutamatergic Synapse
Both ionotropic Glu receptors (orange chevrons) and metabotropic Glu receptors
(mGluR) contribute to the diversity of functions attributed to the major excitatory
neurotransmitter Glu in the mammalian CNS. Glu released from the presynaptic
nerve terminal is primarily removed from the extracellular space by EAAT’s
(yellow cylinders). See text for further details.
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activity, phosphoinositide hydrolysis, and intracellular inositol triphosphate (IP3)
and diacylglycerol (DAG) signaling. This group has been shown to increase Glu
release. Groups II and III mGluRs (mGluR2,3 and mGluR4,6-8, respectively) link
with Gi/Go proteins to decrease adenylate cyclase activity and lower cyclic AMP.
Both groups, but especially group II mGluRs, have autoreceptor function,
providing inhibitory feedback to Glu presynaptic nerve terminals to decrease Glu
release. Several studies on the mGluRs to learn more about their distribution,
additional neuronal and glial functions, and potential as therapeutic targets are
currently underway (Watkins, 2000, Cartmell and Schoepp, 2000, Danbolt,
2001).
Glu neurotransmission is terminated by sodium-dependent excitatory
amino acid transporters (EAATs) (Figure 1.1). Three different EAATs are present
in the rat brain (Glu Aspartate Transporter (GLAST), Glu Transporter-1 (GLT-1),
and Excitatory Amino Acid Carrier 1 (EAAC1)), while five have been discovered
in humans (EAAT1-5). Most Glu uptake is accomplished by glial Glu transporters
(rat GLAST and GLT-1, homologous to human EAAT1 and EAAT2, respectively),
while some is performed by postsynaptic neuronal transporters (rat EAAC1,
homologous to human EAAT3). The presence of a presynaptic EAAT has long
been postulated; however, its identity and physiological relevance remain
disputed. In the rat forebrain, glial Glu uptake is dominated by GLT-1, while
GLAST is the predominant Glu transporter in the rat cerebellum (Meldrum,
Akbar, and Chapman, 1999). EAAC1 can be trafficked to the membrane surface,
and this action has been associated with protein kinase C activity.
Perisynaptically, these transporters can be present in densities on the order of
104/µm3 membrane and account for the rapid return of extracellularly released
Glu to basal levels. Glu uptake is important to maintain low basal levels for fast
signaling (good signal-to-noise) and to avoid overexposing cells to Glu, which
has been shown to be neurotoxic (excitotoxicity) (Danbolt, 2001).
Microelectrode arrays configured to record Glu allow us to investigate Glu
neurotransmission close to the synapse where Glu receptors and transporters
are localized. As an action potential travels along a glutamatergic axon,
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propagated by voltage-gated sodium channels, the wave of depolarization
ultimately reaches the presynaptic nerve terminal. There, voltage-gated calcium
channels are activated, and calcium moves into the terminal allowing the docking
of Glu-filled synaptic vesicles. Glu is released into the synaptic cleft where it
binds AMPA and NMDA receptors in the post-synaptic density to create fast
neuronal excitation (Hudspith, 1997, Meldrum, 2000). The concentrations in the
synaptic cleft rise very quickly (estimated ~1 mM, Meldrum, Akbar, and
Chapman, 1999) and almost immediately Glu begins to diffuse into the
extrasynaptic extracellular space. Glu transporters, located primarily on glial
processes opposed to the synaptic cleft and perisynaptically on the postsynaptic
neuron, quickly begin to actively remove Glu from the extracellular space
(Danbolt, 2001). Some Glu molecules escape immediate uptake and diffuse
farther extrasynaptically where they can act on both ionotropic and metabotropic
Glu receptors located on nearby neurons and glia. It is most likely this fraction of
vesicular Glu which we currently have methods to study. However, information
gained from studying extrasynaptic Glu may reflect Glu signaling in the synaptic
cleft.
The considerable knowledge that already exists about Glu biology has
stimulated intense interest in directly measuring Glu signaling in the intact brain.
In some of the present studies, we focused on investigating normal Glu
neurotransmission in the anesthetized rat and monkey brain and had very
straightforward aims. We questioned how basal Glu is regulated, what we could
learn about its origin, and how we could measure its levels. We also wanted to
study evoked Glu kinetics, or in other words, to directly measure endogenous Glu
as it is released from the presynaptic terminals and cleared from the extracellular
space by the Glu transport system. In some studies, we extended this aim by
applying

exogenous

Glu

and

specifically

investigating

the

limits

and

responsiveness of the uptake system. We wanted to conduct these studies
because no technology has ever before been able to reliably make these
measurements in the intact brain as fast or as close to the synapse. We also
wanted to define some of the normal characteristics of Glu signaling to provide a
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basis to hypothesize and test for alterations in Glu neurotransmission which may
underlie many brain disorders.

The Role of L-Glutamate in Parkinson’s Disease

While much of this work attempts to understand Glu regulation at the
synaptic level, it may be equally important to place those findings in context of a
large neural network with much higher levels of complexity. In fact, this is always
the case in the intact brain where, in any particular brain region, there are
multiple neurotransmitter and neuromodulatory influences not just on dendrites
and soma to manipulate membrane potentials but also on presynaptic terminals
and glial cells to affect neurotransmitter release and uptake kinetics. The
connectivity of networks is perhaps best demonstrated when there is a failure,
sometimes of just one circuit, which disrupts the entire system. Parkinson’s
disease unfolds in a similar fashion, and studying the many changes that occur in
the brain following disease onset is an interesting and important task.
Idiopathic PD is an age-related chronic neurodegenerative disorder that is
classically characterized by resting tremor, cogwheel muscular rigidity, and
slowness or loss of movement (bradykinesia or akinesia) (Lang and Lozano,
1998). PD patients also tend to have postural instability, a shuffling gait, and
masked facies (facial expression). The pathophysiology of Parkinson’s disease
clearly begins with the loss of dopamine neurotransmission along the nigrostriatal
pathway from the substantia nigra pars compacta (SNc) to the striatum (caudate
and putamen) (Wichmann and DeLong, 2003). However, from a network
perspective, the downstream effects of dopamine denervation on brain circuitry
are far reaching, affecting Glu, GABA, acetylcholine, and many other
neurotransmitter systems (Starr, 1995, Wichmann and DeLong, 2003) (Figure
1.2). With the role of dopamine and dopamine-based treatments exhaustively
investigated, many investigators have turned to studying other neurotransmitter
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Adapted from Wichmann and DeLong (2003)

Figure 1.2 Normal and Disease-Altered Basal Ganglia-Thalamocortical
Circuitry
In the normal brain, excitatory influences (gray arrows) and inhibitory influences
(black arrows) act in a balanced fashion to help control movement. In the
parkinsonian brain, the loss of DA from the SNc along the nigrostriatal pathway
alters many neuronal pathways within the basal ganglia-thalamocortical loops.
Progressively, this results in an inhibition of voluntary movement consistent with
the symptoms of PD. Alterations in Glu regulation include hyperactivity along the
corticostriatal and subthalamopallidal pathways. Abbreviation not defined in the
text: globus pallidus external segment (GPe).
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changes in hopes of a greater understanding of PD and finding new therapeutic
targets.
One of the results stemming from this change of focus has been the
widely accepted redefinition of PD as a disease of secondary Glu hyperactivity
along a number of involuntary motor pathways. Specifically, glutamatergic
projections from the cortex (the corticostriatal pathway) and thalamus (THAL)
provide the major driving force to the medium spiny neurons and cholinergic
interneurons, respectively, in the striatum, which embodies the major input nuclei
of the involuntary motor pathways. Furthermore, the subthalamic nucleus (STN)
transmits Glu to the major output structures of the involuntary motor pathways,
namely the internal segment of the globus pallidus (GPi) and the substantia nigra
pars reticulata (SNr) (Wichmann and DeLong, 2003). Evidence supports that
both the corticostriatal pathway and subthalamic nucleus projections are
overactive in PD (Bergman, Wichmann, and DeLong, 1990, Calabresi et al.,
1993, Greenamyre, 2001). Understanding Glu signaling in the parkinsonian brain
may provide insight into the pathophysiology and progression of PD, the
mechanism of action of currently used medications and surgical treatments, and
potentially new therapeutic approaches.
We were interested in using our microelectrodes to study differences in
Glu regulation in an animal model of PD, namely the 6-hydroxydopamine (6OHDA)-lesioned rat, which is thought to model the late stages of PD. We
recorded potassium-evoked endogenous Glu release and uptake kinetics in the
striatum, nucleus accumbens, and frontal cortex of both unilaterally-lesioned
hemiparkinsonian rats and normal rats in the same age range. We then
compared results between the groups and within the lesioned group for
significant differences. This study largely focused on the corticostriatal pathway.
We would liked to have also investigated Glu signaling near the cell bodies and
terminals of the subthalamic nucleus; however, it is a much more difficult target in
the rat brain and more suitable for future studies.
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The Role of L-Glutamate in Epilepsy

Epilepsy is a brain disorder characterized by multiple seizures, each of
which is an episodic motor, sensory, and/or psychic disturbance caused by
abnormal

cerebral

electrical

activity

that

can

be

recorded

using

electroencephalography (EEG). The study of epilepsy may benefit from the
second-by-second monitoring made possible by our microelectrodes because
Glu neurotransmission is central to its pathophysiology. Alterations in excitatory
and inhibitory influences may underlie this brain disorder (During and Spencer,
1993). Throughout the mammalian CNS and especially in the cerebral cortex,
Glu is the major excitatory neurotransmitter and GABA is the major inhibitory
neurotransmitter. Changes in the regulation of either of these chemicals in an
epileptic brain can alter the balance toward uncontrolled excitation and the
potential for seizure onset. The prominent role of these neurochemicals is
evidenced by the fact that many anticonvulsant medications work by enhancing
GABA activity while most animal models of epilepsy work by chemically,
electrically, or genetically altering Glu regulation.
Both animal and human studies support the strong relationship between
Glu and epilepsy. Intracellular recordings from rat hippocampal slices
demonstrate that Glu is responsible for paroxysmal depolarizing shifts
characteristically associated with epileptic burst discharges (Meldrum, Akbar, and
Chapman, 1999). Glu receptor agonists (e.g. kainate and NMDA) can chemically
induce seizures in rats and mice. Genetically altering Glu receptor subunits or
transporters in mice can create epileptic phenotypes, and Glu receptors and their
subunits often display changes in protein levels in electrically or chemically
induced rat models of epilepsy. Studies of resected epileptic brain tissue from
humans reveal alterations in mRNA and protein levels of Glu receptors and Glu
receptor subunits (Meldrum, Akbar, and Chapman, 1999). Of particular interest to
our group are recent data collected from human subjects demonstrating that
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there are increases in extracellular Glu levels that occur immediately before and
during seizures and higher basal Glu in the epileptogenic foci of some patients in
the time period between seizures (During and Spencer, 1993, Ronne-Engstrom
et al., 1992, Wilson et al., 1996, Thomas et al., 2003, Cavus et al., 2005).
Considering the future of intracranial Glu recording microelectrodes, it has
become clear that the first human applications would most likely come from the
neurosurgical arena and specifically from human epilepsy research, where
implanted devices are commonly used intra- and post-operatively to monitor
electrical activity and neurochemicals (During and Spencer, 1993, Engel, Jr.,
1998, Fried et al., 1999, Cavus et al., 2005). Our attempts to bridge the worlds of
basic science, technology development, and patient-oriented research have
proven to be a difficult task, however, and not enough experimental work was
completed to merit a full chapter. Nonetheless, important progress and many
plans for the future have been made. The appendix documents how we may
introduce our microelectrode arrays into the human operating room, presents
preliminary recordings from excised human tissue from an epileptic brain,
discusses additional technological changes that need to be implemented, and
explains how we believe microelectrode arrays may someday benefit patients
who suffer from epilepsy and potentially many other brain disorders.
Copyright © Brian Keith Day 2005
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Chapter Two: Methods

Microelectrode Array Design

Fabrication
Microelectrode arrays were constructed in conjunction with Thin-Film
Technologies, Inc. (Buellton, CA, USA). For a full description of microelectrode
array fabrication, see Burmeister, Moxon, and Gerhardt, 2000 and Burmeister
and Gerhardt, 2001. Because the microelectrode arrays are fabricated using
photolithography, multiple geometries (number, size, shape, and arrangement) of
the microelectrode array’s recording sites are routinely available. For
consistency, most studies used the S2 geometry defined as microelectrode
arrays with four platinum (Pt) recording sites (15 x 333 µm) geometrically
arranged as two pairs of recording sites with 100 µm spacing between pairs and
30 µm spacing between paired sites (Figure 2.1). Microelectrode arrays with a
different geometry (serial recording sites, see Appendix Figure A.1) were
provided to our collaborators at the Brigham Hospital in Boston.

Layer-Dependent Glu Selectivity
Two chemical layers were applied to make the microelectrode array
selective for Glu, one for exclusion and one for sensitivity. First, the Pt recording
sites were coated with Nafion™, which electrostatically repels anionic interferents
such as L-ascorbic acid (AA) and DOPAC (Gerhardt et al., 1984). Thereafter, the
sites were coated with a protein matrix layer (bovine serum albumin
(BSA)/glutaraldehyde (GLUT)) containing the enzyme L-glutamate oxidase
(GluOx). The GluOx layer permits the detection of Glu by enzymatically
degrading it into α-ketoglutarate and H2O2. As H2O2 diffuses through the Nafion™
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100 µm

Figure 2.1 Ceramic-Based Pt Microelectrode Array (S2 Geometry)
The ceramic-based microelectrode array (pictured) has four Pt recording sites
(15 x 333 µm ea.), which are designed as two pairs of adjacent recording sites
(30 µm spacing) arranged 100 µm apart.
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layer and contacts the Pt surface, it is oxidized at an applied voltage of +0.7 V
versus Ag/AgCl reference. This reaction frees 2 electrons per H2O2 molecule to
flow through our electrochemical detection system and record the presence of
Glu (Figures 2.2 and 2.3).
Self-Referencing Configuration
To configure a microelectrode array to record Glu in self-referencing
recording mode, the recording sites were prepared as previously described
except one pair of recording sites was coated with an enzyme-free protein matrix
layer (BSA/GLUT) to provide similar small molecule diffusion and detection
characteristics without the ability to detect Glu (Figure 2.4). Signals on selfreferencing or “sentinel” recording sites may be used qualitatively to verify the
identity of signals as Glu on Glu recording sites or quantitatively to subtract away
background signals, noise, interferences, or artifacts.

Electrode Preparation and Use

Silver/Silver Chloride (Ag/AgCl) Reference Electrodes
All of our studies were conducted using constant potential amperometry in
2 electrode configuration to record Glu in vitro (calibration) and in vivo. This
method requires both a working electrode (microelectrode array) and a
silver/silver chloride (Ag/AgCl) reference electrode. Reference electrodes are
critical for several reasons. First, applying a potential (voltage) at the working
electrode requires having an electrical reference point, which is provided by the
reference

electrode.

Second,

to

measure

electrical

current

related

to

electrochemical events occurring at the working electrode, there must be a
physical path of electron flow connected to a balanced (equal and opposite)
electrochemical event at the reference electrode. Finally, the relationship
between the working electrode and the reference electrode is thermodynamically
stable, which is necessary for electrochemical recordings.
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Figure 2.2 The FAST-16 Electrochemical Recording System
Front and rear views of the FAST-16 potentiostat box are shown. Additonal
information about features, controls, and connections is included. The FAST-16
is used to create a potential difference between the working electrode
(microelectrode array) and the reference electrode to promote electrochemical
reactions. In conjunction with other hardware elements, including the headstage
(pre-amplifier) and PCI card in the computer, the FAST-16 also amplifies the
signal (electrical current) and digitizes it. The FAST-16 software creates secondby-second data files based on this information.

25

Figure 2.3 Layer-Dependent Glu Selectivity
Microelectrode arrays are made selective for Glu by coating layers of polymers
on the Pt surface. NafionTM is first applied to electrostatically repel anionic
interferents

(e.g.

AA

and

DOPAC).

Then,

a

protein

matrix

layer

(BSA/glutaraldehyde) containing the enzyme GluOx is applied. GluOx degrades
Glu to produce H2O2 and α-ketoglutarate. H2O2 can be electrochemically
detected on Pt (+0.7 V vs. Ag/AgCl reference). Other abbreviations: oxygen (O2)
and proton (H+).
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Figure 2.4 Microelectrode Array Configured for Self-Referencing Glu
Recordings
Refer to Figure 2.3 for a detailed explanation of layer-dependent Glu selectivity
on Glu recording sites. A protein matrix layer (BSA/glutaraldehyde (GLUT)) with
GluOx was coated on one pair to configure Glu recording sites (a). A similar
protein matrix layer without GluOx was coated on the other pair to create selfreferencing or “sentinel” sites (b). Enzyme-free sites are not configured to detect
Glu. Other abbreviations: α-ketoglutarate (α-KG), electron (e-).
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Two types of Ag/AgCl reference electrodes were used. Glass-bodied
reference electrodes (RE-5b, Bioanalytical Systems, Inc.) require minimal
preparation. On arrival, these electrodes are stored in 3 M NaCl. The quality of
these electrodes can be tested against a known good Ag/AgCl reference
electrode using a voltmeter; the potential difference should not exceed ±10 mV.
This type of reference electrode is routinely used during microelectrode array
calibration. The glass-bodied type is also preferred for some in vivo
electrochemical recordings because an implanted bare wire Ag/AgCl reference
electrode can damage brain tissue. An RE-5b was used to allow Glu recordings
in the anesthetized nonhuman primates. This is possible because during each
experiment the reference electrode maintained ionic contact with the animal’s
brain.
Bare wire Ag/AgCl reference electrodes were prepared for acute
anesthetized rat experiments. Teflon-coated silver wire was cut to length (10-20
cm), and roughly 5 mm of Teflon was stripped from both ends. One end was
soldered to an amphenol gold pin connector. The other end was placed in a
saturated chloride solution (1 M HCl supersaturated with NaCl) along with a
stainless steel wire. A modified power supply (9 V DC) was plugged into a 120 V
wall outlet, the negative lead was connected to the stainless steel wire, and the
positive lead was connected to the silver wire. AgCl was allowed to electroplate
onto the exposed silver wire for 5-10 minutes. The prepared Ag/AgCl end of the
reference electrode was implanted in the rat’s brain, and the amphenol connector
was plugged into the FAST-16 hardware.

Microelectrode Arrays
The microelectrode arrays were coated to make them selective for Glu.
Clean microelectrode arrays were dipped into fresh, stock Nafion™ and ovendried at 175 oC for 4 minutes. A 10 µL solution containing 1% (w/v) GluOx, 1%
(w/v) BSA, and 0.125% (w/w) glutaraldehyde in ddH2O was prepared. Under a
dissecting microscope, a microsyringe (model 80100, Hamilton Co.) was used to
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coat the recording sites with the enzyme solution. A small drop of the solution
(~0.1 µL) suspended at the tip of the microsyringe needle was put in contact with
the recording sites and removed. The coating was allowed to air dry, and 2-4
additional coatings were applied at one minute intervals to achieve appropriate
thickness. When required, microelectrode arrays were configured for selfreferencing recordings by leaving one or more adjacent recording sites uncoated
and similarly applying an enzyme-free solution containing 1% BSA and 0.125%
glutaraldehyde to these sites as a second coating step (Figure 2.4). All coatings
were permitted to cure (overnight to two weeks) at room temperature in a clean
environment prior to in vitro testing.
To calibrate the microelectrode arrays, constant voltage amperometry was
performed using a FAST-16 high-speed electrochemistry instrument (Quanteon,
L.L.C.) using software (Fast Analytical Sensor Technology (FAST), Quanteon,
L.L.C.)

written

for

simultaneous

four-channel

recordings.

Typically,

measurements were carried out using an applied potential of +0.7 V vs. Ag/AgCl
reference (Bioanalytical Systems, Inc., RE-5b). Some microelectrodes were
calibrated at +0.7 V and separately at +0.25 V for particular experiments. For
calibrations, the microelectrode recording sites were soaked for 45-60 minutes in
a solution of 0.05 M phosphate-buffered saline (PBS) at room temperature, pH
7.4. The microelectrode was then connected to the FAST-16 hardware, and the
recording sites were lowered into 40 ml of PBS at 37 °C in a 50 ml beaker. The
PBS was slowly stirred without creating a vortex, using a 10 x 3 mm magnetic stir
bar. A battery-operated stir plate (Barnant Co.) was used to mix the solution and
to reduce AC (60 Hz) interference. The buffer’s temperature was maintained
using a recirculating water bath (Quanteon, LLC). A combination headstage gain
(2 nA/V) and secondary gain of 10X (200 pA/V final gain) was used for all
amperometric recordings. Aliquots of stock solutions of 20 mM AA, 20 mM Glu,
2 mM DA, and 8.8 mM H2O2 were sequentially added to the buffer to produce the
following final concentrations: 250 µM AA, 20, 40, 60 & 80 µM Glu, 2 µM DA, and
8.8 µM H2O2. Amperometric measurements were taken for each addition.
Selectivity ((∆I/ µM Glu):( ∆I/ µM AA), where I = current), slope (sensitivity, (∆I/
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µM Glu)), limit of detection (LOD, signal-to-noise = 3), and linearity (R2) of the
regression line of current vs. Glu concentration were calculated for each
recording site. We have high confidence in the accurate measurement of Glu
concentrations below the lower limit of our calibration range (i.e. <20 µM Glu)
because of the excellent linearity of the response to the Glu reporter molecule
H2O2 by Nafion™-coated microelectrode array recording sites (R2 > 0.999 ±
0.000, Burmeister, Moxon, and Gerhardt, 2000).
Most experiments required delivering drugs or chemicals intracranially.
When not required, the following steps were omitted. A Kopf model 700C pipette
puller (David Kopf Instruments, Tujunga, CA) was used to pull single barrel glass
capillary micropipettes (1.0 mm × 0.58 mm, 6", A-M Systems, Inc., Everett, WA,
USA). The pulled glass micropipettes were bumped until the inner tip diameter
was 10-15 µm. The micropipette tip was placed central to all recording sites and
between 50 µm and 100 µm from the recording surface and attached to the
microelectrode array’s ceramic paddle using Sticky Wax (Kerr Brand).
With or without an attached micropipette, the microelectrode was stored
with the recording sites in PBS until the in vivo studies. Rats were anesthetized
and surgically prepared for electrochemical recordings as described in the
Animal Preparation for In Vivo Electrochemical Recording section (below). For
intracranial ejections, a solution was loaded into the single-barrel micropipette
using a custom-made, pulled stainless steel needle (30 gauge, Popper and Sons,
Inc., New Hyde Park, NY, USA) attached to a sterile syringe filter (0.22 µm pore
size, Costar, Corning, NY, USA) and a 1 cc syringe. The fully prepared
microelectrode array was implanted into the animal’s brain. A fifteen minute
equilibration period per brain region was allowed prior to beginning each
experiment. Volumes of the solutions were ejected from the micropipette using a
Picospritzer III (Parker Hannifin Corp., General valve operation, 5 to 40 PSI over
0.2 to 2.0 seconds) and monitored using a stereomicroscope fitted with a reticule
(Friedemann and Gerhardt, 1992). The FAST-16 recording system was used to
record in vivo Glu. Specific details regarding recorded brain structures and their
coordinates, intracranially applied drugs and chemicals, changes in recording
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parameters, and data analysis are included with the corresponding experiments
described in chapters three, four, and five and the appendix. See Burmeister et
al. (2002) for additional details (e.g. microelectrode fabrication, microelectrode
cleaning and re-use).

The Durability of L-Glutamate Oxidase
It is important for in vivo applications of enzyme-based detection
technologies that the enzyme used is resistant to being denatured by changing
experimental conditions. Reduced enzyme activity by the loss or altered
conformation of enzyme active sites would impair the microelectrode array’s
sensitivity and limit of detection. Though we had never noted experimental
findings that lead us to hypothesize that GluOx activity was changing due to
denaturation, we did not appreciate the durability of this enzyme until we
attempted to denature it ourselves to create an inactivated form of GluOx
(iGluOx). These efforts were made in an attempt to match our protein matrices
on Glu recording and sentinel/referencing sites more closely (BSA/Glut/GluOx vs.
BSA/Glut/iGluOx, respectively). L-glutamate oxidase (EC 1.4.3.11) is a 140 kD
protein composed of three subunits arranged in a hexameric structure (α2β2γ2)
(Kusakabe et al., 1983). Several attempts to inactivate the enzyme were
conducted as follows.
In initial testing, 5 µl (5 units) of stock enzyme solution were placed in a
microcentrifuge tube and heated in a water bath at 80 °C for 15 minutes. The
resulting condensed pellet, which was lighter in color and reduced in volume,
was reconstituted with ddH2O to a final volume of 5 µl to bring it back to stock
solution concentration. This solution was used in place of the normal GluOx stock
solution to create a potentially heat-inactivated enzyme coating for the sentinel
recording sites. Two microelectrode arrays were prepared using this coating and
calibrated as described in the preceding section. It should be noted that the
potentially-inactivated enzyme coating contained visible aggregates of enzyme
unlike the typical homogenous appearance of normal enzyme coatings. Sentinel
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recording sites on both microelectrode arrays responded well to Glu additions
during calibration demonstrating that the heated enzyme had retained activity.
Four additional methods were attempted to inactivate samples of the
enzyme. Four 2 µl samples (2 units each) of stock enzyme solution were placed
in separate microcentrifuge tubes and subjected to one of the following
conditions: heated in a water bath at 100 °C for 15 minutes, heated by heat block
at 100 °C for 15 minutes, microwaved at maximum power in a 1.1 kW output
microwave oven for 1 minute, and cycled through one freeze-thaw cycle (-80 °C
to room temperature). All samples were capped and sealed with both Parafilm
and tape to prevent the escape of water vapor from the sample. Heated samples
were immediately cooled down in an ice-cold water bath and allowed to rest for
at least 15 minutes prior to activity testing. All samples were tested for activity
using an uncoated microelectrode array as a H2O2 detector. The FAST-16
hardware and software was used to perform a H2O2 calibration (a.k.a. peroxide
test) of the microelectrode array exactly as calibrations are described in the
preceding section except no AA, Glu, or DA was used and 8.8 mM H2O2 was
added to create the following sequence of final volumes: 8.8, 17.6, 26.4, and
35.2 µM H2O2. This peroxide test was not done specifically to produce a
calibration factor but qualitatively to confirm that the microelectrode array had
good sensitivity for H2O2. Also, the microelectrode tip was rinsed thoroughly with
ddH2O between enzyme activity tests.
To prepare each sample for testing, the tape and Parafilm were removed,
any water vapor that had condensed in the top was shaken down, and the tube
was uncapped. Then, the sample was diluted with ddH2O (1:10) to a final volume
of 20 µl to provide an adequate volume and vertical clearance for the
microelectrode tip. The enzyme sample was agitated by a pipettor and/or spun
using a vortexer if it did not readily mix with the added water. Portions of the
microcentrifuge tube were carefully cut and removed until there was only a ~1 cm
portion of the bottom of the tube remaining, which was the reservoir for the
sample. This miniature reservoir was securely held in place by modeling clay to
hold it upright. A bare wire Ag/AgCl reference electrode, prepared as described
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in the preceding section, was placed in the enzyme sample solution, and the
microelectrode tip was lowered stereotaxically until all sites were submerged.
Amperometric recordings (+0.7 V vs. Ag/AgCl reference) were made in the
solution as up to 5 additions of Glu (20 mM, 1 µl) were added. This procedure
has been used to verify GluOx activity in the past to troubleshoot non-responsive
prepared microelectrodes, and it was known that normal stock enzyme would
produce maximum detectable current with one addition of Glu even without
stirring.
None of the methods used to inactivate GluOx completely eliminated
enzyme activity. The enzyme subjected to the 100 °C water bath displayed
activity at the third addition of Glu, and after 5 additions showed ~30% of
maximum detectable current. The enzyme placed in the 100 °C heat block did
not show activity until the fifth addition, which produced ~50% of maximum
response. Both microwaved and freeze-thawed enzyme samples showed
maximal detectable current after the first addition of Glu. In summary, we have
not developed methods to inactivate GluOx for use on sentinel recording sites of
microelectrode arrays configured for self-referencing. Instead, we have found
that GluOx is an extremely durable enzyme, which is an advantage for acute use,
chronic implantation, and future sterilization procedures. The long-term stability
of purified or solubilized GluOx has not been fully determined by any research
group or commercial entity. Initial studies conducted by our group investigating
exogenous Glu detection in the brains of chronically implanted freely-moving rats
indicate that GluOx in our cured protein matrix is active for up to 50 days in vivo.

Animal Preparation for In Vivo Electrochemical Recordings

All animals were handled and cared for using protocols approved by the
institutional animal care and use committees (IACUC) of the University of
Kentucky Chandler Medical Center (UKMC) and the Medical University of South
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Carolina (MUSC). Both institutions are fully accredited by AAALACI (Association
of Assessment and Accreditation of Laboratory Animal Care International).

Normal Young Fischer 344 Rats
Male Fischer 344 rats (3-6 months old, 200-300 g) were used to study
normal Glu regulation and as non-lesioned control animals for the unilateral 6OHDA lesion study. The Fischer 344 rat, an inbred strain of rats, was chosen for
these studies to limit the biological variability between animals. Coordinates used
for stereotaxic surgery and microelectrode implantation were calculated from
bregma using the rat brain atlas of Paxinos and Watson (1986). Rats were
anesthetized with urethane (1.25 mg/kg, i.p.) in three divided doses. First, a
loading dose approximately equal to one-half of the total dose was administered;
the remaining urethane was given in two more injections over the course of up to
1 hour as the rat became sedated. Partially anesthetized rats were weighed
shortly before the second injection to ensure proper dosing. Urethane-injected
rats were rested on a 37 °C heating pad as they approached the surgical plane of
anesthesia. A rat was considered to be fully anesthetized when he was nonresponsive to toe pinch; rats reflexive to noxious stimuli two hours after the initial
loading dose were given additional doses of urethane (0.1 cc of 25% (w/v), i.p.)
at 15 minute intervals until they no longer responded to toe pinch. Anesthetized
rats were placed in a stereotaxic frame (incisor bar: -2.3 mm) and rested on a 37
°C heating pad.
The top of the rat’s head was visualized through a zoom-capable
stereomicroscope (10x eyepiece, 0.5x objective, 0.7 to 4.5 zoom) on a boom
stand. A midline, longitudinal incision (~4 cm) was made through the scalp
overlying the skull. The skin and fascia were reflected bilaterally and held in
retraction by clamps. Throughout the surgery, bleeding was controlled by
cauterization, and the surgical field was cleaned of blood and loose tissue using
physiological (0.9%) saline irrigation, surgical gauze (2 x 2’s), and cotton-tipped
applicators. Identification of skull landmarks (sagittal suture, coronal suture,
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lambdoidal suture, bregma, and lambda) helped guide surgical bone removal; in
particular, bregma was permanently marked prior to drilling. Section(s) of skull
overlying the brain areas of interest were outlined. Perimeters were cut nearly or
completely to the dural surface using a Dremel hand-held drill (Model 395,
Racine, WI) with an engraving cutter drill bit (Dremel bit #105, 106, or 107,
Racine, WI). The resulting bone flap was removed. The dura was carefully
incised and dissected away to expose the cortical surface of the rat brain. A
small burr hole was drilled through the skull at a remote location from the primary
surgical area(s) for Ag/AgCl reference electrode implantation. Starting from
bregma, prepared microelectrode arrays were stereotaxically aligned and
lowered until the center of the recording sites were at the cortical surface.
Microelectrode arrays were advanced into the brain to record different depths by
a microdrive (Narishige, MO-8) (Figure 2.5).

Unilateral 6-Hydroxydopamine-Lesioned Young Fischer 344 Rats
Unilateral 6-hydroxydopamine (6-OHDA)-lesioned male Fischer 344 rats
(5-9 months old, 250-350 g) were used to study the effects of striatal dopamine
denervation on potassium-evoked Glu kinetics. Coordinates used for stereotaxic
surgery and microelectrode implantation were calculated from bregma using the
rat brain atlas of Paxinos and Watson (1986).
Lesioning and rotational testing were performed by Lauren Willis in the lab
of

Anne-Charlotte

Granholm,

Ph.D.

(Department

of

Physiology

and

Neurosciences, Medical University of South Carolina). Rats were anesthetized
with chloral hydrate (400 mg/kg in 0.9% NaCl, i.p.) and stereotaxically lesioned in
the right medial forebrain bundle with 9 µg/4 µl of 6-OHDA in normal saline
containing 0.02% ascorbate (coordinates -4.4 mm AP, +1.3 mm ML, and -7.8 mm
DV from the dural surface; see Granholm et al., 1997). The 6-OHDA neurotoxin
was administered over 4 minutes followed by a 2-minute delay period prior to
needle withdrawal to allow for toxin absorption into the brain tissue. Animals were
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Figure 2.5 The In Vivo Glu Recording Setup for Anesthetized Rat Studies

36

provided with acetaminophen in their drinking water for 24 hours to alleviate
potential post-surgical discomfort.
Lesioned animals were evaluated for apomorphine-induced rotational
behavior beginning one week following 6-OHDA administration and tested once a
week thereafter for a total of 4 weeks. Briefly, animals were placed in rotometer
bowls (Hudson et al., 1993) and secured to the counting sensor by a thoracic
harness. Subjects were allowed to acclimate to the environment for 10 minutes,
and then administered a subcutaneous injection of apomorphine (0.05 mg/kg).
Subsequent rotational behavior was recorded for one hour. Following rotational
testing, animals were released from their harnesses, removed from the rotometer
bowls, and returned to their cages.
A group of rats which responded to apomorphine with average
contralateral rotations ≥300 times/hour were transferred to the University of
Kentucky for in vivo electrochemical recordings. At least three months was
allowed for the lesion to stabilize before recordings were made. Animals were
anesthetized, surgically prepared, and implanted with electrodes exactly as
described in the preceding section.

Normal Anesthetized Rhesus Monkeys (Macaca mulatta)
Three female normal rhesus monkeys (8, 25, and 28 years old) were used
to characterize normal Glu regulation in the motor cortex and frontal cortex of
young and aged nonhuman primates. Several methodological modifications were
required to conduct recordings in the veterinary operating room. Because method
refinement was part of the aims of conducting this study, a full methodological
description is presented in Chapter Four.

Drugs and Chemicals

All chemicals were used as received unless otherwise stated. All solutions
were prepared using distilled, deionized water.
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Chemicals for Microelectrode Preparation and Calibration
Nafion™ (5% (w/v) in a mixture of aliphatic alcohols and water), BSA,
glutaraldehyde (25% (w/w) in water), AA, Glu monosodium salt, and DA were
obtained from Sigma-Aldrich Corp. (St. Louis, MO, USA) (Figure 2.6). GluOx was
purchased from Seikagaku America, Inc. (East Falmouth, MA, USA). The 3%
H2O2 solution was purchased from a local retailer. Sodium chloride, sodium
phosphate monobasic, and sodium phosphate dibasic (used to make 0.05 M
PBS) were obtained from Fisher Scientific (Fair Lawn, NJ, USA). The DA stock
solution

was

prepared

in

1%

perchloric

acid

for

prolonged

stability.

Glutaraldehyde was stored at -20 ºC. Special care was taken to ensure that the
stock Nafion™, BSA, and glutaraldehyde solutions were only used for 1-2
months.

Intracranially-Applied Drugs and Chemicals
Solutions used for intracranial injections were prepared in 0.9% saline,
adjusted to pH 7.2-7.4, and filtered before use using a sterile syringe filter (0.22
µm pore size, Costar, Corning, NY, USA). Sodium chloride, potassium chloride,
and calcium chloride dihydrate (used for 0.9% saline and high potassium
solutions) were obtained from Fisher Scientific (Fair Lawn, NJ, USA).

Glu

monosodium salt and tetrodotoxin (TTX) were obtained from Sigma-Aldrich Corp.
(St. Louis, MO, USA). D,L-threo-β-benzyloxyaspartate (TBOA) was obtained
from Tocris Cookson Inc. (Ellisville, MO, USA) (Figure 2.6).

Anesthetics and Special-Use Drugs and Chemicals
Injectable anesthetics used in rat studies were prepared in 0.9% saline;
sodium chloride was obtained from Fisher Scientific (Fair Lawn, NJ, USA).
Urethane, chloral hydrate, 6-OHDA, apomorphine, and AA (used to delay the
oxidation of the previous two drugs in solution) were obtained from Sigma-Aldrich
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L-ascorbic acid (AA)

Dopamine (DA)

L-glutamic acid (Glu)

Glutaraldehyde (GLUT)

6-Hydroxydopamine (6-OHDA)

Figure 2.6 Molecular Structures of Selected Drugs and Chemicals

39

Figure 2.6 (continued)

NafionTM

D,L-threo-β-benzyloxyaspartate (TBOA)

Tetrodotoxin (TTX)
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Corp. (St. Louis, MO, USA) (Figure 2.6). While recovering, 6-OHDA-lesioned rats
were given acetaminophen, which was provided by the hospital pharmacy at the
Medical University of South Carolina (Charleston, SC). The following drugs and
chemicals were used to prepare the nonhuman primates for anesthesia,
magnetic resonance imaging, and surgery. Ketamine hydrochloride and
chlorhexidine diacetate were obtained from Fort Dodge Animal Health (Fort
Dodge, IA). Atropine sulfate was obtained from Butler Company (Columbus, OH).
Sodium pentobarbital was obtained from Ovation Pharmaceuticals, Inc.
(Deerfield, IL). Isoflurane was obtained from Baxter Healthcare Corporation
(Deerfield, IL). Betadine® was obtained from Purdue Frederick Company
(Stamford, CT). The 70% isopropyl alcohol solution was obtained from Hydrox
Laboratories (Elgin, IL). Chronically-studied nonhuman primates were also given
post-operative pain medication and prophylactic antibiotics. Buprenorphine was
obtained from Reckitt Benckiser Health Care (Richmond, VA). Penicillin G
Benzathine and Penicillin G Procaine were obtained from G. C. Hanford
Manufacturing Company (Syracuse, NY).

Data Analysis
Glu Signal Parameters
Glu signals, produced by evoked Glu release or exogenous Glu
applications, are described by concentration and time measurements, which are
then used to calculate additional signal parameters. Figure 2.7 depicts an
example of a spike-shaped signal and some of the signal parameters that may
be used to describe it. These include amplitude (the maximum change in
concentration (µM Glu)), rise time (TR, the time from onset (stimulation or
exogenous application of Glu) until peak amplitude (sec)), and total signal
duration (TTotal, the time from onset until complete return to baseline (sec)). Other
signal parameters are time measurements related to signal decay. Although
abbreviated similarly, they should be considered separately from TR and TTotal.
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Figure 2.7 Glu Signal Parameters
A schematic example of a spike-shaped Glu signal is shown to illustrate how
different signal parameters are measured and calculated. See text for details.
Typically Glu signals are plotted as concentration versus time. The y-axis has
been changed to percent response to clarify the definitions of certain signal
parameters.
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These often include T50, T80, and T100, and follow the general format of TD (sec),
where T refers to the time from peak amplitude for the signal to decay by D
percent. Next, k-1 (sec-1) is a rate constant (first-order exponential rate of fit)
related only to the decay portion of the curve. The constant k-1 is the slope of the
linear regression of the natural log transformation of this data over time. Finally,
uptake rate (µM Glu/sec) is calculated by multiplying peak amplitude by k-1.
Repeated potassium-evoked Glu releases and Glu ejection signals were
collected at one or more depths within each brain region of interest. Individual
parameters for each signal were pooled across animals by brain region. Each
signal is considered an independent event under the assumption that the
variability of responses within an animal is much greater than the variability of
responses between animals, as has been stated for similar studies of other
neurotransmitters, such as DA (see Cass et al., 1995). The number of data
points (n) used for statistical analyses is the number of Glu signals recorded;
however, the number of animals is also reported for consideration (e.g. n=40
signals in 4 rats).

Other Analytical Approaches
Data analyses with respect to basal Glu regulation (effects of TTX and
TBOA) and basal Glu measures are described in detail in Chapter Three.
Copyright © Brian Keith Day 2005
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Chapter Three: Normal L-Glutamate Regulation in the Anesthetized Rat
Brain

Introduction

The work presented in this chapter focuses on basal and potassiumevoked Glu release in the brains of normal young anesthetized rats. Previous
work by our group had established many characteristics of in vivo Glu dynamics
including fast signaling driven by rapid Glu uptake, limited dose-dependence of
potassium-evoked Glu responses, robust dose-dependence of locally-applied
exogenous Glu, and the reproducible nature of potassium-evoked Glu responses
(Burmeister, Moxon, and Gerhardt, 2000, Burmeister and Gerhardt, 2001,
Burmeister et al., 2002). Nonetheless, the speed and reproducibility of
potassium-evoked Glu signals needed to be more extensively analyzed and fully
documented. In particular, the effects of varying the concentration of potassium
and shortening the time interval between potassium stimulations are reported.
Though we had conducted many Glu kinetics studies, work had not yet
been completed to study basal Glu. Conducting basal Glu studies was especially
important because our technology works much faster and closer to the synapse
than microdialysis and might reveal significant and novel findings. These studies
were delayed, in part, because our technology is especially good at detecting
relative changes in Glu concentration from a defined baseline, an advantage
which we readily used to study basal Glu regulation, but determining the
concentration of Glu that contributed to that baseline is more difficult and
required both technological refinement and new analytical approaches. The
baseline signal (iB) presented a challenge because it is composed of multiple
components, the background current (iBKD) and the current generated by
electrochemical detection of molecules on the Pt surface (iB = iBKD + iX + iY + iZ +
…

). The background current may differ between microelectrodes and changes

over time during an amperometric recording. After equilibration, it is nearly
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constant over a short period of time for all similarly designed, fabricated, and
prepared recording sites within a microelectrode array, but you cannot know
exactly what it is at a particular time point. The latter fact explains why we could
not simply subtract away the background current from the baseline signal to
ultimately calculate basal Glu concentrations. In fact, we conceptually had a
solution for many years, which was self-referencing, but we had not yet carried
out the experiments to test the hypothesis that we could use self-referencing
subtraction methods to quantitate basal Glu levels.
The studies presented in this chapter were conducted in the striatum and
frontal cortex to expand our knowledge of potassium-evoked Glu release and
break new ground into investigations of basal Glu. The high temporal and spatial
resolution of our microelectrode arrays allowed us to study in vivo Glu faster and
closer to synaptic events than previously possible. Furthermore, the selfreferencing capabilities of our microelectrode-based technology produced data
that we could use in new experimental and analytical approaches to determine
basal Glu measures. One of these new approaches utilized the versatility of our
technology by varying the applied voltage (versus Ag/AgCl reference electrode)
at the recording surface. Finally, we used the combination of a self-referencing
recording mode and varying the applied voltage to further confirm that Glu is the
source of our amperometric signal because signal identity is the most cited
potential disadvantage of voltammetric-based microelectrode studies (see
Gerhardt and Burmeister, 2000, Obrenovitch and Zilkha, 2001).

Methods

Refer to Chapter Two for full details. In the Animal Preparation for In Vivo
Electrochemical Recordings section, the Normal Young Fischer 344 Rats
subsection is relevant to studies presented in this chapter.
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Stereotaxic Implantation and Glu Recordings
Microelectrode arrays, with or without attached single-barrel micropipettes,
were stored with the recording sites in PBS until the in vivo studies. For
experiments in which one or more intracranial ejections were required, an
appropriate solution (described below) was loaded into the micropipette. After
aligning the center of the recording sites at the cortical surface, the
microelectrode array was advanced into the brain using a hydraulic microdrive
(Narishige MO-8). Recordings were made in the striatum (AP +1.0, ML -2.5, DV 5.0 mm) and in the frontal cortex (AP +2.7, ML -1.5, DV -2.0 mm). The
microelectrode tip was thoroughly rinsed with physiological saline between
regional recordings. A fifteen minute equilibration period per brain region was
allowed prior to beginning each experiment. The FAST-16 recording system,
software, and recording parameters previously described were used to record in
vivo Glu unless otherwise noted. To study basal Glu regulation, one of the
following solutions was loaded into the micropipette for ejection: physiological
(0.9%) saline, a 100 µM TTX solution, or a 100 µM TBOA solution (barrel
concentrations). To measure basal Glu, microelectrodes configured for selfreferencing Glu recordings were typically used without attached micropipettes.
Passive recordings were made to determine basal Glu at a constant potential
(+0.7 V vs. Ag/AgCl) and varied potentials (+0.25 V compared to +0.7 V, vs.
Ag/AgCl reference). To study evoked Glu release, a potassium solution (70 mM
KCl, 79 mM NaCl, 2.5 mM CaCl2y2H2O, pH 7.4 or 120 mM KCl, 29 mM NaCl, 2.5
mM CaCl2y2H2O, pH 7.4) was locally applied at 10 second to 5 minute intervals.

Data Analysis
For the basal Glu regulation data, a single channel subtraction approach
was used. Following a 15 minute equilibration period to allow the signal to
establish a baseline, pretreatment and post-treatment baselines were defined as
the baseline signals during the 5 minute periods immediately before and after
local intracranial drug applications. An averaged 10 second portion of the
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pretreatment baseline was compared to the maximum averaged 10 second
portion of the post-treatment baseline to determine the change in signal due to
treatment. The change in signal was converted into apparent change in Glu
concentration using a recording site-specific calibration factor. Apparent changes
in Glu concentration due to TTX or TBOA were compared to apparent changes in
Glu concentration due to normal saline for each brain region by an unpaired, twotailed t-test (α=0.05). Average TTX- and TBOA-dependent Glu levels were
calculated by subtracting the average apparent change in Glu concentration due
to saline from each apparent change in Glu from individual TTX and TBOA
experiments. Descriptive statistics were used to characterize the new data sets.
To determine basal Glu measures, paired channel subtraction approaches
were used. A 15 minute equilibration period was allowed for the signals to attain
their baselines. Simultaneously recorded signals on paired channels of the
microelectrode array (enzyme-coated (+GluOx) versus enzyme-free (-GluOx))
were compared. Using a constant voltage method (+0.7 V vs. Ag/AgCl
reference), resulting differences were converted to Glu concentration using the
+GluOx calibration factor (slope m+GluOx = ∆I/µM Glu) from the enzyme-coated
site, calculated from a typical calibration at +0.7 V vs. Ag/AgCl reference. We can
use this slope because the slope calculated from the enzyme-free sentinel site
during the same calibration was approximately zero for all microelectrodes that
were used to measure basal Glu (Figures 3.1 and 3.2). Additionally, using a
varied voltage method, each brain region was recorded at +0.25 V and +0.7 V
(both vs. Ag/AgCl reference) and the voltage-dependent signal changes across
individual channels were compared between +GluOx and -GluOx channels.
Signal differences were converted to Glu concentration using a calibration factor
equal to the difference in +GluOx calibration factors calculated at both +0.25 V
and +0.7 V (both vs. Ag/AgCl reference) (Figure 3.3). Resulting measures from
the two paired channel subtraction methods as well as average calculated TTXdependent changes in Glu concentrations were compared by a 1-way ANOVA
with Bonferroni post-hoc tests (α=0.05) for each brain region.
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Figure 3.1 Typical Calibration of a Microelectrode Array Configured for SelfReferencing Glu Recordings
During calibration, a standard sequence of chemicals was added to determine
each recording site’s sensitivity to Glu, selectivity for Glu over AA, and
responsiveness to other non-anionic electroactive molecules (e.g. DA and H2O2).
An enzyme-coated Glu recording site (+GluOx) responds well to Glu and some
electroactive molecules. An enzyme-free sentinel site (-GluOx) does not respond
to Glu but shows similar responses to the same electroactive molecules. Final
concentrations of each addition shown above: 250 µM AA, 20, 40, 60, and 80 µM
Glu, 2 µM DA, and 8.8 µM H2O2.
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Figure 3.2 Slopes of Glu Recording Sites and Sentinel Sites under Normal
Calibration Conditions
Data from a representative calibration are shown. Though calibrations can be
graphed as current versus time (Figure 3.1), the data can also be replotted to
show the average current at each Glu concentration. The slope of the linear
regression of this plot produces our calibration factor (∆I/µM Glu) for each
recording site. When we subtract raw current data between paired channels to
use self-referencing recordings quantitatively (i.e. I+GluOx minus I-GluOx), the proper
calibration factor to determine Glu concentration is the difference between the
slopes from the paired channels (i.e. m+GluOx minus m-GluOx). Because enzymefree sites do not respond to Glu, m-GluOx ≈ 0, and the calibration term simplifies to
m+GluOx. In short, ∆Glu = (I+GluOx - I-GluOx)/ m+GluOx, where ∆Glu = the change in Glu
concentration between the two paired channels at constant potential (+0.7 V vs.
Ag/AgCl reference).
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Figure 3.3 Slopes of Glu Recording Sites Calibrated at Two Different
Applied Potentials
To use a varied voltage analytical approach to measure basal Glu, we calibrated
the same microelectrode arrays at two different applied potentials (vs. Ag/AgCl
reference). Current versus Glu concentration plots are shown for a representative
enzyme-coated recording site calibrated at +0.7 V (diamonds) and +0.25 V
(squares). A voltage-dependent change in current on an enzyme-coated channel
(∆I+GluOx(∆V) = I+GluOx(+0.7

V)

- I+GluOx(+0.25 V)) minus a voltage-dependent change in

current on an enzyme-free channel (∆I-GluOx(∆V) = I-GluOx(+0.7

V)

– I-GluOx(+0.25

V))

produces the change in current due to Glu revealed by a change in applied
potential (∆IGlu(∆V)). The proper calibration factor to convert this current into Glu
concentration is the difference between the slopes calculated for an enzymecoated recording site calibrated at the different applied potentials (m+GluOx(+0.7 V) –
m+GluOx(+0.25 V) = m+GluOx(∆V), circles). Again, enzyme-free slopes are very close to
zero and do not contribute to the calculations. In summary, ∆Glu(∆V) = ∆IGlu(∆V)/
m+GluOx(∆V), where ∆Glu(∆V) = the change in Glu concentration between the two
paired channels (enzyme-coated and enzyme-free) using a varied applied
potential approach.
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Each potassium-evoked Glu signal was described by the following
parameters: amplitude (µM Glu), rise time (TR (sec)), and total signal duration
(TTotal (sec)). Refer to the Data Analysis section of Chapter Two for detailed
explanations of these signal parameters. Average parameters were compared for
each potassium concentration using an unpaired, two-tailed t-test with Welch’s
correction (α=0.05).

Results

Basal Glu Regulation: Effects of TTX and TBOA
The potent voltage-dependent sodium channel blocker tetrodotoxin (TTX)
was locally applied to inhibit action potential-dependent vesicular release in the
recording area (Figure 3.4A). TTX applications (100 µM barrel concentration,
~100 nl) produced a rapid drop in our signal in both the rat striatum (n=17
recordings in 5 rats) and frontal cortex (n=17 recordings in 5 rats). The observed
decreases were significantly greater than the dilution artifact produced by
physiological saline ejection (striatum: n=11 recordings in 4 rats, frontal cortex:
n=10 recordings in 4 rats). The average TTX-dependent changes in Glu
concentration were 1.9 ± 0.7 µM and 2.0 ± 0.8 µM (mean ± SEM) in the striatum
and frontal cortex, respectively (Figure 3.4B). We also investigated the effects of
the potent, competitive, non-transportable excitatory amino acid transporter
(EAAT) inhibitor D,L-threo-β-benzyloxyaspartate (TBOA). Local applications of
TBOA (100 µM barrel concentration, ~100 nl) caused a transient but detectable
signal increase compared to physiological saline ejection within 5 minutes in both
the rat striatum (n=54 recordings in 3 rats) and frontal cortex (n=44 recordings in
4 rats) (Figure 3.5A). The average TBOA-dependent changes in Glu
concentration were 1.6 ± 0.1 µM and 2.8 ± 0.4 µM (mean ± SEM) in the striatum
and frontal cortex, respectively (Figure 3.5B).
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Figure 3.4 The Effects of TTX on Basal Glu Recordings
A) The composite trace demonstrates the typical effects of locally applied
physiological saline and TTX (100 µM, ~100 nl) in the rat brain. B) The average
decrease in apparent Glu concentration was significantly larger for TTX (dark
gray bars) than saline applications (light gray bars) in the striatum and frontal
cortex (inset, *p<0.05). Subtracting the apparent change in Glu due to saline
(dilution artifact) from the apparent change in Glu due to TTX, the TTXdependent Glu concentration was approximately 2 µM in both brain regions.
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Figure 3.5 The Effects of TBOA on Basal Glu Recordings
A) The recording trace demonstrates a transient increase in signal following local
application of the potent, general EAAT inhibitor TBOA (100 µM, ~100 nl). B) The
average maximal change in apparent Glu concentration was significantly different
following TBOA application (dark gray bars) compared to saline (light gray bars)
in the striatum and frontal cortex (inset, **p<0.0001). Correcting for dilution, the
average TBOA-dependent Glu concentration ranged from 1-3 µM in these brain
regions.
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Basal Glu Measures
Based on the TTX-dependent Glu levels that we observed, we were
interested in determining overall steady-state basal Glu levels in the anesthetized
rat striatum and frontal cortex. Investigating this question by analyzing channels
individually is not possible because the baseline signal on each enzyme-coated
channel is not a pure measurement of basal Glu. Instead, we recorded Glu in a
self-referencing mode (see Burmeister and Gerhardt, 2001) to quantify basal Glu
levels. We used two different methods based on comparing signals from paired
enzyme-coated (+GluOx) and enzyme-free (-GluOx) channels; hereafter referred
to simply as paired channels. First, we compared paired channel recordings at a
constant applied potential (+0.7 V vs. Ag/AgCl) (Figure 3.6A). Calculated average
signal differences were then converted to Glu concentration using an appropriate
calibration factor (Figures 3.2 and 3.6B). Using this method, we measured an
average basal Glu level of 1.4 ± 0.2 µM (n=16 recordings in 8 rats) in the striatum
and 1.6 ± 0.3 µM (n=13 recordings in 8 rats) in the frontal cortex (Figure 3.6C).
We also used a second approach that employed our ability to record at different
applied potentials. By calibrating and conducting in vivo recordings separately at
two different applied potentials (+0.25 V vs. +0.7 V, vs. Ag/AgCl reference), we
could compare voltage-dependent signal changes between paired channels.
Differences on enzyme-free channels primarily reflect changes in the background
current due to the change in applied voltage. This change in background current
also occurs on enzyme-coated channels. However, the voltage-dependent
differences also reflect an increased ability to detect Glu (Figure 3.7A). Once
again, average signal differences are converted to Glu concentration using an
appropriate calibration factor (Figures 3.3 and 3.7B). Using this approach, we
measured an extracellular Glu level of 1.8 ± 0.3 µM (n=16 recordings in 8 rats) in
the striatum and 1.8 ± 0.4 µM (n=15 recordings in 8 rats) in the frontal cortex
(Figure 3.7C). There was no significant difference in brain region-specific
average basal Glu measures between the constant potential and varied potential
methods. Recall that our TTX-saline comparisons revealed a TTX-dependency of
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Figure 3.6 Basal Glu Measures Using a Constant Applied Potential Method
Passive simultaneous recordings from paired channels (enzyme-coated and
enzyme-free) were compared and signal differences were converted to average
Glu concentrations using appropriate calibration factors (see Figure 3.2). A)
Recording in a self-referencing mode at a constant potential (+0.7 V vs. Ag/AgCl)
allowed the detection of basal Glu on the enzyme-coated channel (+GluOx)
which increases the baseline signal compared to the simultaneous response on
the enzyme-free channel (-GluOx). B) The product of sychronized signal
subtraction and conversion to Glu concentration is demonstrated. C) Average
basal Glu measures for the striatum and frontal cortex were 1.4 ± 0.2 and 1.6 ±
0.3 (µM Glu, mean ± SEM), respectively.
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Figure 3.7 Basal Glu Measures Using a Varied Applied Potential Method
A) Self-referencing signal analysis was used in conjunction with varied applied
potential (+0.25 V vs. +0.7 V, vs. Ag/AgCl) to measure basal Glu. Recording at
+0.25 V nearly eliminated the detection of the Glu reporter molecule H2O2. At
+0.7 V, H2O2 detection is restored. Aligned voltage-dependent signal changes
from paired channels showed a universal increase due to heightened
background current. The +GluOx channel increase was larger due to additional
Glu detection. B) The result of sychronized signal subtraction and conversion to
Glu concentration is shown. The appropriate calibration factor was previously
described (Figure 3.3). C) Average basal Glu measures for the striatum and
frontal cortex were 1.8 ± 0.3 and 1.8 ± 0.4 (µM Glu, mean ± SEM), respectively.
Basal Glu measures did not significantly differ by method (c.f. Figure 3.6).
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1.9 ± 0.7 µM in the striatum and 2.0 ± 0.8 µM in the frontal cortex (Figure 3.4).
These differences did not significantly differ from our paired channel subtraction
determinations of average basal Glu measures for either brain region. Taken
together, our data support the hypothesis that basal Glu levels in two regions of
the urethane-anesthetized rat brain are fully TTX-dependent and likely arise from
neuronal vesicular release.

Potassium-Evoked Glu Release
To further explore potassium-evoked Glu release, we examined Glu
responses under different depolarizing conditions and focused on their
reproducibility. Pressure ejections of both 70 mM and 120 mM KCl solutions (50275 nl, average volume 113 nl) evoked reproducible Glu release in the
anesthetized rat striatum and frontal cortex (Table 3.1). The 120 mM KCl
stimulations produced Glu signals with larger peak amplitudes (µM Glu) than 70
mM KCl in both the striatum (13.3 ± 0.9 vs. 5.7 ± 0.3, mean ± SEM, p<0.0001)
and frontal cortex (15.9 ± 0.9 vs. 8.4 ± 0.5, p<0.0001). Rise times (TR in seconds)
were slightly longer for 120 mM KCl versus 70 mM KCl in the striatum (2.8 ± 0.2
vs. 1.6 ± 0.1, mean ± SEM, p<0.0001) but were not significantly longer in the
frontal cortex (2.0 ± 0.1 vs. 1.7 ± 0.1, N.S.). Signal durations (TTotal in seconds)
were also significantly longer after 120 mM KCl compared to 70 mM KCl in the
striatum (13.0 ± 0.3 vs. 9.7 ± 0.3, mean ± SEM, p<0.0001) and frontal cortex
(13.4 ± 0.3 vs. 9.6 ± 0.3, p<0.0001). In Figure 3.8A, local stimulations (70 mM
KCl, 100 nl) in the anesthetized rat striatum produced signals that rose to peak
amplitude in 1-4 seconds and lasted approximately 10-20 seconds. Evoked Glu
signals in the frontal cortex maintained similar amplitudes and durations at
stimulation intervals as short as 15 seconds (120 mM KCl, 100 nl, Figure 3.8B)
and began to overlap with extracellular Glu accumulation at intervals of 10
seconds (Figure 3.8C). Other neurotransmitters, such as DA, fail to show readily
reproducible potassium-evoked responses when stimulated at rapid intervals
(see Gerhardt, Rose, and Hoffer, 1986).
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Table 3.1 Potassium-Evoked Glu Kinetics
Average peak amplitudes in both the striatum and frontal cortex significantly
differed (p<0.0001) between responses to 70 and 120 mM potassium solutions.
Typical Glu responses rose to peak amplitude in 1-2 seconds and lasted
approximately 10-20 seconds. Reported values for peak amplitude, TR, and TTotal
represent the mean ± SEM.

Number of rats
Number of responses
Peak amplitude (µM Glu)
Rise time (TR (sec))
Signal Duration (TTotal (sec))

Striatum
70 mM KCl
120 mM KCl
4
3
160
80
5.7 ± 0.3
13.3 ± 0.9

Frontal Cortex
70 mM KCl
120 mM KCl
4
3
140
90
8.4 ± 0.5
15.9 ± 0.9

1.6 ± 0.1
9.7 ± 0.3

1.7 ± 0.1
9.6 ± 0.3

2.8 ± 0.2
13.0 ± 0.3
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2.0 ± 0.1
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Figure 3.8 The Speed and Reproducibility of Potassium-Evoked Glu Signals
A) The 70 mM potassium ejections (100 nl, black arrows, 20 second ejection
intervals, striatum) evoked rapid Glu releases. Following each release, the robust
Glu transport system quickly cleared the extracellular space back to basal Glu
levels. B) and C) Responses to local 120 mM potassium applications (75 nl each,
black arrows, frontal cortex) provide evidence for tremendous reserve and/or
rapid replenishment within the Glu neurotransmitter pool in the rat brain. Multiple
serial stimulations with decreasing ejection intervals produced signals that were
readily reproducible. Each application stimulated Glu release and uptake events
that showed a high degree of similarity within the series but remained distinct
with as little as 15 seconds between applications. Glu began to accumulate and
distinct signals were lost at 10 second stimulation intervals.
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Further Confirmation that Glu is the Source of the Potassium-Evoked
Glu Signals
To further address the identity of our potassium-evoked signals, we
designed experiments to study Glu in a self-referencing recording mode (see
Burmeister and Gerhardt, 2001). Enzyme-free sites can detect all of the
molecules that enzyme-coated sites can detect except Glu. Qualitatively, these
sites act as “sentinels”, alerting us to the presence of interferences. When there
are no signal changes recorded on enzyme-free channels, we have very high
confidence that detected signals on enzyme-coated sites result purely from the
presence of extracellular Glu. Figure 3.9 shows a Glu recording in the
anesthetized rat striatum at +0.7 V and +0.2 V (both vs. Ag/AgCl reference). At
the higher potential, an enzyme-coated site (+GluOx) recorded potassiumevoked Glu signals (70 mM KCl, 125 nl) while the adjacent enzyme-free site (GluOx) showed no change in signal. At the lower potential, we repeated the
stimulations but observed no responses on either channel. The Glu reporter
molecule H2O2 oxidizes efficiently at an applied potential of +0.7 V but poorly at
+0.2 V. By contrast, many interferents, such as DA, can produce a detectable
signal at the lower potential (Pomerleau et al., 2003). Taken together, the
potassium-evoked Glu releases that we recorded were both enzyme-dependent
and voltage-dependent, supporting that the major source of the potassiumevoked signals is Glu.

Discussion

Using enzyme-coated multisite Pt-based microelectrode arrays to study in
vivo Glu regulation in the anesthetized rat brain, we have found that Glu levels
are tightly regulated in the mammalian CNS, making the dynamics of Glu release
and uptake very rapid. Basal Glu is regulated by active release and uptake
mechanisms, including TTX-dependent vesicular release. A self-referencing
recording mode can be used to further verify the identity of our signal. We also
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Figure 3.9 Selectivity of Glu Measures
The upper trace shows the signals recorded from an enzyme-coated recording
site (+GluOx). The lower trace represents a simultaneous recording on an
adjacent enzyme-free recording site (-GluOx). At an applied potential at which
H2O2 will readily oxidize on platinum (+0.7 V versus Ag/AgCl reference
electrode), 70 mM potassium ejections (black arrows) evoked signals detected
only on the enzyme-coated channel. This indicates that our signal is enzymederived. To further test the theory that the enzyme-derived Glu reporter molecule
H2O2 is responsible for our signal, we lowered the applied voltage to +0.2 V and
repeated the stimulations. At +0.2 V, H2O2 oxidizes very poorly on platinum,
unlike other electroactive species such as DA. At +0.2 V, we detected no evoked
signal on any channel.
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used this recording mode to determine absolute basal Glu levels, which were
approximately 2 µM in the rat striatum and frontal cortex. These levels did not
significantly differ from TTX-dependent Glu concentrations, supporting the
hypothesis that basal Glu likely originates from neuronal vesicular release in two
regions of the urethane-anesthetized rat brain. Following short burst local
potassium stimulations, most Glu signals rose to peak amplitude in 1-2 seconds
and lasted approximately 10-20 seconds, creating a characteristic spike pattern
of evoked Glu release and uptake kinetics. Both neuronal vesicular Glu release
and the Glu uptake system were robust, as potassium-evoked Glu signals were
readily reproducible at stimulation intervals as short as 15 seconds.
In the present studies, we used multiple approaches to study basal Glu
including examining drug effects on underlying release and uptake mechanisms
and implementing new analytical approaches and technological refinements to
measure basal Glu levels. Basal measures of Glu may reflect an extracellular
steady-state, controlled by active Glu release and uptake mechanisms (HerreraMarschitz et al., 1996, Lada, Vickroy, and Kennedy, 1998). Known release
mechanisms include neuronal vesicular

release, excitatory amino acid

transporter (EAAT) uptake reversal, and metabolic Glu exchange for other
molecules (e.g. cystine) (Fillenz, 1995, Anderson and Swanson, 2000, Baker et
al., 2002). In fact, the relationship between basal Glu and the Glu-cystine
antiporter has been studied in the rat striatum by Baker et al. (2002). They found
that blocking neuronal release had a relatively small effect (0-30% decrease) on
microdialysis measures of extracellular Glu compared to inhibition of the Glucystine antiporter (60% decrease). Independent TTX and TBOA applications
allowed us to inhibit voltage-gated sodium channel-dependent vesicular Glu
release and glial and neuronal Glu uptake to reveal the significance of these
processes in maintaining steady-state basal Glu levels. We observed a
significant but transient increase in our signal following TBOA, supporting that
there are steady-state Glu release mechanisms that require active Glu uptake to
keep basal Glu levels well-controlled. TBOA was chosen for its potency and nontransportable properties. TBOA inhibits EAAT’s by blocking the transporters
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without inducing transport currents or heteroexchange for Glu, unlike competitive
transporter substrates such as D,L-threo-β-hydroxyaspartate (THA) or L-trans2,4-pyrrolidine dicarboxylate (PDC) (Shimamoto et al., 1998, Shigeri et al., 2001).
The transient nature of these signal changes may be explained by the fact that
local TBOA application leaves a large number of EAAT’s unaffected at the
periphery of the relatively small drug-affected area. These EAAT’s may be
clearing Glu as it diffuses along its concentration gradient. Also, because TBOA
is a competitive inhibitor, some of the Glu may have been cleared by EAAT’s in
the recording area if rising levels of extracellular Glu sufficiently increased to
dislodge TBOA from the transporters. The TTX-dependent signal decreases that
we recorded were significantly greater than the dilution artifacts created by
intracranial saline ejections, demonstrating that basal Glu levels are maintained
to some extent by action potential-dependent vesicular release. We extended our
saline-TTX comparison to quantify how much of the signal change observed
following TTX was drug-dependent by subtracting the effects of dilution and
arrived at approximately 2 µM Glu in both the striatum and frontal cortex.
However, the prior approach does not necessarily reveal the overall basal
Glu levels, and the question of what percentage of total basal Glu is TTXdependent remained. We configured our microelectrode arrays in a selfreferencing recording mode and took two additional approaches based on
constant potential and varied potential paired channel recordings to measure
total basal Glu. We observed no significant differences in brain region-specific
Glu measures between the methods; the average basal Glu was ~2 µM Glu in
both the striatum and frontal cortex. Comparing this to our TTX studies, we
discovered that basal Glu levels in two regions of the urethane-anesthetized rat
brain are fully TTX-dependent and likely arise from neuronal vesicular release.
Interestingly, all three subtraction methods that we used to quantify measures of
total or neuronally-derived basal Glu yielded very similar results. Basal Glu in the
chloral hydrate-anesthetized rat brain has previously been studied using
microsensors with electrochemical detection (Kulagina, Shankar, and Michael,
1999). This study used similar investigational strategies including comparing
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enzyme-coated and enzyme-free adjacent electrodes and local TTX applications.
Both their measures of resting (29.0 ± 9.0 µM Glu) and TTX-dependent Glu
levels were larger than our measures possibly due to differences in anesthetic
drugs or their recording methods; however, they observed significant signal
decreases following TTX applications (100 µM, 200 nl, resulting in a 25-85%
decrease vs. original baseline signals), which were similar to our results.
Alternatively, published studies support that less than 50% of basal Glu
measured by microdialysis is TTX-dependent (Herrera-Marschitz et al., 1996,
Timmerman and Westerink, 1997, Baker et al., 2002). The differences that we
observed in our assessments of the magnitude and TTX-dependency of basal
Glu levels compared to prior electrochemical and microdialysis studies may stem
from altered basal Glu regulation related to the anesthetic drug urethane. There
are reports of decreased Glu release (Hudspith, 1997) and increased Glu uptake
(Danbolt, 2001) due to other anesthetics such as halothane and isoflurane.
Highly relevant ongoing Glu recordings in our lab in the awake, freely-moving rat
(unpublished data) have started to reveal differences in basal Glu regulation,
which support a significant effect of urethane anesthesia on basal Glu measures.
We may discover with further investigation that basal Glu levels are much higher
in the awake rat brain than those measured in the urethane-anesthetized rat
brain, that other anesthetics alter basal Glu regulation to different degrees, and
that the fraction of basal Glu that is TTX-dependent differs under awake or
alternatively anesthetized conditions.
Previously reported in vivo measures have supported the hypothesis that
potassium-evoked Glu has fast kinetics of release and uptake (Hu et al., 1994,
Burmeister et al., 2002, Burmeister and Gerhardt, 2003). Our experiences with
evoked Glu dynamics have consistently resembled the fast release and uptake
parameters observed by Hu et al. (1994) who used similar enzyme-based
amperometric recording techniques that were highly selective for Glu. Their
studies demonstrated Glu responses to potassium stimulations (100 mM KCl,
1000 nl) that rose to peak amplitude in a few seconds and lasted roughly 1
minute, which were reproducible given a 20 minute rest interval. They also
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demonstrated fast responses to Glu ejections (1 mM, 200-1000 nl) that peaked in
a few seconds and returned to baseline in ~20 seconds, which is consistent with
some of our previous observations using Glu selective microelectrode arrays
(Burmeister and Gerhardt, 2001). In this chapter, we expanded our studies of
potassium-evoked Glu kinetics using two different concentrations of potassium
solutions and further investigated the reproducibility of potassium-evoked Glu
release. There were potassium concentration-dependent effects on the peak
amplitudes, rise times, and total signal times. Interestingly, the rise time data sets
did not appear to have normal Gaussian distributions. Instead, at our current
sampling rate (1 Hz), the data appeared to follow a Poisson distribution, with over
half of the recorded rise times at 1 second (70 mM KCl in both brain regions, 120
mM KCl in the frontal cortex) or within 2 seconds (120 mM KCl in the striatum).
These observations emphasize not only that evoked Glu release is rapid, but that
even with second-by-second monitoring, we still do not have an accurate
measure of the speed of all of our potassium-evoked Glu signals. Overall, the 70
mM potassium solution evoked Glu signals that were slightly smaller and faster
than the 120 mM potassium-evoked Glu signals. Potassium-evoked Glu signals
stimulated at 20 second intervals displayed a high level of reproducibility. In fact,
we were able to stimulate highly reproducible Glu signals at intervals as short as
15 seconds. Most evoked Glu signals lasted approximately 10-20 seconds, so
that if we reduced the time interval to 10 seconds, we could stimulate a Glu
signal and then evoke additional Glu release before the first Glu signal was
cleared (Figure 3.8C). This is an important difference compared to potassiumevoked Glu measures reported by Hu et al. (1994). Our data do not support the
hypothesis that there is a lengthy refractory period for evoked Glu release, which
was the explanation offered by the authors for the 20 minute rest interval that
they observed between reproducible potassium-evoked Glu signals. Though the
potassium concentration was similar, their volumes of potassium were higher
(1000 nl vs. 50-275 nl) which may explain their larger average signal amplitudes
(60.5 ± 9.1 µM Glu), but this does not necessarily explain the lengthy rest period.
They were also recording potassium-evoked Glu release in the hippocampus of
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urethane-anesthetized rats, while our recordings were reported for the striatum
and frontal cortex. However, we have observed rapid reproducibility of
potassium-evoked signals in the rat hippocampus (unpublished data), so that the
difference is likely not brain region-specific and may relate to their electrode
design or other differences in experimental variables. High levels of extracellular
potassium and Glu have both been reported to initiate spreading depression in
cortical areas (Somjen, 2001), which might explain their findings. The
reproducibility of our potassium-based methods for measuring evoked Glu
release demonstrate that spreading depression likely does not occur in the brains
of the animals that we record. Overall, we have shown that evoked Glu release
and uptake are very fast, potassium concentration-dependent, and reproducible.
Our results highlight how our microelectrode-based sampling and detection
technology with superior spatial and temporal (second-by-second) resolution is
well-suited to study Glu kinetics.
We have previously demonstrated that our enzyme-based microelectrode
recording technique can reliably measure Glu (Burmeister et al., 2000,
Burmeister et al., 2001). However, it is necessary to critically evaluate underlying
basal and evoked signals in vivo because other electroactive species might
interfere with our recordings (Gerhardt and Burmeister, 2001, Robinson et al.,
2003). Generally, the major interferent for voltammetric recordings at lower
potentials in the extracellular space of the mammalian CNS is AA (Hu et al.,
1994, Fillenz, 1995, Kulagina, Shankar, and Michael, 1999, Cui et al., 2000,
Gerhardt and Burmeister, 2000). To date, we have successfully used Nafion™
coated on the recording sites to repel anionic interferents such as AA and
DOPAC and virtually eliminate their contribution to the overall signal.
Furthermore, GluOx is critical to measuring Glu and provides additional
specificity. In many brain areas, these coatings allow us to use constant potential
amperometry at +0.7 V (vs. Ag/AgCl reference) to measure Glu with confidence
in the identity of our signal. However, high potassium stimulation in some brain
areas can cause the release of interfering electroactive species. The
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demonstrated enzyme- and voltage-dependence of our potassium-evoked
measures further support that the major source of our signal is Glu.
Measuring basal and potassium-evoked release of Glu is a beginning to
understanding tonic and phasic release of Glu in the mammalian CNS. Tonic Glu
is the steady-state extracellular Glu levels thought to be maintained at a low
concentration range by the activities of neurons and glia within a brain region
(Herrera-Marschitz et al., 1996, Lada, Vickroy, and Kennedy, 1998, Baker et al.,
2002). Tonic Glu may be maintained in part by neuronal vesicular release, even
basal level burst firing of neurons; however, the tonic Glu concentration is
currently not thought to dramatically change on a second-by-second basis.
Compared to tonic Glu release, phasic Glu release is a more entrained
phenomenon in which synchronized or temporally overlapping neurotransmitter
releases raise extracellular Glu higher than background tonic Glu levels. Phasic
Glu release is followed by robust active neurotransmitter uptake, which returns
the extracellular concentration to basal levels, and the entire process may
change the extracellular Glu concentration very rapidly (Timmerman and
Westerink, 1997, Danbolt, 2001). Basal and evoked Glu measures may simulate
tonic and phasic Glu characteristics. Studies of both basal and evoked Glu
regulation are important for understanding the normal glutamatergic system and
the role of Glu in brain disorders. In this chapter, the development of methods to
measure basal Glu levels using microelectrode arrays was inspired in part by
microdialysis techniques, which have the capabilities to measure unstimulated
levels of Glu in microdialysate fractions. A strength of microelectrodes coupled
with electrochemical detection over microdialysis, however, is better temporal
resolution (800 msec vs. commonly 5-20 minutes for microdialysis), which
allowed us to monitor both basal and evoked Glu release on a second-by-second
basis. Proponents of microdialysis have recognized the need to improve the
temporal resolution of their measures and made considerable progress using online separation and detection technologies (i.e. CE-LIF), which have reduced the
temporal resolution to 5-12 seconds (Lada, Vickroy, and Kennedy, 1997, Lada,
Vickroy, and Kennedy, 1998, Kennedy et al., 2002). Ultimately, the temporal
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resolution of microdialysis techniques is limited by sampling extracellular
neurochemicals through a microdialysis membrane in a medium that is removed
from the brain. This may be an important constraint for correlating both basal and
evoked measures with electrophysiological events because such investigations
may need second-by-second to subsecond temporal resolution to distinguish
some of the roles of Glu.
In summary, the present studies using microelectrode arrays configured to
record Glu signals on a second-by-second basis have helped us begin to
understand basal and potassium-evoked Glu release in two areas of the
anesthetized rat brain, the striatum and frontal cortex. We found that basal Glu is
actively regulated by TTX-dependent release mechanisms and EAAT-dependent
uptake. Quantifying the TTX-dependent portion of the signal changes revealed
that a significant, measurable portion of the overall basal Glu levels were TTXsensitive. Two self-referencing Glu recording methods (constant and varied
applied potential) measured the total average basal Glu at roughly 2 µM in both
brain regions. These measures did not significantly differ by method, nor were
they significantly different from the average TTX-sensitive measures. These
findings support that basal Glu is completely TTX-dependent and is likely due to
neuronal vesicular release. The spatial resolution, direct sampling, and low
micrololar limit-of-detection of our technology are advantageous for both basal
and evoked Glu studies, which may simulate tonic and phasic Glu, respectively.
Potassium-evoked Glu release and uptake are robust, transient, potassium
concentration-dependent, and highly reproducible at intervals as short as 15
seconds.
Copyright © Brian Keith Day 2005
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Chapter Four: Alterations in L-Glutamate Regulation in the Unilateral 6Hydroxydopamine (6-OHDA)-Lesioned Rat Brain

Introduction

The studies in this chapter build on our knowledge of normal Glu signaling
in the rat brain and extend the applications of our microelectrode-based
technology to include studies of Glu in an altered rat brain. Although there are
several rat models of diseases in which Glu measures may be altered, our group
is most interested in neurodegenerative disorders. Keeping with our dual role as
members of both the Center For Sensor Technology (CenSeT) and one of
currently eleven Morris K. Udall Centers of Excellence For Parkinson’s Disease
Research

nationwide,

we

enthusiastically

focused

on

studying

Glu

neurotransmission in a rat model of PD, the hemiparkinsonian unilateral 6hydroxydopamine (6-OHDA)-lesioned rat. As previously described in Chapter
One, PD has been examined more closely over the last decade as a disease of
secondary Glu hyperactivity. Two major glutamatergic pathways associated with
the involuntary motor system are strongly implicated, the corticostriatal pathway,
which is largely the focus of the studies presented in this chapter, and projections
from the subthalamic nucleus, which are also extremely interesting but more
suitable for future studies.
The rat corticostriatal pathway emanates diffusely from all areas of the
cortex to make synaptic connections bilaterally in the striatum (caudate and
putamen) (Calabresi et al., 1996, Mitchell, Cooper, and Griffiths, 1999, Calabresi
et al., 2000) (Figure 4.1). The caudate and putamen represent the major input
nuclei of the involuntary motor pathways, which contain predominantly (95%) cell
bodies of GABAergic medium spiny neurons (MSN) as well as some
interneurons

(INT,

large

aspiny

neurons,

5%)

which

transmit

several

neurotransmitters including acetylcholine (Centonze et al., 1999, Mitchell,
Cooper, and Griffiths, 1999). The MSN’s project along two distinct pathways: the
69

Figure

4.1

The

Corticostriatal

Pathway

and

the

Basal

Ganglia-

Thalamocortical Circuitry
Predominantly, Glu descends to the striatum from all areas of the cortex along
the corticostriatal pathway (red arrow). The direct and indirect pathways
described in the text are also illustrated. See also Figure 1.2 for more details
regarding the basal ganglia-thalamocortical pathways.
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direct pathway, which facilitates voluntary movement, and the indirect pathway,
which inhibits it (Mitchell, Cooper, and Griffiths, 1999, Marino et al., 2002).
Glutamatergic projections descending from the cortex are thought to synapse on
the heads of the dendritic spines of MSN’s. Glu along the corticostriatal pathway
provides the major excitatory driving force for the firing patterns of these neurons
(Calabresi et al., 1996, Centonze et al., 1999, Calabresi et al., 2000). In the
normal rat brain, DA ascends to the striatum from the SNc along the nigrostriatal
pathway which is thought to synapse on the dendritic shafts of MSN’s, closely
apposed to Glu synapses, to modulate cell firing (Figure 4.2). It is also known
that both Glu and DA heteroreceptors exist on these presynaptic terminals, so
that DA can directly affect presynaptic Glu release events, and vice versa
(Calabresi et al., 1996, Bamford et al., 2004).
In the unilateral 6-OHDA-lesioned rat model of PD, the synthetic
neurotoxin 6-OHDA is injected into the medial forebrain bundle on one side
where it is selectively taken up through the DA transporter into dopaminergic
neurons. The 6-OHDA destroys both nerve terminals through axonal disruption
and cell bodies through retrograde transport and the production of reactive
oxygen species (Hudson et al., 1993, Reader and Dewar, 1999, Schober, 2004).
The nigrostriatal pathway on the side of injection may be fully lesioned by this
neurotoxin, resulting in unilateral DA denervation in the striatum. As the loss of
DA neurotransmission along the nigrostriatal pathway is known to be central to
human idiopathic PD, so does this loss of DA neurotransmission in the rat brain
produce hemiparkinsonian motor abnormalities. These deficits are revealed in a
stably lesioned rat brain by the administration of drugs which act on the DA
system such as apomorphine, which is more effective in the supersensitized
striatum ipsilateral to lesion and promotes movement in an imbalanced fashion
that results in the rat exhibiting contralateral rotations (Perese et al., 1989,
Hudson et al., 1993, Deumens, Blokland, and Prickaerts, 2002, Schober, 2004).
Rats are considered to be >90% lesioned when they exhibit low dose
apomorphine-induced contralateral rotations at a rate of >300/hour (>5/minute)
(Hudson et al., 1993).
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Figure 4.2 Glu-DA Interactions in the Striatum
Glu and DA can influence the firing of striatal projection neurons through direct
activation of their receptors on the dendrites of MSN’s. Synaptic spillover of these
neurotransmitters may also occur, so that both Glu and DA can influence their
own or each other’s presynaptic release. For example, striatal DA inhibits Glu
release through activation of D2-like receptors located on the glutamatergic
presynaptic terminals.
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The motor deficits in animal models of PD may begin with DA denervation
in the striatum, but a large number of neurotransmitter systems are affected
including Glu neurotransmission along the corticostriatal pathway (Albin et al.,
1989). Such Glu alterations have been reported by several investigators
(Tossman, Segovia, and Ungerstedt, 1986, Lindefors and Ungerstedt, 1990,
Calabresi et al., 1996, Meshul et al., 1999); however, we had a unique
opportunity to examine the dynamics of Glu release and uptake in the 6-OHDAlesioned rat brain with greater temporal and spatial resolution than prior methods.
We focused our studies on potassium-evoked Glu kinetics in the frontal cortex
and striatum to collect information about the corticostriatal pathway. We
additionally investigated potassium-evoked Glu release and uptake in the
nucleus accumbens. Although the nucleus accumbens is cellularly organized
almost identically to the striatum, DA is primarily transmitted from a different brain
region, the ventral tegmental area (Mitchell, Cooper, and Griffiths, 1999, Lancia
et al., 2004). Furthermore, although these structures have overlapping functions
(Mitchell, Cooper, and Griffiths, 1999), the nucleus accumbens is primarily a
limbic structure whereas the striatum may be more dedicated to movement; thus,
there may be interesting regional differences in Glu measures. Potassiumevoked Glu signals from two groups of rats (unilateral 6-OHDA-lesioned and
similarly-aged, non-lesioned rats) were characterized by signal parameters and
compared by hemisphere both between groups and within the lesioned group.
Our hypotheses were that evoked Glu kinetics would differ between lesioned and
non-lesioned rats and that there would be ipsilateral and contralateral differences
in Glu kinetics within the 6-OHDA-lesioned group.
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Methods

Refer to Chapter Two for full descriptions. In the Animal Preparation For In
Vivo Electrochemical Recordings section, the Normal Young Fischer 344 Rats
and

Unilateral

6-Hydroxydopamine-Lesioned

Young

Fischer

344

Rats

subsections are relevant to the studies presented in this chapter.

Stereotaxic Implantation and Glu Recordings
Prior to implantation, a 45 mM potassium solution (45 mM KCl, 104 mM
NaCl, 2.5 mM CaCl2y2H2O, pH 7.4) was loaded into the single-barrel
micropipette attached to the microelectrode array. The 45 mM potassium solution
was tested in pilot animals and reliably evoked highly reproducible Glu signals
with very few instances of simultaneously evoked DA release. The fully prepared
microelectrode/micropipette assembly was implanted into the striatum (AP +1.0,
ML ±2.1, DV -3.5 to -6.0 mm), the nucleus accumbens (AP +1.0, ML ±2.1, DV 6.5 to -7.0 mm), and the frontal cortex (AP +2.7, ML ±1.5, DV -2.0 to -4.0 mm).
The striatum and nucleus accumbens were recorded in one pass. The
microelectrode was removed from the brain, rinsed with 0.9% (physiological)
saline, and stereotaxically implanted in the frontal cortex in a second pass. From
the initial depth, the microelectrode was advanced into the brain using a
hydraulic microdrive (Narishige MO-8) in 0.5 mm steps. This was repeated for
the opposite hemisphere. A fifteen minute equilibration period per implantation
was allowed prior to initial potassium stimulation, and a two minute equilibration
period was allowed between depths. If spontaneous neurotransmitter release
occurred when entering a new depth, additional time was permitted for the signal
to return to basal levels before applying potassium. Ejections of 45 mM KCl
(~300 nl) were made at one minute intervals at each depth to obtain five Glu
responses evoked within the acceptable dose range (250 to 350 nl). Evoked Glu
signals were recorded on a second-by-second basis by the FAST-16 recording
system. At the end of the recording sessions of lesioned rats, the microelectrode
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was removed from the brain and rinsed as before. Then, the 45 mM potassium
solution was removed from the micropipette and replaced with a 70 mM
potassium solution (70 mM KCl, 79 mM NaCl, 2.5 mM CaCl2y2H2O, pH 7.4). The
microelectrode/micropipette assembly was implanted in the striatum (AP +1.0,
ML ±2.1, DV -5.0). Following equilibration, ejections of 70 mM KCl (~1800 nl)
were made, and the resulting Glu and/or DA signals were recorded by the FAST16 recording system.

Data Analysis
Each potassium-evoked Glu signal was analyzed and characterized by the
following parameters: amplitude (µM Glu), uptake rate (µM Glu/sec), and T80
(sec). Refer to Chapter Two for a full description of signal parameters. Average
signal parameters were compared between hemisphere-matched signals
recorded in the 6-OHDA-lesioned animals and age-matched, non-lesioned
control animals. They were also compared between signals recorded ipsilateral
to lesion and contralateral to lesion within the unilateral 6-OHDA-lesioned group.
Statistical comparisons were made using a one-way ANOVA with Bonferroni
multiple-comparisons post-hoc test (α=0.05, α*=0.0083). Values for signal
parameters identified as outliers (values greater than 3 standard deviations from
the mean) were excluded from analysis. Signals from the first brain area
recorded per hemisphere (AP +1.0 ML ±2.1, DV -3.5, slightly superficial to the
striatum) were primarily recorded to fine tune our pressure ejection system to
deliver volumes of potassium solutions within the accepted dose range. As such,
these signals were not considered in the data analysis.

75

Results

Contralateral DA Release
Unilateral 6-OHDA-lesioned rats were included in this study only if they
met established criteria for a full (>90%) lesion of the nigrostriatal pathway on the
side of injection (apomorphine-induced contralateral rotations ≥300 turns/hour).
To verify this indirect measure of DA depletion, we ejected an extremely high
dose of potassium (70 mM, ~1800 nl) bilaterally in the striatum of lesioned rats at
the end of the recording sessions to depolarize all of the nerve terminals and
directly measure some of the released neurotransmitters. As configured for the
present studies, our microelectrode arrays are selective for Glu over anionic
interferents such as AA and DOPAC, but display poor selectivity for Glu over the
cation DA, which can also be detected (See Figure 3.1). DA is transmitted along
the non-myelinated nigrostriatal pathway (Cooper, Bloom, and Roth, 1996),
which requires much higher stimulation than myelinated (e.g. glutamatergic)
pathways to evoke neurotransmitter release (unpublished data). Figure 4.3
shows that at a level of potassium stimulation approximately 10 times the typical
amount used in these studies, we were able to stimulate and detect the release
of both Glu and DA on the contralateral side (characteristic spike-dome signal
shape). Furthermore, enzyme-free sentinel sites, which are not configured to
detect Glu, recorded the DA release only on the contralateral side. Finally, Glu
but not DA kinetics were recorded in the ipsilateral striatum (characteristic spike
signal shape). Taken together, these results support that there was a full lesion
on the ipsilateral side and functional DA terminals on the contralateral side.

Potassium-Evoked Glu Signals in the Striatum
Glu signaling in the striatum originates predominantly from cortical regions
along the corticostriatal pathway which provides the primary excitatory influence
on MSN cell firing behavior. We bilaterally recorded potassium-evoked (45 mM,
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Figure 4.3 Contralateral DA Release
We used an extremely high dose of potassium (70 mM, ~1800 nl, black arrow) to
evoke neurotransmitter release from both myelinated (e.g. glutamatergic) and
non-myelinated (e.g. dopaminergic) projections. The upper trace (dashed line)
shows a typical response on the ipsilateral side, a signal with rapid (spike)
kinetics that are characteristic of Glu. The lower trace (solid line) shows a typical
biphasic (spike-dome) response to the same stimulation on the contralateral side.
The shape of this signal demonstrates simultaneous detection of Glu and DA
release and uptake. Inset: A simultaneous recording from an enzyme-free
(sentinel/referencing) site shows only the DA kinetics on the contralateral side.
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~300 nl) Glu signals in the striatum (5 signals/Glu recording site/depth for 5
depths) of unilateral 6-OHDA-lesioned and non-lesioned rats within the same age
range. The recorded signals were analyzed by average signal parameters that
provide information about Glu release and uptake events and mechanisms
(Table 4.1). Figure 4.4 shows representative traces of potassium-evoked Glu
signals in the striatum of both groups of rats. Average Glu signal amplitudes (µM
Glu) and uptake rates (µM Glu/sec) were significantly increased bilaterally in
lesioned rats compared to hemisphere-matched, non-lesioned rats. Average
T80’s (sec) were slightly but significantly faster on the ipsilateral side and did not
differ on the contralateral side compared to matched hemispheres in nonlesioned rats. Within the lesioned rat group, there were no significant differences
between hemispheres in any of the reported signal parameters (Figure 4.5).

Potassium-Evoked Glu Signals in the Frontal Cortex
Glu terminals in the frontal cortex originate bilaterally from the thalamus
and cortex (corticocortical pathways). We bilaterally recorded potassium-evoked
(45 mM, ~300 nl) Glu signals in the frontal cortex (5 signals/Glu recording
site/depth for 5 depths) of unilateral 6-OHDA-lesioned and non-lesioned rats (5-9
months old). Reported values for average signal parameters are included in
Table 4.1. Representative traces of potassium-evoked Glu signals for both
groups of rats are shown in Figure 4.6. Average amplitudes, uptake rates, and
T80’s of Glu signals from lesioned animals were significantly increased bilaterally
compared to matched hemispheres from non-lesioned rats. Within the lesioned
group, there were no significant differences between hemispheres for any of the
reported signal parameters (Figure 4.7).

Potassium-Evoked Glu Signals in the Nucleus Accumbens
The nucleus accumbens is organized similarly to the striatum and receives
Glu projections from similar areas. We bilaterally recorded potassium-evoked (45
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Table 4.1 Potassium-Evoked Glu Signal Parameters
All Glu signal parameters are reported as mean ± SEM (*p<0.05, **p<0.01,
***p<0.001, vs. matched hemisphere in non-lesioned rat). The numbers of
signals analyzed are indicated in parentheses below each average value.
Amplitude, uptake rate, and T80 are expressed in µM Glu, µM Glu/sec, and sec,
respectively. Within the lesioned group, there were no significant differences in
average signal parameters between hemispheres ipsilateral and contralateral to
lesion with the following exceptions. In the nucleus accumbens, the average
amplitude (†p<0.05) and uptake rate (‡p<0.001) were increased on the ipsilateral
side.

Amplitude
Uptake Rate
T80

Amplitude
Uptake Rate
T80

Amplitude
Uptake Rate
T80

Number of rats

Right Side/Ipsilateral
Left Side/Contralateral
Non-lesioned
Lesioned
Non-lesioned
Lesioned
Group
Group
Group
Group
Striatum
2.8 ± 0.1
5.4 ± 0.3***
3.2 ± 0.1
5.9 ± 0.3***
(199)
(251)
(172)
(247)
0.4 ± 0.0
2.0 ± 0.1***
0.7 ± 0.1
2.1 ± 0.1***
(193)
(251)
(169)
(247)
5.9 ± 0.2
4.6 ± 0.1***
4.9 ± 0.2
4.8 ± 0.1
(194)
(249)
(194)
(248)
Frontal Cortex
2.8 ± 0.2
4.9 ± 0.3***
3.8 ± 0.3
4.9 ± 0.3*
(198)
(252)
(175)
(245)
0.8 ± 0.1
1.6 ± 0.1***
1.3 ± 0.1
1.9 ± 0.2**
(187)
(244)
(173)
(243)
4.1 ± 0.1
5.3 ± 0.1***
3.9 ± 0.1
5.2 ± 0.1***
(202)
(245)
(202)
(243)
Nucleus Accumbens
2.2 ± 0.2
5.0 ± 0.5***,†
4.7 ± 0.4
3.6 ± 0.3
(77)
(98)
(69)
(98)
,‡
0.4 ± 0.1
1.7 ± 0.2***
1.5 ± 0.2
0.9 ± 0.1*
(75)
(98)
(67)
(97)
11.3 ± 1.4
5.3 ± 0.2***
4.0 ± 0.1
5.2 ± 0.1
(74)
(98)
(80)
(100)
All Brain Regions
4
4
4
4
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Figure 4.4 Representative Potassium-Evoked Glu Signals in the 6-OHDAlesioned and Non-lesioned Rat Striatum
Potassium-evoked Glu signals (45 mM KCl, ~300 nl, black arrows) in the striatum
of lesioned animals were significantly larger bilaterally compared to non-lesioned
rats. Within the unilaterally lesioned rat group, Glu signals in the striatum were
similar bilaterally despite the extensive loss of DA transmission only on the
ipsilateral side (see Figure 4.3).
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Figure 4.5 Average Potassium-Evoked Glu Kinetics in the Striatum of
Unilateral Lesioned and Non-lesioned Rats
The average A) peak amplitudes and B) uptake rates of potassium-evoked Glu
signals were significantly longer in the striatal hemispheres of lesioned rats
bilaterally (vs. non-lesioned matched hemispheres) but did not differ between
hemispheres within the unilaterally lesioned group. C) The average elapsed time
from signal peak until 80% signal decay (T80) showed a small but significant
decrease in 6-OHDA-lesioned rats on the ipsilateral side (compared to nonlesioned matched hemispheres) but did not differ within the lesioned group. The
average T80 did not differ between lesioned and non-lesioned rats on the
contralateral (left) side.
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Figure 4.6 Representative Potassium-Evoked Glu Signals in the 6-OHDAlesioned and Non-lesioned Rat Frontal Cortex
Potassium-evoked Glu signals (45 mM KCl, ~300 nl, black arrows) in the frontal
cortex of lesioned animals were significantly larger bilaterally compared to nonlesioned rats. Once again, within the lesioned group, Glu signals in the frontal
cortex were similar bilaterally.
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Figure 4.7 Average Potassium-Evoked Glu Kinetics in the Frontal Cortex of
Unilateral Lesioned and Non-lesioned Rats
The average A) peak amplitudes, B) uptake rates, and C) T80’s of potassiumevoked Glu signals were significantly higher in the cortical hemispheres of
lesioned rats bilaterally (vs. non-lesioned matched hemispheres) but did not differ
between hemispheres within the unilateral lesioned group.
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mM, ~300 nl) Glu signals in the nucleus accumbens (5 signals/Glu recording
site/depth for 2 depths) of lesioned and non-lesioned rats. Reported values for
average signal parameters are shown in Table 4.1. Representative traces of
potassium-evoked Glu signals for both groups of rats are shown in Figure 4.8.
Within the right (ipsilateral) nucleus accumbens of both lesioned and nonlesioned rats, the previously reported trends were maintained. Average amplitude
and uptake rate on the ipsilateral side of 6-OHDA-lesioned rats were significantly
increased compared to the right side of non-lesioned rats. In contrast, the
average T80 on the right side was significantly decreased in lesioned vs. nonlesioned rats. Considering the left (contralateral) nucleus accumbens between
lesioned and non-lesioned rats, the average amplitude and T80 did not
siginificantly differ, but the uptake rate was significantly slower. Looking
specifically within the lesioned group, the average amplitude and uptake rate
were increased on the ipsilateral side, while the average T80 did not differ. Within
the nucleus accumbens especially in these studies, there is evidence for
hemispheric differences within the normal non-lesioned rat group. Note that the
average amplitude for Glu signals was significantly increased on the left side,
and the average T80 showed a roughly 2 to 3-fold increase on the right side (nonlesioned right vs. left side) (Figure 4.9).
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Figure 4.8 Representative Potassium-Evoked Glu Signals in the 6-OHDAlesioned and Non-lesioned Rat Nucleus Accumbens
Potassium-evoked Glu signals (45 mM KCl, ~300 nl, black arrows) in the nucleus
accumbens of lesioned animals did not completely follow the trends seen in the
other brain areas. As previously observed, evoked Glu signals on the side
ipsilateral to lesion were significantly larger when compared to matched (rightsided) non-lesioned rat hemispheres. In contrast, evoked Glu signals on the side
contralateral to lesion were significantly decreased compared to signals from
both the ipsilateral hemispheres within the lesioned group and the matched (leftsided) non-lesioned rat hemispheres. In addition, normal potassium-evoked Glu
signals were significantly larger on the left side within the non-lesioned rat group.
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Figure 4.9 Average Potassium-Evoked Glu Kinetics in the Nucleus
Accumbens of Unilateral Lesioned and Non-lesioned Rats
A) and B) In the nucleus accumbens on the right (ipsilateral) side, the average
peak amplitude and uptake rate of potassium-evoked Glu signals were
significantly higher in lesioned rats (vs. non-lesioned). These measures were
also significantly higher compared to the contralateral side within the lesioned
group (†p<0.05, ‡p<0.001). The average contralateral amplitude and uptake rate
tended to be decreased in lesioned rats (vs. hemisphere-matched, non-lesioned
rats). C) The average T80 showed a significant decrease on the ipsilateral side
(compared to non-lesioned matched hemisphere) but did not differ within the
lesioned group. Significant hemispheric differences (R vs. L) of evoked Glu
signaling in the non-lesioned (normal) rat nucleus accumbens are apparent.
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Discussion

The present studies were conducted in Fischer 344 rats to evaluate
alterations in potassium-evoked Glu kinetics resulting from loss of DA
neurotransmission to the right striatum. The unilateral 6-OHDA-lesioned rat is a
commonly used model of PD, and the hemiparkinsonian effects observed in this
model are considered desirable because the non-lesioned (contralateral)
hemisphere can serve as an “internal control structure” (Schober, 2004). We also
investigated Glu dynamics in the non-lesioned rat brain bilaterally to serve as
another control group, especially to determine if there were changes in Glu
regulation in brain regions contralateral to lesion that would go undetected
otherwise. Based on the current understanding of Glu alterations in the
parkinsonian brain, we expected to see significant changes on the ipsilateral side
compared to both the contralateral side and the hemisphere-matched right side
in non-lesioned rats. We also considered that there might be changes on the
contralateral side of lesioned rats compared to the hemisphere-matched left side
of non-lesioned rats. Animals were recorded at approximately the same age (5-9
months old) to minimize age-related changes that might affect the results. Work
conducted in our lab has shown that Glu regulation in normal rats does not
dramatically differ from our age group (~6 months old) until after 18 months old
(Nickell et al., 2005).
Interpreting hemispheric comparisons both within and between rat groups
hinges largely on the assumption that, within a unilateral lesioned rat, there is
little or no DA in the striatum on the ipsilateral side and good DA
neurotransmission on the contralateral side. This assumption is commonly tested
by administering drugs that act on the DA system and evaluating their effects on
locomotion. In response to DA denervation, there is an increased number and
surface expression of DA receptors, creating a supersensitivity to DA agonist
drugs such as apomorphine (Deumens, Blokland, and Prickaerts, 2002). Thus,
the administration of low dose apomorphine to a unilateral 6-OHDA-lesioned rat
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will act in an imbalanced fashion (ipsilateral > contralateral striatum) to stimulate
movement. The gold standard used to determine the lesion status of a unilateral
6-OHDA-treated rat is an average number of apomorphine-induced contralateral
rotations greater than or equal to 300 turns per hour. Post-mortem analyses have
confirmed that rats that display this drug-induced response have full (>90%)
ipsilateral lesions (Hudson et al., 1993). The unilateral 6-OHDA-lesioned rats
used in this study were lesioned and subjected to rotational testing at the Medical
University of South Carolina. Only rats which met or exceeded this criterion were
shipped to the University of Kentucky for electrochemical recordings.
Our use of the animals was somewhat unique, in that we used technology
that was capable not only of recording extracellular Glu kinetics but also of
detecting DA (See Figure 3.1). This afforded us the opportunity to further verify
the lesion status of the 6-OHDA treated group through direct measurement of
evoked DA neurotransmission, which we conducted at the end of the recording
sessions for each lesioned rat. Figure 4.3 demonstrates that we were able to use
a high dose of potassium (approximately ten times the stimulation typically used
in these studies) to stimulate and detect DA only on the contralateral side (solid
lines). Glu recording sites simultaneously recorded Glu and DA kinetics (spikedome) while sentinel sites, which are not configured to detect Glu, only recorded
the DA kinetics (inset). Figure 4.3 also shows that on the ipsilateral side, no DAlike kinetics were observed, only spike-like signal kinetics that are consistent with
pure Glu release and uptake. These results support the full ipsilateral lesion
status of the animals predicted by apomorphine testing with no evoked DA
signaling on the side of lesion and good DA release and uptake on the
contralateral side. Note that the use of very high potassium stimulation was
important to stimulate the non-myelinated DA fibers and to fully test the ipsilateral
side, which likely had few, if any, DA terminals.
Although in Figure 4.3, the simultaneous detection of Glu and DA was
useful, typically we are interested in studying pure Glu signals, and DA is an
undesirable interferent. Fortunately, recording DA interferences is not a problem
in brain regions that are not DA-rich, such as the frontal cortex or the DA-
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depleted striatum in these studies. In DA-rich areas, Glu uptake is very fast
relative to DA uptake, which contributes to the characteristic signal shapes of
evoked release and uptake (Glu spike vs. DA dome). Signals which reflect
simultaneous release of Glu and large amounts of DA (spike-dome, see Figure
4.3 and Burmeister et al., 2002) or smaller amounts of DA (uncharacteristic
prolonged signal decay times) were easily recognized and excluded from Glu
signal analysis. Furthermore, potassium-evoked DA signals do not show rapid
reproducibility unlike Glu signals; this characteristic can also be used during the
course of an experiment to evaluate any suspected DA signals (see Gerhardt,
Rose, and Hoffer, 1986).
Efforts to discriminate between pure Glu and unwanted, DA-contaminated
Glu signals in DA-rich areas have become rare, however, largely because of two
methodological advancements. First, all but one of the microelectrode arrays
used in this chapter’s studies were configured for self-referencing Glu recordings,
and DA kinetics could easily be evaluated on sentinel sites. When Glu signals
are detected on Glu recording channels while no signals are recorded on sentinel
sites, we feel highly confident in the identity of our signal as Glu (see Figure 3.9).
Secondly, DA is transmitted along non-myelinated axons that require higher
stimulation than myelinated fibers (e.g. glutamatergic) to cause neurotransmitter
release; thus, we are able to avoid eliciting DA release in many experiments
simply by lowering the potassium concentration and/or volume. Prior to these
studies, preliminary work was done in normal Fischer 344 rats testing the effects
of 30 mM, 45 mM, and 70 mM potassium solutions. Whereas 30 mM potassium
did not reliably evoke Glu release and 70 mM evoked DA release too often for
the experimental design, 45 mM potassium reliably evoked Glu signals with good
reproducibility and very few instances of simultaneous DA release. Thus,
potassium stimulations used in these studies (45 mM, ~300 nl) were specifically
chosen to evoke Glu release without stimulating DA release in areas like the
striatum and nucleus accumbens.
Glu signal parameters, described in detail in Chapter Two, provide
information about Glu release and uptake systems. Often we consider certain
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measures (e.g. rise time, amplitude) to be reflective of Glu release mechanisms
while others (e.g. decay times, k-1) give us information about Glu uptake. In fact,
this split has some validity for potassium-evoked Glu measures because the two
divisions may be primarily influenced by the two respective systems. In reality,
the rapid fluctuations in extracellular Glu recorded by our technology are driven
by the balance between these systems. Glu concentrations rise when Glu
release is greater than uptake, fall when Glu uptake is greater than release, and
peak or plateau when release and uptake mechanisms are balanced. Often we
must consider what multiple signal parameters are supporting to make
conclusions about particular Glu systems.
In the striatum of unilateral 6-OHDA-lesioned rats, we found evidence for
bilateral effects from a unilateral lesion, consistent with previous studies of
hemiparkinsonian animal models (see Cass et al., 1995). Using the same level of
potassium to stimulate all signals in both lesioned and non-lesioned rats in our
studies, the average amplitudes of signals were significantly increased in the
lesioned animals bilaterally compared by hemisphere to non-lesioned control
rats. Higher amplitude is most often thought to reflect an increase in evoked Glu
release, but could signify a decrease in Glu transport because the extracellular
Glu level is determined by the balance between Glu release and uptake.
Considering the average decay time T80, which is primarily a measure of Glu
transporter function, striatal Glu signals on average did not extraordinarily differ.
Even though the mean difference (~1 second) reached statistical significance on
the ipsilateral/right side, this change in transport time may not be physiologically
significant. Taken together, the higher amplitudes most likely reflect an increased
ability to release Glu on stimulation. Bilaterally increased uptake rates were also
observed and may seem to contradict the preceding statements; however, the
uptake rate (calculated by multiplying the amplitude by the decay constant k-1)
can be increased by either increased release or uptake. More Glu was likely
released on stimulation, but it took roughly the same amount of time to be
cleared from the extracellular space; thus, in this case, the increased uptake
rates are most likely due to increased evoked Glu release, as the EAAT’s are not
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operating at their Vmax. Strikingly, there were no statistical differences between
any of the measures between hemispheres ipsilateral and contralateral to the
lesion within the treated group.
The increased Glu release ipsilateral to lesion can be explained by the DA
denervation on that side. In the striatum of normal rats, DA is thought to act on
D2-like receptors on presynaptic Glu terminals to inhibit Glu release (Calabresi et
al., 1996, Bamford et al., 2004) (Figure 4.2). DA denervation would disinhibit Glu
terminals and allow increased evoked Glu release. Increased Glu release
contralateral to lesion cannot be explained in this manner because DA
neurotransmission remains intact on that side (see Figure 4.3). Two possible
explanations for contralateral effects include contralateral changes in DA
regulation and bilateral effects stemming from the neuroanatomy of the
corticostriatal pathway. First, DA levels have been reported to increase on the
contralateral side possibly as a compensatory mechanism following unilateral
nigrostriatal lesion (Nieoullon et al., 1977, Cass et al., 1995). Increased DA could
cause receptor internalization in presynaptic Glu terminals, desensitizing them to
the inhibitory effects of DA. In effect, there might be a functional disinhibition of
evoked Glu release. Alternatively, the bilateral projections of the corticostriatal
pathway may play a role in creating the contralateral effect. The corticostriatal
pathway is not a discrete tract but rather a collection of projections that emanate
from all areas of the cortex and synapse in the striatum. Nonetheless, two distinct
corticostriatal pathways have recently been reported, a unilateral and a bilateral
pathway. The unilateral pathway stems largely from lower layer V pyramidal
neurons in the motor cortex, which travel along the corticospinal tract carrying
commands of voluntary movement. Collateral striatal afferents peeling off this
pathway

make

up

the

unilateral

corticostriatal

pathway.

The

bilateral

corticostriatal pathway begins in layer III and upper layer V of the cortex and
sends projections to the cortex and striatum ipsilaterally and across the corpus
callosum to these structures contralaterally (Reiner et al., 2003, Lei et al., 2004).
In association with the bilateral corticostriatal pathway, changes in Glu signaling
in the DA depleted striatum may be able to affect Glu signaling on the opposite
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side. In fact, reproducing these experiments in conjunction with corpus
callosotomy to further investigate the role of the bilateral corticostriatal pathway
would be an especially interesting future study. Of course, other explanations are
possible, and these hypotheses require further testing.
Bilateral effects on evoked Glu signaling were also seen in the frontal
cortex. As explained for the striatum, the bilaterally increased amplitudes taken
together with what may be physiologically insignificant changes in decay times
(~1 second mean difference) lead to the conclusion that the increased
amplitudes are most likely due to increased Glu release with stimulation. Also, as
before, the bilaterally increased uptake rates probably reflect increased evoked
Glu release. Once again, there are no significant differences in any of the
reported parameters between signals recorded in the ipsilateral and contralateral
cortical hemispheres within the lesioned rat group. The direct effects of DA loss
likely do not explain these differences because there is no nigrostriatal and
limited mesocortical DA signaling in the discrete areas of the frontal cortex that
we recorded. However, the loss of DA neurotransmission along one of the
nigrostriatal pathways creates alterations in several neurotransmitters within and
connected to nuclei of the involuntary motor pathways. Impulse flow diagrams of
network changes associated with PD often show decreased tone along the
glutamatergic pathways from the thalamus to the cortex and from the cortex to its
targets, including the striatum (Wichmann and DeLong, 2003). This might lead
one to think that we should be observing decreased Glu release in both the
striatum and frontal cortex. However, these diagrams are oversimplifications and
do not consider all of the local effects of neurotransmitter alterations, such as
receptor-coupled release and uptake modulations. Furthermore, although our
data in both the striatum and frontal cortex support the hypothesis that there is
increased evoked Glu release, which may simulate phasic Glu behavior, our
electrochemical recordings do not give us information about cell firing patterns or
frequency. Multiple single-unit recordings of ensembles of striatal neurons in
freely moving unilateral 6-OHDA-lesioned rats have shown that basal cell firing of
medium spiny-like neurons and large aspiny-like neurons increased on the
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lesioned side and on both sides, respectively (Kish et al., 1999). Together, these
studies support the hypothesis that there is increased excitation bilaterally to the
striatum. Similar electrophysiological studies of the frontal cortex under
hemiparkinsonian conditions have not been reported. Increased Glu release in
the frontal cortex may be a compensatory mechanism for decreased excitatory
influences from the thalamus, predicted by impulse flow diagrams, or other
cortical regions (ipsilateral and contralateral thalamocortical and corticocortical
pathways) and could explain the bilateral effects. In addition, bilateral changes in
cortical Glu regulation might affect cortical targets, such as the striatum, in both
hemispheres.
In the nucleus accumbens, we did not observe similar bilateral effects
when we compared matched hemispheres from the lesioned and non-lesioned
groups, and for the first time, we observed significant differences in signal
parameters between ipsilateral and contralateral hemispheres within the lesioned
group. In the non-lesioned rat group (R vs. L nucleus accumbens), we found on
average smaller amplitudes (<50%) and prolonged T80’s (200-300%) on the right
side. The long decay time leads us to conclude that Glu transport is much slower
on the right side, which would tend to increase amplitudes if there was robust
release; however, the small average amplitude reveals that Glu release is
instead decreased. Combined, low release and slow uptake explain the low
uptake rate. On the left side of non-lesioned rats, we found evidence for much
more robust evoked Glu signaling. A higher average amplitude and faster decay
time support comparatively increased release and uptake, and a much faster
uptake rate. These findings might support the hypothesis that there are normal
hemispheric biases in Glu regulation in the nucleus accumbens. Alternatively, the
high variability in signal parameters that we observed across the nucleus
accumbens data sets may have resulted from difficulties in microelectrode
placement. Unlike larger, more superficial intracranial targets such as the frontal
cortex and striatum, the nucleus accumbens is a deeper structure with more
complicated neuroanatomy. At the anterior-posterior coordinates of this study,
the shell of the nucleus accumbens in the rat is medial and deep to the core of
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the nucleus accumbens. Although the trajectory of our coordinates should have
placed our microelectrode recording sites only in the core, small deviations from
this trajectory or biological variances in neuroanatomy may have altered our
recording regions within this structure. Of particular concern is the presence of
the anterior commissure (AC) traversing through the core ~0.2 mm medial to our
final recording depth. Microelectrode placement in the AC dramatically lowers
potassium-evoked DA signaling using carbon fibers (unpublished data), and
would

likely

alter

potassium-evoked

Glu

signaling.

Without

histological

confirmation of the microelectrode tract, it is difficult to conclude that normal
hemispheric biases truly exist.
If we assume that our recordings were made in the accumbens core, we
can continue discussing the nucleus accumbens data, limiting our comparisons
to matched hemispheres between lesioned and non-lesioned rats. It is tempting
to posit that decreased DA neurotransmission along the lesioned side
disinhibited presynaptic Glu release mechanisms, as explained for the ipsilateral
effects in the striatum. This might increase Glu release and stimulate the Glu
transporter system to function more efficiently, explaining the observed lowered
average T80 and increased average uptake rate. Cortical afferents carrying Glu to
the nucleus accumbens on the contralateral side largely showed no statistically
significant changes in evoked Glu signaling compared to the left nucleus
accumbens in non-lesioned rats. However, on average, amplitude tended to be
lower and the T80 longer; slightly less Glu release and slightly slower Glu uptake
combined to significantly decrease the Glu uptake rate. A slight decrease in Glu
release might be explained by a compensatory increase in DA signaling to the
contralateral side, which did not reach the level to internalize DA receptors on
presynaptic Glu terminals. Following unilateral 6-OHDA injection in the medial
forebrain bundle, the loss of DA to the ipsilateral nucleus accumbens is often less
than the loss to the ipsilateral striatum (Lancia et al., 2004); thus, it is conceivable
that contralateral DA compensation might also be less and have different effects.
The decreased uptake rate on the contralateral side may be a glutamatergic
compensatory mechanism in response to the slight lowering of Glu release.
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Overall, evoked Glu signaling in the unilateral 6-OHDA-lesioned rat nucleus
accumbens showed a very different pattern of effects compared to the striatum,
possibly due to inherent hemispheric differences in Glu regulation and/or
differences in the loss of DA neurotransmission to these areas.
The striking bilateral effects seen in the striatum and frontal cortex put the
use of the contralateral side as a control in unilateral 6-OHDA-lesioned rats in
question, at least for some investigations. It has been recognized for a long time
that patients with PD often are more severely affected on one side, and that
treatments targeted to the more severely affected side have bilateral efficacy
(Spencer et al., 1992, Molina et al., 1994). Bilateral projections exist throughout
the involuntary motor nuclei and associated brain regions and may help explain
these findings (Glowinski, Bessen, and Cheramy, 1984, Barbeito et al., 1989).
The data presented in this chapter, in particular, strongly implicate Glu signaling
from the cortex as a region and system that might play a central role in
connecting unilateral lesion-induced alterations bilaterally. This also opens up the
possibility that cortical Glu may be playing a role in the bilateral effects of
unilateral PD treatments.
In summary, we investigated differences in potassium-evoked Glu kinetics
(45 mM KCl, ~300 nl) in the striatum, frontal cortex, and nucleus accumbens of
unilateral

6-OHDA-lesioned

rats

by

comparing

measured

changes

by

hemisphere both within the lesioned group and to similarly aged non-lesioned
rats. Contrary to one of our original hypotheses, we did not find significant
changes within the lesioned rat group in the striatum or frontal cortex. Instead,
we found strikingly matched bilateral effects of a unilateral lesion compared to
non-lesioned rats. In these brain regions, Glu release was primarily affected,
showing significant increases on the ipsilateral and contralateral sides. Ipsilateral
effects in the striatum may be directly related to the loss of DA, while
contralateral effects in the striatum and all of the effects in the frontal cortex may
be due to parkinsonian changes in neurotransmitter signaling and/or the
neuroanatomical bilateral connectivity of the involuntary pathways and
associated brain regions. Evoked Glu signaling in the nucleus accumbens
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showed a similar effect on the ipsilateral side, while the contralateral side
remained largely unchanged compared to hemisphere-matched recordings from
non-lesioned rats. There was, however, evidence for hemispheric differences
within the non-lesioned rat group, which made interpretation of this data difficult.
Glu signaling from the cortex may play a central role in bilateral alterations
observed in unilateral animal models of PD.
Copyright © Brian Keith Day 2005
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Chapter Five: Normal L-Glutamate Regulation in the Nonhuman Primate
(NHP) Cortex

Introduction

In this chapter, we once again build upon our investigations of normal Glu
neurotransmission in the anesthetized rat brain by developing and implementing
methods to study normal Glu regulation in the brains of anesthetized nonhuman
primates. Inherently, this is an interesting pursuit because much of the basic
science that is conducted in lower mammalian species is assumed to be
applicable

to

human

conditions;

however,

important

biological

species

differences may exist which can limit the relevance of experimental findings
(Roth, Ingram, and Lane, 2001). Species which are more closely related to
humans, such as the rhesus monkeys used in these studies, may be more
suitable to model humans and represent a logical step along the pathway toward
applying our technology in the clinical setting. As such, these studies are
examples of our commitment to conducting translational research at the
University of Kentucky. However, nonhuman primate studies are not just a
stepping stone to human research but also stand alone as important
investigations of basic biological processes in a presumably more relevant,
higher mammalian species. As this idea relates to our particular research, we
explored aspects of basic neurobiology in these animals by conducting
microelectrode arrays studies of Glu regulation in the normal young and aged
nonhuman primate cortex.
Glutamate has often been suspected to contribute to alterations in brain
function in aging and age-related neurodegenerative conditions. The current
leading theories of aging primarily implicate free radical formation, largely
generated by mitochondria, and the resulting long term effects on cell function
and viability (Harman, 1956, Linnane et al., 1989, Ozawa, 1997, Balaban et al.,
2005). In other words, cell aging may reflect the cumulative effects of
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metabolically-produced

reactive

oxygen

species

(ROS)

on

cellular

macromolecules (Michaelis, 1998). Furthermore, calcium signaling has been
shown to be altered with age (Foster and Kumar, 2002). Both changes in calcium
signaling and ROS production may begin with alterations in the regulation of Glu
neurotransmission; thus, extracellular Glu merits study in the aging brain. Such
investigations are encouraged by some groups who have reported an increased
susceptibility to Glu-induced excitotoxicity with age (Liu et al., 1996, Brewer,
2000). Yet relatively few studies on the regulation of extracellular Glu in the aging
brain have been conducted, and the results have been highly inconsistent with
respect to basal Glu levels and Glu clearance capacity (Segovia et al., 2001).
These inconsistencies may stem in part from some of the limitations of brain slice
methods and microdialysis. These techniques do not have the spatial and
temporal resolution to adequately characterize neurotransmitters with fast
kinetics of release and uptake, such as Glu, and often do not differentiate
between neuronal and glial Glu sources (Nickell et al., 2005). Our technology
allows us to investigate basal Glu and evoked Glu dynamics in the intact brain
closer to the synapse and faster than previously possible.
Faced with the opportunity to conduct research in rhesus monkeys, we
were also presented with new challenges. Significant differences exist between
working with acutely-studied rats in the laboratory setting and chronicallyinvestigated monkeys in the veterinary operating room. The tasks of general
animal handling, anesthesia, surgery, and recovery fell on collaborating teams of
experts, and our role was relegated to experimental and technological
specialists. We were concerned primarily with how to design the study and
modify our voltammetry-based techniques to transition as easily as possible into
this new venue. One of our primary concerns was creating a mobile FAST-16
electrochemical detection system that could easily be moved between settings
and closely positioned to the anesthetized monkey in the operating room without
compromising the sterile field. We also sought to make the system highly selfcontained to move all components as a single unit and require minimal setup or
additional equipment. Further concerns were related to modifying our preparation
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procedures, providing external nitrogen to our pressure-ejection system,
implanting a Ag/AgCl reference electrode, and handling sterility with respect to
direct contact between our electrodes and surgically-exposed tissue from
chronically-used animals.
Briefly, we designed our studies to investigate normal Glu regulation in the
anesthetized monkey cortex in three ways. First, all microelectrode arrays used
in these studies were configured for self-referencing Glu recordings. This allowed
us to use a constant potential paired channel subtraction approach (described in
Chapter Three) to monitor basal Glu. Secondly, we investigated potassiumevoked Glu kinetics. In particular, we wanted to compare signal parameters of
nonhuman primate evoked Glu release and uptake to the rapid Glu dynamics we
had previously observed in the anesthetized rat brain. Next, we ejected
exogenous Glu in the recording area to evaluate the Glu uptake system in a
more isolated fashion. Finally, all of these experiments were performed in three
monkeys from two different age groups, young and aged, to collect preliminary
data regarding age-related changes in Glu regulation in the monkey cortex.

Methods

Refer to Chapter Two for full descriptions of microelectrode array design,
electrode preparation and use, drugs and chemicals, and data analysis. Any
deviations from those procedures are noted below, and a full description of
animal preparation for Glu recordings is also described.

Animals
One young (8 years old) and two aged (25 and 28 years old) female
rhesus monkeys (Macaca mulatta) obtained from a commercial supplier
(Covance, Alice, TX) were used in this study. The animals were maintained on a
12-h light/12-h dark cycle and housed in individual cages measuring 9 square
feet each, with an elevated perch, front access doors and side rear access doors.
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Each cage is a double over-under design containing two monkeys. Each pair of
two housing cages has an activity module in the middle, connected to the
housing cage via the side rear doors (Figure 5.1). Their diet consisted of certified
primate biscuits in the morning (7:30 AM) supplemented daily in the afternoon
(1:30 PM) with fresh fruit or vegetables, and water was available ad libitum. All
procedures, except the MR imaging, were conducted in the Laboratory Animal
Facilities of the University of Kentucky, which are fully accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care
(AAALAC).

Veterinarians skilled in the health care and maintenance of

nonhuman primates supervised all animal care, and all protocols were approved
by the University of Kentucky’s Institutional Animal Care and Use Committee
(IACUC). The 28 year-old monkey had congenital malformations of the head,
including one ear, which made placement in the stereotaxic head frame difficult.
For other health considerations, this animal was euthanized and underwent a
necropsy following her Glu recording session.

Anatomical MRI Procedures
After being sedated with ketamine hydrochloride (~20 mg/kg; i.m.) plus
atropine sulfate (~0.04 mg/kg; i.m.), the animals were anesthetized with sodium
pentobarbital (~10 mg/kg; i.v.) and imaged to provide stereotaxic coordinates for
implantation of the microelectrode arrays. At the end of the imaging sessions, the
animals were recovered and returned to their housing. All MR images were
obtained on a 1.5T clinical imager (Siemens Magnetom Vision) using a standard
cross polarized extremity coil. The animal’s head was positioned in the extremity
coil using an MRI compatible stereotaxic head frame (David Kopf Instruments,
Model 1430M). This frame kept the animal’s head level and immobilized at the
center of the radio frequency coil using ear and mouth bars. An initial set of
coordinates (antero-posterior, dorsal-ventral, and midline) was taken using the
earbars, toothbar and a zeroing bar targeted to the gum line between the two
upper middle incisors to allow replication any time the animal was replaced in the
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Figure 5.1 Nonhuman Primate Housing System
Pairs of monkeys are housed together to promote social behavior. A variety of
customized animal toys are included in the activity module (middle section with
monkey) for environmental enrichment.
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stereotaxic apparatus. The coil/frame assembly was then positioned to place the
animal’s head at magnet isocenter. Following acquisition of scout images to
confirm correct positioning, sets of T1-weighted 3D-FLASH images were
collected for determination of the brain coordinates (TR/TE = 22/9 ms; FA = 35°;
FOV = 96 × 96 × 90 mm; Matrix = 128 × 128 × 90; Nacq = 2; TA = 6 min 48 sec).
All images were acquired as coronal slices of the brain. Antero-posterior, lateral
and vertical coordinates for stereotaxic surgery were derived from the T1weighted coronal sections through the brain. The interaural line was identified on
the scans by modified earbars containing Vitamin E. This provided a precise
reference-point on the MRI and frame, which allowed for antero-posterior
measurements. Lateral measurements were determined by measuring the
distance from midline (defined by the sagittal sinus and/or third ventricle) to the
target site. Vertical measurements were determined from the surface of the brain
to the target at the lateral coordinate.

Electrochemical Recording System Preparations
We made several preparations in the weeks to months prior to the first
experiment day. First, we assembled the mobile FAST-16 electrochemical
detection system (Figure 5.2). Components included a computer (tower, monitor,
keyboard, and mouse), a 4-channel FAST-16 setup (potentiostat, headstage
(pre-amplifier), custom-made plexiglass headstage stand, and dip-socket
connector), and a Picospritzer III pressure-ejection system. These components
were secured onto a plastic push-cart, all of the data cables were connected, and
the power cords were plugged into a central power strip. Additional equipment
and materials necessary for conducting the experiment (some of which are
shown in Figure 5.2) included a hydraulic microdrive (Narishige, MO-8), a
stereotaxic holder, micropipette loading materials, a glass-bodied Ag/AgCl
reference

electrode

(Bioanalytical

Systems,

Inc.,

RE-5b),

and

a

stereomicroscope on a boom stand. Finally, fully prepared microelectrode/
micropipette assemblies were securely rested above a bath with the recording
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Figure 5.2 Mobile FAST-16 Electrochemical Recording System

103

sites soaking in PBS. All of the additional components were easily stowed on the
push-cart along with the mobile FAST-16. To protect the delicate glass
micropipette tips from movement-induced damage, either the microelectrode/
micropipette assemblies were separately hand-carried or the PBS was removed
from the bath before transport and refilled when the push-cart was finally
positioned in the operating room.
A nitrogen tank was secured in the central tank room for the veterinary
surgical suites. It was dedicated to a spigot near the head of the operating table
where the mobile FAST-16 was planned to be positioned. A custom-made
coupling allowed us to connect our Picospritzer III directly to the spigot on the
operating room wall. This setup was tested for gas delivery to the operating room
and worked well without any apparent leaks.

Electrode Preparation and Use
Our electrode preparation and use was consistent with most established
protocols (see Chapter Two for detailed descriptions); however, certain
methodological approaches were refined as follows. Approximately one week
prior to scheduled experiment day, we configured four microelectrode arrays to
record Glu in self-referencing recording mode. The day before the experiment,
single barrel micropipettes were pulled, bumped to an inner diameter of 10-15
µm, and attached to the microelectrode arrays. Also, the mobile FAST-16 was
set up and tested. Three and a half hours before the surgical technician team
was scheduled to retrieve the rhesus monkey, microelectrode arrays were
soaked in PBS for one hour and then calibrated in the laboratory using the
mobile FAST-16 system positioned at the benchtop. Based on calibration data,
the four microelectrode arrays were ranked by performance. The top two
microelectrode arrays were assigned for use with potassium and Glu ejections,
respectively. The other two microelectrodes were planned to be used as backups
in case of accidental breakage or other unforeseen problems. At this point, the
surgical technician team was contacted and told to begin their preparations for
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surgery. We purposefully scheduled the experiment day to progress like this, so
that we could abort the experiment prior to animal handling in case of any Glu
recording system problems. To date, we have recorded from three rhesus
monkeys and have never needed to cancel the experiment.

Surgical Procedures
Following sedation with ketamine hydrochloride (~20 mg/kg; i.m.) plus
atropine sulfate (~0.04 mg/kg; i.m.), each animal was intubated via the
orotracheal method, and intravenous lines were secured. Then, the animal was
anesthetized with isoflurane (1-3%) and placed in an MRI-compatible stereotaxic
apparatus (David Kopf Instruments, Model 1430M) in a ventral-lateral position.
The animal was maintained on a heated blanket and had cardiac and respiratory
parameters monitored during the procedure. Coordinates for microelectrode
array implantation were determined by MRI prior to the surgery as described
above. After being shaved, the scalp area was cleaned with antiseptic. Starting at
the incision site and moving circumferentially to the periphery, the shaved area
was gently scrubbed with sterile 4 x 4 sponges soaked in chlorhexidine diacetate
surgical scrub followed by 70% isopropyl alcohol. This procedure was repeated.
After the alcohol dried, Betadine® prep was applied, and the animal was covered
with sterile drapes (Figure 5.3). Then, a 5-7 cm incision was made through the
scalp, and the skin and muscles were reflected to expose the skull. Small (2 mm
diameter) holes were drilled in the skull directly over the targeted areas using a
dental drill and a rounded drill bit, and the overlying meninges were removed to
expose the surface of the brain. A lateral pocket was made in the fascia at the
posterior extent of the incision using blunt dissection. A 70% isopropyl alcoholcleaned glass-bodied Ag/AgCl reference electrode (Bioanalytical Systems, Inc.,
RE-5b) was inserted into the pocket. Sterile saline irrigation was used to maintain
ionic contact between the reference electrode and the exposed brain.
Microelectrode/micropipette assemblies were slowly lowered into each target
using a stereotaxic holder as described below. After completion of the recording
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Figure 5.3 Recording Glu in the Operating Room
Rhesus monkeys were anesthetized and prepared for electrochemical recordings
under sterile field conditions. The mobile FAST-16 was positioned in the room at
the head of the operating table. First, a small group of surgeons exposed small
areas of cerebral cortex and helped implant the microelectrode/micropipette
assembly. Then, a two-person team conducted the experiment, while a separate
team of veterinary technicians maintained anesthesia and monitored the
monkey’s vital signs throughout the procedures.
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session, bone wax was placed in the drill holes, and the scalp incision was
sutured over the exposed areas per normal procedures. The animal was then
given an analgesic (buprenorphine, 0.01 mg/kg, i.m.) and prophylactic antibiotics
(combination Penicillin G Benzathine and Penicillin G Procaine, 20,000 U/kg,
s.c.). Temperature, heart rate, respiratory rate, and femoral pulse were monitored
until the animal recovered from anesthesia. Full recovery was defined as selfsustained balance and posture.

Stereotaxic Implantation and Glu Recordings
Prior to MRI-assisted implantation, a 70 mM potassium solution (70 mM
KCl, 79 mM NaCl, 2.5 mM CaCl2y2H2O, pH 7.4) or a 5 mM Glu solution (5 mM
Glu in physiological (0.9%) saline, pH 7.4) was loaded into the single-barrel
micropipette attached to the microelectrode array. First, a custom-made, pulled
stainless steel needle (30 gauge, Popper and Sons, Inc., New Hyde Park, NY,
USA) was cleaned externally and rinsed internally with 70% isopropyl alcohol
and allowed to air dry. Then, a solution was drawn into a 1 cc syringe, and a
sterile syringe filter (0.22 µm pore size, Costar, Corning, NY, USA) and pulled
needle were attached. The fully prepared syringe was used to load the sterilefiltered solution into the micropipette. The fully prepared microelectrode/
micropipette assemblies were implanted into the frontal cortex (frontal eye field)
and the motor cortex, based individually on coordinates measured from each
monkey’s MRI. After initially advancing the center of a microelectrode array to the
cortical surface (David Kopf Instruments, Model 1760 electrode manipulator), an
assembly was sequentially moved through the recording depths (-1.0 mm to -2.0
mm in 0.25-0.50 mm increments) using a microdrive (Narishige, MO-8) (Figure
5.4). In the case of potassium-evoked signals in the frontal cortex, additional
depths were recorded (-2.25 mm and -2.5 mm). Potassium-evoked Glu signals
were recorded in one hemisphere, while exogenous Glu was ejected and
recorded in the opposite hemisphere. For each solution, a separate
microelectrode/micropipette assembly was used. For each hemisphere, the
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Figure 5.4 The In Vivo Glu Recording Setup for Anesthetized Monkey
Studies
The microelectrode/micropipette assembly was stereotaxically lowered into
cortical regions based on coordinates derived individually from each monkey’s
MRI. A four-channel headstage (pre-amplifier) plugged into the FAST-16 was
placed near the recording area and connected to the microelectrode array using
a custom-made connector. A stereomicroscope on a boom stand, focused on the
meniscus within the micropipette, was used to monitor the volumes of solutions
that were pressure-ejected into the brain.
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frontal cortex was recorded in one pass, and then the microelectrode was
removed from the brain, rinsed with 0.9% (physiological) saline, and
stereotaxically implanted in the motor cortex in a second pass. A fifteen minute
equilibration period per implantation was allowed prior to beginning the ejections,
and a two to three minute equilibration period was allowed between depths.
Basal Glu levels were assessed at each depth in real time, and additional time
was allowed to record basal Glu activity when necessary prior to ejections.
Ejections of 70 mM KCl or 5 mM Glu were made at one minute intervals at each
depth until at least three to five reproducible Glu responses were recorded. For 5
mM Glu ejections, we adjusted our ejection volumes to amplitude-match the
signals between monkeys in the ~50-100 µM range for analytical purposes.
Volumes were controlled by a pressure-ejection system and monitored using a
stereomicroscope fitted with a reticule (see Friedemann and Gerhardt, 1996). Glu
signals were recorded (+0.7 V vs. Ag/AgCl reference) on a second-by-second
basis by the FAST-16 recording system.

Data Analysis
Average measures from one young monkey were compared to those from
one aged monkey. A second aged monkey with congenital head malformations
was recorded. On necropsy, we discovered that our recordings were too far
anterior. Thus, measures from this animal are not presented with one exception.
We observed extraordinary basal Glu activity in an area of this aged monkey’s
brain that was identified as the frontal cortex during post-mortem examination.
Basal Glu measures were calculated for each depth by a constant applied
potential paired channel subtraction approach (described in Chapter Three). Low
basal Glu measures require within-array performances that exceed normal
recording requirements. Microelectrode array recordings that displayed obvious
mismatches in performance were omitted. Briefly, at the end of equilibration, a
stable paired channel (enzyme-coated vs. enzyme-free) Glu recording of one
minute duration was evaluated. For extraordinary basal Glu activity, longer
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comparison times (three to five minutes) were used. Paired channel signal
differences were converted into Glu concentrations using an appropriate
calibration factor. Average Glu concentrations over these time intervals were
calculated for each depth, and the average Glu concentration for each brain
region was also determined. Both potassium-evoked and Glu ejection-produced
Glu signals were analyzed and characterized by the following parameters:
amplitude (µM Glu), rise time (sec), TTotal (sec), T80 (sec), and uptake rate (µM
Glu/sec). Refer to Chapter Two for full descriptions. The average amplitude per
nanoliter of ejected solution (amp/nl, µM Glu/nl) was also calculated. Average
basal Glu measures and Glu signal parameters were compared between the
young and aged monkey using unpaired t-tests (α=0.05). Welch’s correction was
used when required.

Results

Potassium-Evoked Glu Signals in the Motor Cortex
We recorded fast kinetics of potassium-evoked Glu release and uptake in
the motor cortex of both the young and aged monkey. These signals displayed a
characteristic spike shape (Figure 5.5) and were very similar in character to the
signals that we routinely observed in the normal young rat cortex. Glu signals in
the normal young monkey (n=20) rose to peak amplitude in 2.0 ± 0.1 seconds
and lasted 16.1 ± 1.0 seconds (mean ± SEM used throughout the Results
section). This is comparable to potassium-evoked Glu signals in the young rat
cortex, which rose to peak amplitude in 1-2 seconds and lasted 10-20 seconds
(see Chapter Three). Glu signals in the normal aged motor cortex (n=30) rose
more slowly (3.3 ± 0.1 sec, p<0.0001) but lasted approximately the same time
(14.4 ± 0.3 sec, N.S.). Likewise, the average time from signal peak to 80% decay
(T80) did not significantly differ between the young and aged monkey (10.4 ± 0.6
sec vs. 11.2 ± 0.2 sec, N.S.). The average signal amplitude was significantly
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Figure 5.5 Potassium-Evoked Glu Signals in the Motor Cortex
Potassium ejections at one minute intervals (black arrows) in the monkey motor
cortex evoked fast Glu release and uptake. Smaller amplitude signals were
observed in the motor cortex of the young monkey (top trace (blue), responses to
100 nl potassium volumes) compared to the aged monkey (bottom trace (red),
responses to 250 nl potassium volumes).
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larger in the aged monkey (3.3 ± 0.4 µM Glu vs. 13.3 ± 0.3 µM Glu, young vs.
aged, p<0.0001) as was the average uptake rate (0.21 ± 0.04 µM Glu/sec vs.
1.37 ± 0.06 µM Glu/sec, young vs. aged, p<0.0001); however, the potassium
dose (volume) was also much larger in the aged monkey (100.0 ± 0.0 nl vs.
236.7 ± 17.9 nl, young vs. aged, p<0.0001).

Glu Ejections in the Motor Cortex
Glu ejection-produced Glu signals in the motor cortex of young and aged
monkeys were well-matched (Figures 5.6 and 5.7). The average amplitude of
these signals (young: n=30, aged: n=29) fell into our targeted 50-100 µM range
(73.9 ± 2.5 µM Glu vs. 67.1 ± 3.4 µM Glu, young vs. aged, N.S.). The volumes of
5 mM Glu required to achieve these amplitudes dramatically differed (48.3 ± 1.7
nl vs. 531.7 ± 11.6 nl, young vs. aged, p<0.0001) as did the resulting amp/nl (1.6
± 0.1 µM Glu/nl vs. 0.1 ± 0.01 µM Glu/nl, young vs. aged, p<0.0001). Average
T80’s were significantly longer in the aged monkey (10.5 ± 0.3 sec vs. 14.4 ± 0.3
sec, young vs. aged, p<0.0001), and the average uptake rate was significantly
slower in the aged monkey (18.5 ± 0.6 µM Glu/sec vs. 7.1 ± 0.6 µM Glu/sec,
young vs. aged, p<0.0001).

Potassium-Evoked Glu Signals in the Frontal Cortex
Glu signals with fast release and uptake kinetics were also observed in the
young monkey frontal cortex but not in the aged monkey. These signals differed
from the Glu signals that were recorded in the monkey motor cortex and in the rat
cortex primarily with respect to size. Low amplitude Glu signals (1.8 ± 0.2 µM
Glu, n=18) in the young monkey frontal cortex were recorded at an average
potassium dose (152.8 ± 14.7 nl) that typically evokes robust Glu release and
uptake. These signals rose to peak amplitude in 2.2 ± 0.1 seconds but lasted
only 7.7 ± 1.2 seconds. Overall, most potassium-evoked Glu signals in the
monkey frontal cortex were atypical low amplitude, slow release, slow uptake
signals (young: n=6, aged: n=40). Figure 5.8 demonstrates that this population of
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Figure 5.6 Glu Ejections in the Motor Cortex
Ejections of 5 mM Glu (black arrows) were volume-adjusted to produce Glu
signals of similar amplitudes for comparison. The top trace (blue) shows
recorded ejections of 50 nl of Glu in the young monkey motor cortex while the
bottom trace (red) shows Glu ejections in the same brain region of the aged
monkey. Much larger volumes of Glu solution (550, 525, 550 nl) were needed in
the aged animal to achieve amplitudes between 50 and 100 µM. Increased time
for signal decay and decreased uptake rate are also apparent in the aged animal.
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Figure 5.7 Measures of Glu Ejections in the Motor Cortex
A) Glu ejection-produced Glu signals in the motor cortex were amplitudematched for comparison. B) Volumes of 5 mM Glu approximately ten times those
used in the young monkey were required to achieve the same amplitudes
(p<0.0001). C) The time from peak amplitude until 80% Glu signal decay was
significantly increased in the aged monkey (p<0.0001). D) At similar average
amplitudes, the average uptake rate was significantly decreased in the aged
monkey (p<0.0001).
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Figure 5.8 Potassium-Evoked Glu Signals in the Frontal Cortex
We observed unusually slow potassium-evoked Glu signaling in the frontal
cortex. These signals were seen at one depth in the young animal (top trace
(blue), 175 and 50 nl ejections marked with arrows). Slow evoked Glu signals
were seen at all depths in the aged animal (bottom trace (red), 250 nl ejections
marked by arrows).
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Glu signals achieved average amplitudes of 1.5 ± 0.6 µM Glu and 1.3 ± 0.2 µM
Glu (young vs. aged, N.S.), rose to peak amplitude very slowly (39.0 ± 6.5 sec
vs. 22.8 ± 1.7 sec, young vs. aged, p<0.01), and decayed very slowly (young vs.
aged, average T80: 99.3 ± 13.7 sec vs. 37.8 ± 2.1 sec, p<0.05; average uptake
rate: 0.0038 ± 0.0008 µM Glu/sec vs. 0.0098 ± 0.0028 µM Glu/sec, p<0.05). The
volumes of potassium used to stimulate these signals did not significantly differ
between the differently aged monkeys.

Glu Ejections in the Frontal Cortex
We adjusted volumes of Glu ejections in the frontal cortex to produce Glu
signals (young: n=30, aged: n=30) that were amplitude-matched (107.8 ± 7.4 µM
Glu vs. 109.3 ± 6.3 µM Glu, young vs. aged, N.S.) (Figures 5.9 and 5.10). On
average these signals were very similar in the young and aged monkeys (rise
times: 2.7 ± 0.2 vs. 2.2 ± 0.1, p<0.05, T80’s: 9.9 ± 0.5 vs. 11.3 ± 0.5, N.S.).
Average uptake rates were also nearly identical (19.8 ± 2.2 µM Glu/sec vs. 20.6
± 1.6 µM Glu/sec, young vs. aged, N.S.). However, as we had previously
observed in the motor cortex, the aged monkey required much larger volumes of
5 mM Glu to achieve the same amplitudes (46.7 ± 2.3 nl vs. 413.3 ± 37.9 nl,
young vs. aged, p<0.0001), and the amp/nl significantly differed (2.4 ± 0.2 µM
Glu/nl vs. 0.3 ± 0.04 µM Glu/nl, young vs. aged, p<0.0001).

Basal Glu Measures
Basal Glu measures were made at three depths in the motor cortex (n=6
for each monkey) and five depths in the frontal cortex (n=10 for each monkey) in
both the young and aged monkey. Average basal Glu measures in the young
monkey tended to be larger than those in the aged monkey in the motor cortex
(5.3 ± 1.8 µM Glu vs. 0.7 ± 0.2 µM Glu, N.S.) and were significantly larger in the
frontal cortex (10.3 ± 3.3 µM Glu vs. 2.7 ± 0.5 µM Glu, p<0.05). Significantly
larger average basal Glu measures in the young monkey’s frontal cortex resulted
in part due to extraordinarily large basal Glu measures (Figure 5.11) at two
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Figure 5.9 Glu Ejections in the Frontal Cortex
Adjusted volumes of 5 mM Glu were ejected in the monkey frontal cortex (black
arrows) to produce similar Glu signals for comparison. Glu signals in the aged
animal (bottom trace (red), 550, 525, 525) required larger volumes than the
young animal (top trace (blue), 50, 50, 25 nl). Note that the signals have very
similar release and uptake characteristics.

117

A.

B.
120
100
80
60
40
20

400
300
200
100

0

0
Young

Aged

C.

Young

Aged

D.
Uptake Rate (µM Glu/sec)

14
12
10
T80 (sec)

***

500
Volume (nl of 5 mM Glu)

Amplitude (µM Glu)

140

8
6
4
2
0
Young

Aged

25
20
15
10
5
0
Young

Aged

Figure 5.10 Measures of Glu Ejections in the Frontal Cortex
A) Glu ejections in the monkey frontal cortex produced Glu signals that were
amplitude-matched. B) The aged animal required nearly ten times the volume of
5 mM Glu to achieve similar amplitudes (p<0.0001). C) and D) Measures of Glu
uptake did not significantly differ.
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Figure 5.11 Novel Basal Glu Activity in the Frontal Cortex
(Figure legend on the following page)
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Figure 5.11 (continued)
Microelectrode arrays configured for recording Glu in self-referencing mode were
used in these studies. Each graph shows the apparent Glu concentrations from
the paired channel traces (enzyme-coated (top-most trace, colored solid line) and
enzyme-free (middle trace, colored dashed line)) which were subtracted to
quantify basal Glu levels (bottom trace, solid black line). Black arrows indicate
lowering the microelectrode array to a new depth. A) Upon lowering to -2.25 mm
(DV) in a young monkey’s frontal cortex, we passively recorded a robust rise in
basal Glu levels which leveled and oscillated around an average measure of 13.4
µM Glu over 3 minutes and 20 seconds. This activity disappeared when the
microelectrode array was lowered to the next depth (not shown). B) When we
lowered to a depth of -1.25 mm (DV) in an aged monkey’s frontal cortex, we
passively recorded a dramatic increase in basal Glu levels which irregularly
oscillated around an average measure of 44.4 µM Glu over 5 minutes. Once
again, this activity was not observed at the next depth.
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depths in this animal. Figure 5.11A shows an example of such measurements
from the frontal cortex of the young monkey. As stated previously, Glu signals in
a second aged animal were recorded. In this animal, we observed extraordinary
basal Glu activity at two depths in a brain region that was visually confirmed to be
the frontal cortex on post-mortem examination. Figure 5.11B shows an example
of this novel basal Glu finding from an aged monkey. We observed dynamic
basal Glu activity with oscillatory behavior in the frontal cortex of both a young
and an aged rhesus macaque. Such activity has never been observed in the rat
brain.

Discussion

We successfully achieved our goal of applying our Glu detection
technology in a higher mammalian species in an operating room setting. This
would not have been possible without a professional team effort and careful
planning based on the collective expertise of all involved. The rhesus monkey
handling team, surgery team, and veterinary technicians were experienced and
prepared to fulfill their responsibilities, so that the primary obstacles fell on the
Glu recording team. Our main challenges were developing a mobile recording
and experimental setup and modifying our methodologies so that both would be
compatible with operating room conditions. Creating the mobile FAST-16 was
simplified by the compact design and limited number of hardware elements
required to conduct electrochemical recordings. A dry run was made from our
laboratory to the veterinary operating room and back to assess the security of the
components and the effects of movement vibrations on our connections. At the
end of this run, the FAST-16 system was tested and performed without error.
Once in the OR, all the mobile setup needed was electrical power and a nitrogen
supply for our pressure-ejection system. Fortunately, modern operating rooms
have central vacuum and gas supplies with wall spigots in the individual surgical
suites. We simply had to transport a nitrogen tank to the central tank room one
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time in advance and develop a custom-made coupling to gain control over our
supply of pressurized nitrogen for all experiments. This was an important
challenge to overcome because transporting a nitrogen tank to the surgical suite
and securing it in the room for each experiment would be a laborious, timeconsuming, and possibly dangerous task.
In addition to these advanced preparations, we also modified our methods
to progress in a timely and logical fashion and adapted them for chronic animal
use in a sterile OR setting. Potentially time-intensive elements such as
micropipette attachments were performed the day before an experiment, and
calibrations were started hours before the scheduled OR time to ensure that we
had good functioning Glu recording devices prior to animal retrieval. We
increased the number of prepared microelectrode arrays per experiment from
two to four also for this reason and to have backups in case of accidental
damage or other unforeseen problems. We also modified our Ag/AgCl reference
electrode implantation protocol for the safety of the rhesus monkey because
prolonged exposure to bare wire Ag/AgCl reference electrodes can damage brain
tissue. The use of bare wire Ag/AgCl reference electrodes is highly acceptable
for acute animal studies, but might be inappropriate for chronic animal use,
especially when we have a good previously-tested alternative (see Gerhardt et
al., 1995, Cass et al., 1995). We were able to implant the glass-bodied reference
electrode under a saline-irrigated skin flap because the Ag/AgCl reference
electrode works as long as it remains in ionic contact with the brain. The sterilely
gowned and gloved surgery team handled the reference electrode by holding the
non-sterile end with sterile gauze and rinsing the implanted portion with 70%
isopropyl alcohol which was allowed to dry before making contact with the
exposed monkey tissue. Sterilizing the implanted microelectrode arrays remains
a challenge because both commonly-used heat and gas sterilization techniques
disrupt the layered coatings that make the recording sites selective for Glu. It is
common practice to use small, clean but non-sterile, implantable devices, such
as microdialysis probes and carbon-fiber microelectrodes, in animal research
including chronic nonhuman primate studies. Standard veterinary protocols
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already include prophylactic antibiotics following surgery in a chronically-used
large animal. Neither of the recovered monkeys developed a post-experimental
brain infection or any other poor outcome, so we feel confident that our
techniques are safe. Nonetheless, we continue to research ways to sterilize our
microelectrode arrays without compromising performance.
We

applied

this

technology

to

a

pilot

study

of

normal

Glu

neurotransmission in the cerebral cortex of young and aged rhesus monkeys in a
sterile field operating room setting. Most importantly, we were able to assemble
collaborative teams of experts and modify our methods successfully to conduct
Glu recordings in the intact brain of monkeys in a safe and efficient manner. This
was our primary goal and achieving it creates opportunities for many important
future studies using this technology in nonhuman primates and/or the operating
room setting. We observed Glu signaling that was both very familiar and very
different from our experiences with Glu regulation in the rat brain. These facts
validate our research in lower mammals while also highlighting the need to
advance this technology into higher mammals to improve our studies’ relevance
to human conditions. All Glu measures were compared between one young and
one aged animal. The low number of animals per age group and the lack of a
middle-aged group limit the contributions of this study to aging research.
Nonetheless, we were able to detect significant differences in Glu regulation in
two cortical areas from individual monkeys of different ages. These results
support that alterations in Glu regulation likely occur with aging, as has
previously been reported in recent rat studies (Nickell et al., 2005); thus, a larger
study is merited.
If the monkeys used in this study prove to be representative of their age
groups, significant age-related alterations occur in Glu release and uptake
mechanisms which affect evoked and basal Glu regulation. Within the motor
cortex, we observed some of the most familiar evoked Glu signaling to our
experiences with potassium-evoked Glu regulation from the young rat cortex. In
particular, average potassium-evoked Glu signals in the young monkey motor
cortex rose to peak amplitude in ~2 seconds and lasted ~16 seconds. This
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compares well with our 70 mM potassium-evoked signaling from the rat brain
which rose to peak amplitude in 1-2 seconds and lasted 10-20 seconds (see
Chapter Three). The same stimulations in the aged monkey motor cortex
produced signals that closely matched these times. Larger signal amplitudes in
the aged monkey represent the primary difference between the two animals.
Higher amplitudes without significant differences in Glu transporter function (i.e.
non-significant difference in T80’s) drove the significant increases that we
observed in the uptake rate. The measures support that we were observing a
difference in Glu release while uptake was unchanged at the low Glu release
levels. We cannot, however, attribute this change solely to differences in age
because the potassium doses were also significantly higher in the aged monkey
motor cortex. We have previously observed a limited dose-response to
increasing potassium volumes in the young (see Burmeister et al., 2002) and
aged rat brain (unpublished data); thus, the higher amplitudes in the aged animal
may simply be due to higher depolarizing stimulations.
While we could not detect significant differences in the Glu uptake system
by studying low volume 70 mM potassium-evoked Glu signals, highly significant
uptake changes were evidenced by the recordings of 5 mM Glu ejections. We
adjusted the ejected volumes to match Glu signal amplitudes in a targeted range
to better compare signal parameters, especially measures of the Glu uptake
system (e.g. T80 and uptake rate). While uptake rate can reflect changes in Glu
release or uptake (see above, Chapter Two Data Analysis, and Chapter Four
Discussion), it is mainly reflective of the Glu uptake system when signals have
the same amplitudes. The higher volumes of 5 mM Glu that were needed to
produce target amplitudes in the aged monkey can be explained in at least two
ways. First, there may be increased uptake in the aged monkey because more of
the ejected Glu was being cleared from the extracellular space in the 50-100 µm
distance between the micropipette tip and the microelectrode array recording
sites. Second, there may be an age-related change in the excitability of Glu fibers
(i.e. a change in the level of exogenous Glu-induced endogenous Glu release).
Further analysis of our signals shows that Glu uptake-related signal parameters
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in the aged monkey (longer T80 and decreased uptake rate) support a decrease
in Glu uptake. Recently, a series of studies in young (6 month old), late middleaged (18 month old), and aged (24 month old) rats have expanded our
understanding of age-related changes in the mammalian Glu system. Consistent
with our pilot work in monkeys, Nickell et al. (2005) showed that, in the aged rat
brain, greater volumes of 5 mM Glu were required to produce amplitude-matched
signals, and there was a decrease in the average uptake rate compared to
younger rats. Additional Western blots analyses were completed to examine the
amount and surface expression of rat Glu transporters (GLAST and GLT-1 (glial)
and EAAC1 (neuronal)), which revealed that there were no age-related changes
in total protein levels; however, the surface expression of GLAST was
significantly decreased in the late middle-aged and aged rats. Thus, although
gliosis (an increased number of glial cells, such as astrocytes that account for
most of Glu uptake) has been reported in the aged mammalian brain (Unger,
1998), data in rats support an age-related decrease in the number of Glu
transporters available for Glu uptake. This may explain the decreased uptake
rate seen in both the aged rat and monkey. Furthermore, there is no supporting
evidence to conclude that increased uptake accounted for the increased volumes
of 5 mM Glu needed to produce amplitude-matched signals in either the aged rat
or monkey brain. Instead, this may reflect an age-related decrease in the
excitability of Glu terminals.
We also recorded potassium-evoked Glu signals in the monkey frontal
cortex, yet many of the characteristics of these signals differed from the typical
evoked Glu kinetics that we observed in the motor cortex. First, we evoked both
fast and relatively slow Glu signals in the young monkey, while only slower Glu
signals were seen in the aged monkey. The fast Glu signaling differed from our
typical signals primarily with respect to amplitude. It is interesting to consider that
we also recorded extraordinarily high basal Glu activity in this brain region, which
may have been tonically activating presynaptic metabotropic Glu autoreceptors
that inhibit Glu release. This may explain the reduction in amplitude and
decreased signal times. That we did not see fast Glu signaling at all in the aged
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monkey may have been due to the age difference; however, this animal was
being maintained at a higher level of anesthesia (3% isoflurane, an induction
level) than the young monkey during these recordings. Isoflurane has been
reported to decrease Glu release and increase Glu uptake in mammals
(Hudspith, 1997, Danbolt, 2001), and the higher dose in the aged animal makes
definitive conclusions difficult. The anesthesia was lowered to a more typical
maintenance level (2%) before additional Glu recordings were made. In both the
young and aged monkey frontal cortex, we also observed unusual Glu signals
which showed reproducible slow release and uptake characteristics. Once again,
the higher basal Glu activity may explain the lowered Glu release but does not
explain the decreased uptake. At least two possibilities can explain the
decreased Glu uptake at these low levels of Glu release. First, the frontal cortex
may be a more susceptible region to the effects of isoflurane on Glu regulation,
which may have also contributed to decreased Glu release, and secondly, we
may be observing novel normal Glu regulation. The complementary Glu ejections
in the frontal cortex do not support that this region has diminished Glu transporter
function. In fact, the Glu uptake rate was roughly equivalent or even higher than
that seen following Glu ejections in the motor cortex. If this region is predisposed
to higher, often oscillatory, basal Glu levels, an increase in extracellular Glu
concentration of ~1-2 µM (average potassium-evoked Glu signal amplitudes
seen in the frontal cortex) may not always elicit the fast uptake responses that we
have previously characterized and may represent a new kind of Glu signaling in
the brain. Interestingly, low level evoked Glu release and uptake was faster
(faster rise times and T80’s) in the aged monkey frontal cortex.
Once more, when we challenged the Glu uptake system with much higher
levels of exogenous Glu ejections, Glu uptake was robust and revealed a
difference in Glu uptake between the young and aged animals. In nearly every
measure, these Glu signals were very closely matched. The most striking
difference was that average volumes of nearly ten times as much 5 mM Glu were
needed to achieve the target amplitudes in the aged monkey, which may again
be explained by an age-related change in glutamatergic excitability (decreased
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Glu-induced Glu release in the aged monkey). Unlike in the motor cortex, the
average uptake rates and T80’s were not different, so that the Glu uptake system
appears to remain functionally unchanged with age in the frontal cortex.
Average basal Glu measures were larger in both cortical regions of the
young monkey compared to the aged monkey. The young monkey measures
showed a statistically significant mean increase in the frontal cortex but only
tended to be larger in the motor cortex despite a large mean difference
(p=0.052). Basal Glu signals were recorded in a second aged monkey in two
brain regions. Extremely high basal Glu measures (43.4 ± 14.9 µM Glu, n=10)
were calculated for a brain region that was identified as the frontal cortex on
post-mortem examination. These levels were much larger than the average
frontal cortical levels from the young monkey and the other aged monkey (10.3 ±
3.3 µM Glu and 2.7 ± 0.5 µM Glu, respectively). Thus, it is difficult to conclude
that there is any age-related change in basal Glu levels in this region, as aged
monkeys individually showed much lower and much higher basal Glu levels in
the frontal cortex than a young monkey. This emphasizes that many of the
comparisons discussed for the various Glu measures so far may not be due to
age differences but simply biological variability between animals. As previously
mentioned, this discussion of age-related differences in Glu regulation assumes
that these animals are representatives of their age groups. This assumption can
only be tested by conducting a much larger study.
Particularly interesting findings in two of the three monkeys were strikingly
increased basal Glu levels at discrete depths within the frontal cortex. Both the
temporal behavior and, in the case of the 28 year-old monkey, the magnitudes of
the average basal Glu measurements (129.2 µM Glu and 44.4 µM Glu, both over
5 minutes) had never been seen before in any Glu recording from a mammalian
brain. As we lowered into these depths, the sentinel recording sites maintained
baseline activities, while the Glu recording sites passively displayed high basal
Glu levels that tended to oscillate over time. The periodicities of these oscillations
were approximately 30 seconds to a minute, time periods much too long to
correspond to other biological or mechanical interferences such as heart rate or
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ventilation. In fact, the aged monkey traces showed a smaller, superimposed
higher-frequency oscillation on both the sentinel and Glu recording channels (see
Figure 5.11B). These fluctuations may reflect the pulse pressure created by a
typical anesthetized rhesus monkey heart rate, which leads us to hypothesize
that, in the case of the aged monkey, we may have been recording basal Glu
levels near a cortical blood vessel. In this animal, the average basal Glu level
dropped in an almost logarithmic fashion as we lowered the microelectrode array
further supporting the hypothesis that we began close to a concentrated source
of Glu and moved away from it. In the young animal, however, we saw neither
the superimposed frequency nor did the level drop in a predictable fashion. Both
depths that showed extraordinary basal Glu activity in the young monkey were
inferior and superior to depths that had much lower basal Glu levels. These new
and exciting findings would not have been possible without the spatial and
temporal resolution that implantable microelectrode arrays provide.
In summary, we achieved our primary goal of safely and efficiently
advancing second-by-second microelectrode array Glu recordings into the
nonhuman primate brain in the veterinary operating room. This began with
careful planning on the parts of several collaborating teams of specialists who
helped recognize the challenges of this task. Specifically, we developed a mobile
Glu recording setup, made several advanced preparations, and adapted our
protocols to maximize the likelihood of executing successful experiments.
Accomplishing our primary goal creates many opportunities for future studies in
nonhuman primates and/or in the OR setting. These efforts were also part of a
pilot study of age-related changes in Glu regulation in the nonhuman primate
cerebral cortex. Although we collected data from only three animals in two age
groups, we were already able to see differences in Glu regulation in differently
aged individual animals. Our Glu recordings in the rhesus monkey cortex
displayed both the fast kinetics that we had previously characterized in the rat
brain and novel potassium-evoked and basal Glu activities. Larger studies are
merited to further explore differences in normal Glu signaling and age-related
alterations in Glu regulation in the nonhuman primate brain.
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Discussion & Conclusions

Our

development

of

ceramic-based

enzyme-coated

multisite

microelectrode arrays that use electrochemical detection to selectively record Glu
levels with high spatial and temporal resolutions (15 x 333 µm, 800 msec)
created an exciting new research tool to examine direct Glu measures in the
intact mammalian CNS. The premier conclusion that emerged from the initial
work using Glu selective microelectrode arrays confirmed that in vivo measures
of extracellular Glu displayed fast kinetics of release and uptake that required a
fast monitoring technology (see Burmeister, Moxon, and Gerhardt, 2000,
Burmeister and Gerhardt, 2001, and Burmeister et al., 2002). The second-bysecond recording capabilities are a distinct advantage of microelectrode array
studies of Glu. In this dissertation, these capabilities were used repeatedly to
investigate the dynamics of Glu release and uptake in the mammalian brain.
However, we also expanded the use of this technology to study basal Glu
regulation including achieving the important task of measuring basal Glu levels.
In addition to technological advancements that expanded and improved our Glu
recording capabilities, we also advanced the biological applications of
microelectrode arrays to complement the initial in vivo recordings in the normal
rat brain and pushed this technology into a rat model of PD and into young and
aged normal rhesus monkeys in the veterinary operating room setting. Ultimately,
as our technology and biological applications progress, we would like to conduct
Glu recordings in the intact human brain in the clinical setting to advance our
scientific understanding of Glu regulation and possibly benefit patient care.
In Chapter Three, we used microelectrode arrays to study basal and
potassium-evoked Glu regulation in the normal anesthetized young rat brain. Glu
kinetics studies had already been performed in the normal rat CNS using both
potassium and Glu ejections; however, the speed and reproducibility of different
concentrations of potassium had not been fully investigated, and no work had
been carried out to explore basal Glu using microelectrode arrays. Our studies in
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the striatum and frontal cortex revealed that TTX lowered while TBOA increased
signals across individual Glu recording channels to significantly different levels
than physiological saline ejections alone, which lowered the signal slightly due to
dilution of the recording area. The TBOA-dependent effects (1-3 µM Glu
increase) support the hypothesis that active Glu release and uptake occurs at a
basal level. The TTX-dependent effects (~2 µM Glu decrease) support the
hypothesis that a significant measurable portion of basal Glu originates from
action potential-dependent neuronal release. To determine what fraction of basal
Glu was TTX-dependent, we had to further develop our technology to quantify
overall basal Glu levels. We developed two methods using the self-referencing
capabilities of our microelectrode arrays. The first method measured baseline
signal differences between pairs of enzyme-coated and enzyme-free channels at
constant applied potential (+0.7 V vs. Ag/AgCl reference). The second was a
varied applied potential method that switched the potential between +0.25 V and
+0.7 V (both vs. Ag/AgCl reference) and measured the differences in voltagedependent signal changes between the same paired channels. We applied these
techniques in the rat striatum and frontal cortex to find that the overall basal Glu
level was ~2 µM Glu in both regions with no significant difference between the
methods. Taken with the previous TTX-saline comparisons, our data support that
basal Glu is fully TTX-dependent in two regions of the urethane-anesthetized rat
brain. Our results compare favorably in concept to another voltammetry-based
investigation of basal Glu (Kulagina, Shankar, and Michael, 1999) except the
magnitude of our TTX-induced signal changes and overall basal Glu levels are
lower. Alternatively, our basal Glu levels are similar to reported microdialysis
measures; however, microdialysis studies do not support greater than 50% TTXdependency of basal Glu levels. These differences may be related to our use of
the anesthetic drug urethane, which may be lowering basal Glu levels and
altering the TTX-dependent fraction. Investigations in the awake, freely-moving
rat in our laboratory to resolve this issue are ongoing. We also investigated 70
mM and 120 mM potassium-evoked Glu signals in the same brain regions and
determined the speed of these signals. Overall, the potassium-evoked signals
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supported robust Glu release and uptake, rising to peak amplitude in 1-4
seconds and lasting 10-20 seconds. The 70 mM potassium-evoked Glu signals
were slightly smaller and faster than 120 mM and were less likely to show any
signs of interference from other electroactive molecules such as the
neurotransmitter DA. All potassium-evoked signals were routinely reproducible at
20 seconds intervals and remained distinct at intervals as short as 15 seconds.
These results are comparable to earlier studies of potassium-evoked Glu release
using similar technology (Hu et al., 1994), especially with respect to the fast
kinetics of Glu release and uptake. Finally, we responded to one of the most
common criticisms of microelectrode-based detection systems, signal identity. To
address this issue, we recorded potassium-evoked Glu responses in a selfreferencing mode to demonstrate that our evoked signals were both enzymeand voltage-dependent, further confirming that the major source of our evoked
signals is Glu.
In Chapter Four, we built on our previous investigations of normal Glu to
advance this technology to study a rat model of PD. In the last decade, PD has
been reexamined as a disease of secondary Glu hyperactivity along pathways
related

to

the

disease-altered

involuntary

motor

system,

namely

the

glutamatergic corticostriatal and subthalamopallidal pathways. Conducting
microelectrode array studies in the brains of unilateral 6-OHDA-lesioned young
rats, we focused on the corticostriatal pathway, recording in both the striatum and
frontal cortex. We also examined evoked Glu signaling in the nucleus
accumbens, a brain area that is cellularly organized almost identically to the
striatum but receives DA primarily from a different area of the midbrain. Like
many investigators, we used the unilateral lesioned rat model so that we could
make comparisons to the contralateral side as a within-animal control. We also
recorded non-lesioned rats in the same age range as another control group. Our
hypotheses entering the study were that there would be ipsilateral and
contralateral differences in evoked Glu kinetics within the 6-OHDA-lesioned
group and that evoked Glu kinetics would differ between matched hemispheres
of lesioned and non-lesioned rats. Potassium ejections (45 mM KCl, ~300 nl)
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were used to stimulate Glu signals in all animals. At the end of the recording
sessions, we used roughly ten times higher potassium stimulation in the striatum
to record simultaneous Glu and DA release to further confirm the unilateral lesion
status of the 6-OHDA-treated animals. In the striatum and frontal cortex, there
were no significant differences in any of the reported average signal parameters
(amplitude, uptake rate, T80) between hemispheres within the unilaterally
lesioned group; however, Glu signal measures were significantly altered in both
lesioned hemispheres compared to matched hemispheres in non-lesioned rats.
Taken together, we observed a striking bilateral effect of a unilateral lesion on
Glu signaling in the striatum and frontal cortex. Closer examination of the signal
parameters supported that the primary difference in lesioned rats was increased
Glu release on stimulation. In the normal rat striatum, DA release tends to inhibit
Glu release through D2-like receptors on the presynaptic Glu nerve terminals. In
the DA denervated striatum on the ipsilateral side, the presynaptic Glu terminals
may be disinhibited so that they release more Glu when evoked. In the DA
innervated striatum on the contralateral side, the same disinhibition cannot occur
because DA is present; however, an increased DA compensation on this side, as
previously reported (Nieoullon et al., 1977, Cass et al., 1995), might internalize
some DA receptors and cause a functional disinhibition of Glu release.
Alternatively, a distinct bilateral corticostriatal pathway has been reported (Reiner
et al., 2003, Lei et al., 2004), which may play a role in sychronizing events
between the ipsilateral and contralateral striatum due to bilateral connectivity
through the cortex. In fact, bilaterally increased potassium-evoked Glu release in
the frontal cortex was also measured in the unilateral lesioned rat group. These
findings may result from the downstream effects of lesioning the nigrostriatal
pathway as the cortex is known to be involved in parkinsonian motor
abnormalities. Again, the bilateral effects may relate to the high connectivity of
the cortex to the striatum and to other cortical areas within both hemispheres. In
the nucleus accumbens, we measured significant differences in evoked Glu
signaling within the lesioned rat group; however, we also found compelling
evidence for normal hemispheric differences within the non-lesioned rat group
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that may have reflected greater difficulties in microelectrode array placement in
this brain region. Restricting our discussion to hemisphere-matched comparisons
between lesioned and non-lesioned rats, the increased evoked Glu release was
maintained in the ipsilateral nucleus accumbens; however, there was also a
significant increase in Glu uptake. In the contralateral nucleus accumbens, there
was no significant effect of lesion on evoked Glu measures except for a slight but
significant decrease in Glu uptake. Interestingly, DA depletion to the nucleus
accumbens is relatively spared following 6-OHDA treatment (Lancia et al., 2004),
which may have contributed to some of the differences that we measured
compared to similar brain areas like the striatum. Overall, this work puts the use
of the contralateral side in the unilateral 6-OHDA-lesioned rat as a control into
question for some measures, as we would not have recognized any difference in
evoked Glu kinetics in the striatum and frontal cortex of lesioned animals without
another control group. Furthermore, the effects that we measured in both
hemispheres in lesioned rats place the cortex and the neurotransmitter Glu as
prime candidates for modulating bilateral effects of unilateral treatments,
including 6-OHDA-lesions and possibly PD therapies.
In Chapter Five, we returned to investigating normal Glu regulation by
advancing our technology to study both young and aged rhesus monkeys. Our
primary goal was to modify our technology and methods to safely and efficiently
conduct nonhuman primate Glu recordings in the veterinary operating room. We
also wanted to compare characteristics of normal Glu regulation between our
initial rat work and the higher mammalian species, determine if there were
regional changes within the monkey cortex, and collect preliminary data to
evaluate whether there were age-related differences in Glu regulation.
Accomplishing our primary goal began with extensive planning between the
collaborating teams and a number of modifications to our standard Glu recording
approach.

First,

we

created

the

mobile

FAST-16,

a

self-contained

electrochemical recording system that could be easily moved between the
laboratory and operating room with minimal setup requirements. In advance, we
supplied the surgical facilities with pressurized nitrogen and created a custom-
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made coupling so that our pressure-ejection system would be compatible with
typical OR gas supply lines. We also modified our experimental preparations to
conform to the timeline of nonhuman primate surgery and improve our chances
for successful Glu recordings. First, we increased the number of microelectrode
arrays prepared per animal from two to four. Then, we moved time-intensive
steps such as micropipette attachment to the day before surgery. Finally, we
calibrated the microelectrode arrays several hours before surgery to evaluate
their quality prior to the start of pre-surgical monkey preparation. We did this so
that, if necessary, the experiment could be cancelled in a timely manner to avoid
inefficient animal use. With these new methods in place, we successfully
recorded Glu signals in three rhesus monkeys (8, 25, and 28 YO) with no
experiments cancelled. We measured basal Glu levels and studied Glu signals
resulting from local ejections of 70 mM potassium and 5 mM Glu solutions. In the
motor cortex of all monkeys, we observed the fast kinetics of Glu release and
uptake that we had previously characterized in the rat brain. Fast Glu uptake was
also seen in the frontal cortex of all monkeys following exogenous Glu challenge;
however, potassium-evoked Glu responses were unusual in this brain region. All
potassium-evoked signals were low amplitude (<2 µM Glu), and both fast (young
monkey) and slow (both young and aged monkey) Glu release and uptake
kinetics were recorded. Interestingly, novel basal Glu activity was also observed
in this brain region in both a young and an aged monkey, which might contribute
to some of the atypical release and uptake characteristics. The average basal
Glu levels in the isoflurane-anesthetized monkeys were higher in the frontal
cortex than those we have measured in the urethane-anesthetized rat frontal
cortex, and both species and anesthetic changes may play a role in these
differences. More strikingly, average basal Glu levels at discrete depths were
often very high (~10-120 µM Glu) and displayed dynamic oscillatory behavior.
These basal Glu magnitudes and activities had never before been recorded in
the anesthetized mammalian brain. The primary age-related difference that we
observed was related to Glu uptake. In both cortical regions, we had to deliver
roughly ten times the volume of 5 mM Glu in the aged monkey to match the
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amplitudes we achieved in the young monkey. This may be due to an age-related
decrease in the excitability of Glu fibers in the monkey cortex. We also saw an
age-related decrease in uptake rate in the motor cortex. The low number of
animals per group limits the relevance of these findings to aging research;
however, we already have data supporting differences in Glu regulation in young
and aged individual monkeys, and a larger study is merited.
Overall, we have made good progress to both advance and refine the
technology and expand its biological applications to better study Glu in the
mammalian brain. Beginning with the characteration of basal and potassiumevoked Glu regulation in the anesthetized rat brain, we moved the technology
forward to study disease-altered Glu regulation in the hemiparkinsonian rat brain
and normal Glu neurotransmission in young and aged rhesus monkeys. Based
on our experiences to date, we would like to continue pushing our technology
forward to record Glu in the intact human brain. This dissertation began by
introducing the idea that using implantable microelectrode arrays to advance
science and medicine is neither science-fiction nor radical, but potentially a
common and valuable tool that might be used by physicians to improve patient
care. The appendix documents our first experience with excised human brain
tissue and how we might logically proceed to introduce Glu selective
microelectrode arrays into clinical applications.
Copyright © Brian Keith Day 2005
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Appendix: Investigating Glu Neurotransmission in the Human Brain

Introduction

Throughout the graduate studies of my combined M.D./Ph.D. training, I
have been especially interested in advancing our technology toward clinical
applications. Because the initial use of microelectrode arrays to study normal Glu
dynamics in the intact rat brain shortly predated the start of my dissertation
research, my role in this effort began at the benchside. Though we had published
data supporting the rapid nature of extracellular Glu signaling, many aspects of
Glu neurotransmission required further investigation. In response, I conducted
several additional studies of normal Glu regulation in the rat brain, focusing on
both basal and potassium-evoked measures. Building on these studies, we also
investigated Glu signaling alterations in the unilateral 6-OHDA-lesioned rat model
of PD. Together, these acute investigations provided biological, methodological,
and analytical bases for moving our technology into chronically-used nonhuman
primates in the veterinary operating room. This effort represented a logical step
in the advancement of our technology toward human applications and an
important opportunity for us to begin modifying our methods to transition into a
clinically-relevant setting. In a parallel fashion, actual human brain tissue
recordings have begun at the benchside, and hopefully they will ultimately be
applied in the clinical arena to benefit patient care.

Preliminary Human Tissue Study

In collaboration with neurosurgeon Craig van Horne M.D., Ph.D. and his
laboratory team at the Harvard Institutes of Medicine (HIM, Boston, MA), we
attempted to record Glu from a piece of excised human brain tissue. We began
working toward this goal in the Spring of 2003 when I traveled to the Brigham
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Hospital and the HIM to deliver, set up, and test his FAST-16 electrochemical
detection system. During this trip, I also supplied his laboratory with many of the
materials and equipment necessary to conduct independent microelectrode array
studies and trained his staff. With these basic requirements satisfied, we allowed
time for our partners to become proficient with the technology, and set up
additional training for a new member of Dr. van Horne’s team here at the
University of Kentucky later that year. I spent one more week in Boston during
the Spring of 2004, and we recorded signals from a small piece of freshlyexcised human brain provided by Dr. van Horne.
Our goal was simply to prove that we could record Glu from a surgically
resected piece of human brain tissue. At the same time, we wanted to plan ways
to refine our excised human tissue methods to conduct safe and efficient Glu
recordings in the future. Several refinements are needed as we faced many
challenges from the onset of this first effort. Our equipment was primarily limited
to the basic FAST-16 recording setup and a brain slice recording chamber. We
did not have timely access to oxygenation, perfusion, or heating systems for the
chamber. The resected brain tissue had to be evaluated by the Pathology
Department before it was released for further testing. Furthermore, the physical
dimensions of the tissue also presented a problem for implantation-based Glu
recordings.
To overcome these limitations, we had to adapt new ways to conduct the
experiment and stimulate detectable Glu release. Microelectrode arrays
configured for recording Glu on all sites were calibrated beforehand. We could
not implant a microelectrode array due to the size and shape of the brain tissue.
Instead the brain tissue was removed from ice storage and floated in a pool of
0.05 M PBS in the central reservoir of the recording chamber at room
temperature. The microelectrode array was lowered into the saline pool at a
shallow angle, and recordings were begun. Using microforceps, the brain tissue
was gently moved toward the microelectrode until it rested atop all four recording
sites (see Figure A.1). To stimulate endogenous Glu release from the tissue, we
applied small drops of a 120 mM potassium solution (120 mM
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Figure A.1 Recording Setup for Our First Experience with Excised Human
Brain Tissue
Our basic setup included the FAST-16 recording system and a brain slice
recording chamber. The inset photographs show the relationship of the
microelectrode array and tissue before (left) and after (right) positioning the
tissue onto the recording sites. The four platinum recording sites are clearly
visible in the left inset picture.
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KCl, 29 mM NaCl, 2.5 mM CaCl2y2H2O, pH 7.4) directly onto the tissue using a
pipettor. Because the microelectrode arrays were not configured for selfreferencing Glu recordings, we could not assess steady-state Glu levels.
These simple manipulations gave us the following results. Figures A.2 and
A.3 demonstrate that when we moved the tissue onto the Glu recording sites
(white arrows), we recorded signal increases on all four channels. Figure A.3
also shows the recorded responses to high potassium applications (black
arrows). The initial potassium application created prolonged signal increases on
all four channels, while a second application had diminished or virtually no effect
on the recorded signals. The final application floated the tissue off of the
recording sites, and we observed universal signal decreases.
Unfortunately, at this point, we cannot definitively conclude that we
achieved our goal of recording Glu from an excised piece of human brain tissue.
This is primarily because we were not able to use microelectrode arrays
configured to record Glu in a self-referencing mode for this experiment. Without
evidence that our signal changes were not due to interfering neurochemicals, we
simply cannot be sure that our results were wholely or partially due to
endogenous Glu release. Whereas monitoring interferences is routinely
beneficial, it is especially important when attempting to record from a piece of
traumatized brain tissue that may be releasing chemicals that do not normally
exist in the extracellular fluid at such high concentrations. Nonetheless, the
behavior of the signals in response to our manipulations might be consistent with
spontaneous (initial tissue contact) and evoked (potassium-driven depolarization)
Glu releases, and we are hopeful that with appropriate modifications we will
succeed in definitively recording Glu from human brain tissue. Ultimately, this
experiment was an important opportunity to identify difficulties associated with
excised human tissue recordings so that we can design better future studies.
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Figure A.2 Initial Contact of the Excised Human Brain Tissue with the
Microelectrode Array
Immediately upon contact between the excised human brain tissue and the
microelectrode array (white arrow), we observed dramatic signal increases on all
four channels. The signals immediately began to approach steady levels, and
remained higher than pre-contact levels after several minutes of recording. If
these changes in signal are due to Glu detection, a 0.1 nA change in signal is
approximately equal to 17.3 µM change in Glu concentration according to the
calibration slopes for the microelectrode array used in these recordings. The
traces have been offset from one another for clarity.
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Figure A.3 Potassium-Evoked Signals from Excised Human Brain Tissue
(Figure legend on the following page)
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Figure A.3 (continued)
A) As we previously observed, all four channels displayed signal increases upon
contact between the tissue and the recording sites (white arrow). Individual
differences in response may be due to the fact that each recording site is
contacting a different part of the brain tissue’s surface. The signals were allowed
to equilibrate for a few minutes before applications of a 120 mM potassium
solution were made directly onto the tissue (black arrows). The third application
disrupted the seal between the array and the tissue, and all signals decreased
uniformly. B) A closer look at the first and second potassium applications is
shown. We observed signal increases on some of the channels in response to
depolarizing stimuli, especially following the first application. If these signals are
due to Glu release, a 0.02 nA change in current is roughly equal to a 3.5 µM
change in Glu according to the calibration slopes for the microelectrode array
used in the experiment. The traces have been offset from one another for clarity.
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Future Patient-Oriented Research

Our initial attempt to record Glu from a piece of excised human brain
tissue represents the first of a series of steps that we may have to take to
introduce our microelectrode-based Glu detection technology into the clinical
setting. Our rationale unfolds in the following way. First, we would like to prove
that we can record Glu from human brain tissue. Of course, the safest tissue to
use is excised human brain tissue that has been removed by a neurosurgeon for
a medically prescribed reason. Epileptogenic foci and brain tumors are often
removed as surgical treatments of some forms of epilepsy and cancer. Once we
have satisfactorily proven that we can record Glu from human brain tissue, the
next step would be to target intact brain tissue. Once again, both epileptics and
brain tumor patients scheduled for resections would be good candidates for our
patient population. In fact, we would record the same type of brain tissue as
previously described; however, we would conduct intraoperative recordings
before the tissue was removed. During these studies, we would characterize Glu
activity

in

abnormal

brain

tissue.

Once

we

have

demonstrated

that

microelectrode arrays can be used in a safe and efficient manner during
neurosurgery, we would like to design similar intraoperative studies to
characterize Glu regulation in normal brain tissue. The normal brain regions that
we sample would not be removed following our recordings. Ultimately, we would
have preliminary data to compare normal and abnormal Glu measures for each
brain disorder so that we could use to propose larger studies. Furthermore, Glu
measures might correlate with disease parameters so that our Glu detection
technology could have an apparent therapeutical use.

Excised Abnormal Human Brain Tissue Recordings
In future attempts to record Glu from a piece of excised human brain
tissue, we would benefit from gaining additional control over the tissue. Ideally,
our methods would closely resemble those used for brain slice recordings. Our
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first goal would be accessing adequate volumes of brain tissue in a timely
manner. The size of the excised tissue should be large enough that it can be
sliced very thinly (300-400 µm thick) either immediately after resection in the
surgical suite using a McIllwain tissue chopper or soon thereafter using brain
sectioning equipment in the recording laboratory. The tissue sample should also
be large enough so that the other physical dimensions provide substantial mass
for the ceramic tip of our microelectrode array to be implanted through the slice
without fracturing it. One cm3 blocks of resected brain tissue are standardly
reported by groups who study human neocortical slices both in Europe and the
United States (Burkhart et al., 1998, Gorji et al., 2002). Timing between removal
of brain tissue and oxygenation is important to maintaining living cells within the
slice. Research groups who study human neocortical slices often report
preincubation procedures beginning within two to five minutes of resection.
Depending on the nature of the excised tissue or the standard operating
procedures of the medical center, the removed brain tissue may need to be
evaluated by the Pathology department before it can be prepared for slice
recordings. With proper approval by the Institutional Review Board and likely the
informed consent of the patients, all or a portion of the resected brain tissue may
bypass this step and immediately be entered into a research protocol.
The brain tissue slices would then be placed in oxygenated (95% O2, 5%
CO2) artificial cerebrospinal fluid (aCSF, in mM: 124 NaCl, 5 KCl, 1.5 MgCl2. 2.5
CaCl2, 1.4 NaH2PO4, 10 D-glucose, 26 NaHCO3, pH 7.3-7.4) and allowed to
recover for 1-2 hours. Thereafter, a section would be placed in a recording
chamber warmed to 32-34 °C and perfused with oxygenated aCSF.
Microelectrode arrays configured for self-referencing Glu recordings would be
prepared and calibrated beforehand. A prepared microelectrode array or
microelectrode/micropipette assembly would be lowered by micromanipulator
until the recording sites were positioned within the slice. Basal Glu levels could
be monitored as previously described. Endogenous Glu release could be
stimulated by local application (Picospritzer III via micropipette) or recording
chamber perfusion (Minipuls 3 peristaltic pump, Gilson Inc., Middleton, WI) of an
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appropriate high potassium solution. Volumes of 5 mM Glu could also be ejected
by micropipette to further study the Glu uptake system. At this level of control, we
would not only maximize our chances of successfully and definitively recording
Glu from excised human brain tissue, but also have an opportunity to begin
characterizing the human neocortical Glu system.

Intact Human Brain Tissue Recordings
After we accomplish Glu recordings from excised human brain, the next
step is to move the recordings from the laboratory to the neurosurgical suite
where we can record Glu from an intact human brain. We would enroll patients
with brain disorders, such as medically refractory epileptics, who are being
surgically treated by having a section of their brains removed. Risks to the patient
would be minimized primarily to increased surgical and anesthetic time, as we
will only record Glu from abnormal tissue targeted for resection. In some ways,
the methodology becomes much simpler for these recordings because we do not
have to handle the tissue and artificially keep it alive, oxygenated, or warmed.
Furthermore, concerns about alterations in the chemical composition of the
extracellular fluid or changes in Glu regulation created by disrupting axonal
connections, tissue trauma, and secondary injury are highly reduced.
Many of our primary goals to establish Glu recordings in the intact human
brain are similar to those we set during the transition to Glu recordings in the
brains of chronically-used nonhuman primates (see Chapter Five). Basically we
need to modify our technology and methodology to safely and efficiently record
Glu in the human neurosurgical operating room setting. We started to understand
the challenges of this task first-hand as part of my experiences at the Brigham
hospital. I was allowed to accompany Dr. van Horne to one of his cases and
study the physical layout of a standard neurosurgical suite, learn about some of
the equipment and technology that already exist in the OR, and observe the work
dynamics among the scrub nurses, anesthesiologists, and surgeons. This
experience provided an opportunity to envision conducting Glu recordings in this
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setting, specifically to imagine the logical progression of events before, during,
and after the surgery and to identify the specific challenges of this endeavor.
The intraoperative recording session would be straightforward, and the
major changes would be hardware modifications. Specifically, we need to create
a more sophisticated version of the mobile FAST-16 (see Chapter Five) in which
the computer and FAST-16 components would be efficiently housed and
protected within a stable, mobile tower. All of the sensitive components including
the cable connections would be behind a locked panel, and an outside user
would only be able to access the computer power button, keyboard, mouse,
monitor, and data ports, and the face of the FAST-16 potentiostat box. To protect
the sterile field environment and avoid unnecessarily obstructing the walking
workspace of the surgical suite staff, we would also need to lengthen our cable
that connects the headstage (pre-amplifier) with the FAST-16 potentiostat from a
few feet to 20-30 feet. Currently, a separate connector is used between the
headstage and microelectrode array, but the new longer cable would likely have
the headstage and microelectrode connector integrated at one end. Because we
will be visualizing the brain area targeted for recordings, we will secure the
connected microelectrode array onto the patient’s head frame and manually
advance it using existing, approved electrode implantation equipment. Finally, we
would not implant a Ag/AgCl reference electrode either in the brain or under a
skin flap. Instead, we would use existing skin Ag/AgCl epoxy reference
electrodes (e.g. BetterSkinTM Electrodes, World Precision Instruments, Inc.,
Sarasota, FL) that require double-sided adhesive disks and conductive recording
gel to maintain good electrical contact with clean, shaven skin. Although this
electrode would not be in ionic contact with the brain per se, the electrical
environment of the gel on the skin simulates that of the brain extracellular fluid.
We have tested this type of reference electrode on the shaven backs of Fischer
344 rats with good experimental results (Figure A.4). The background current
and amplitudes of similar volumes of 5 mM Glu in the same brain area increased
slightly, but many of the characteristics of Glu signaling were maintained.
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Figure A.4 Comparison of Ag/AgCl Reference Electrodes
Initial testing was carried out in the rat frontal cortex to assess the feasibility of
using skin-adhered Ag/AgCl reference electrodes (Ref) during electrochemical
recordings of Glu. 5 mM Glu ejections (black arrows, ~62.5 nl each) were
recorded at an applied voltage of +0.7 V versus a typical bare wire, brainimplanted Ag/AgCl reference electrode (first three Glu responses). Then, the
hardware’s reference electrode connection was switched to the Betterskin™
Ag/AgCl epoxy reference electrode adhered to the animal’s back, and the 5 mM
Glu ejections were repeated (black arrows, ~62.5 nl, ~62.5 nl, 50 nl, last three
Glu responses).
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We also need to develop methods to efficiently conduct microelectrode
calibrations within the sterile field. The intraoperative calibration might progress
as follows. A side table with a non-sterile stir plate is set up and sterilely draped.
A sterile cup is placed on the drape over the stir plate and filled with sterile PBS
along with a small sterile stir bar. A sterilized microelectrode array is removed
from its packaging and connected it to the headstage/connector cable. The
recording sites are placed in the PBS using a standard clamp system. A sterile
glass-bodied Ag/AgCl reference electrode is then removed from its packaging,
placed in the PBS, and connected. The opposite end of the headstage/connector
cable is handed off and connected to the FAST-16 potentiostat. Note that at this
point the cable will have a non-sterile portion and a sterile portion that will be
clearly defined to the surgical staff, which is a routine scenario in the human OR.
One-step calibrations of the interferent AA, the analyte Glu, and other test
molecules are conducted using sterile pipetting techniques. These procedures
require at least two people, a sterilely gowned and gloved person from the
surgical team and the FAST-16 user who works outside of the sterile field.
To properly complete this protocol, the headstage/connector cable,
prepared microelectrode arrays, and some of the calibration equipment need to
be sterile. Fortunately, many of the materials are commercially available
sterilized including the cup, PBS, pipette tips, and calibration chemical storage
vials. The headstage/connector cable, magnetic stir bar, and glass-bodied
Ag/AgCl reference electrode would be sterilized using standard gas or heating
procedures. The calibration chemicals could be prepared and sterilely filtered into
the storage vials in advance. The last and possibly most important challenge that
we must overcome is the sterilization of the microelectrode arrays themselves
without compromising electrode performance. We hypothesized that although the
enzyme GluOx might withstand heat sterilization (see Chapter Two’s The
Durability of L-Glutamate Oxidase subsection), the NafionTM and/or BSA might be
damaged by the high temperatures. Initial testing of gas sterilization conducted in
collaboration with Dr. van Horne’s team demonstrated that in vitro microelectrode
performance suffered and the protein matrix layers were visably disrupted
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following treatment. Recently, we have partnered with AdTech Medical
Instruments Corporation (Racine, WI) specifically to study the physical tolerances
of the microelectrode materials. With their data, we hope to devise a sterilization
strategy that maintains the integrity of the layers that make our microelectrodes
selective for Glu.
Final concerns relate to simplifying the experiment so that it is streamlined
and straightforward. An advantage of our use of microelectrodes as research
tools has been our ability to acquire kinetics data using local applications of
intracranial solutions. However, these Glu recordings require time, additional
preparation and equipment, and extensively trained personnel, which can be
disadvantages in the human OR setting. Instead, we would concentrate on
conducting passive recordings of basal Glu levels in different parts of the
targeted brain tissue. Furthermore, we currently have sophisticated software
written

for

scientists

familiar

with

designing

and

performing

in

vivo

electrochemical recordings. We would like to simplify this software package and
make it more user-friendly, easy-to-learn, and accessible.
In addition to the acquired Glu data, we are just as interested in the safety
measures for our patient population. Surgeons commonly worry about increased
OR time contributing to surgical complications, so in response, we are already
planning to simplify and shorten our Glu recordings. There is also a valid concern
about the increased risk of infection and bleeding that might result from
intraoperative recordings. By initially focusing on brain tissue that will be excised,
these concerns are minimized, but still exist. We never observed a brain infection
or any other poor outcome in the nonhuan primates we recorded using nonsterile implanted microelectrode arrays (Chapter Five) which supports the low
risks of post-operative complications related to microelectrode use. Nonetheless,
we must be extraordinarily cautious especially with respect to sterility before we
implant our microelectrodes in a living human brain. We must also follow all of
our patients and document any post-operative incidents to evaluate the safety of
conducting intraoperative Glu recordings in the human brain. When we are
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convinced of the safety to the patient, we can shift our target from abnormal to
normal human brain tissue and repeat both the Glu and safety measures.

Future Clinical Applications

During the course of these initial investigations of the normal and diseasealtered human cortex, significant differences in Glu regulation might be revealed
that expose opportunities to use our microelectrode array technology
therapeutically. The choice of both epileptic and brain tumor patients as our first
subjects for Glu recordings was not simply based on neurosurgical access to
brain tissue but also because there is evidence supporting that Glu regulation is
altered by these diseases. Chapter One describes in detail the support for Glu
alterations in epilepsy. Perhaps most importantly, extracellular Glu levels have
been shown to be increased immediately before and during a seizure, and basal
Glu levels are increased in the epileptogenic foci of some patients in the time
period between seizures (During and Spencer, 1993, Ronne-Engstrom et al.,
1992, Wilson et al., 1996, Thomas et al., 2003, Cavus et al., 2005). Furthermore,
some brain tumors, specifically gliomas, have been shown to have altered,
typically higher, basal Glu levels in the tumor and the adjacent brain tissue
compared to normal cortex (Behrens et al., 2000, Roslin et al., 2003, Bianchi et
al., 2004). In fact, Glu may connect these brain disorders because a seizure may
be the first symptom of a low-grade glioma (Recht and Bernstein, 1995).
By focusing on the basal Glu levels in abnormal and normal intact human
brain tissue, we are gathering information that might allow us to use Glu
recording microelectrode arrays to determine the normalcy of brain tissue
intraoperatively. In other words, we may be able to use our technology alone or
in conjunction with other techniques to better define the borders of abnormal
areas of the human brain. In epilepsy treatment, this might help the
neurosurgeon determine the proper amount of brain to remove to reduce or
eliminate seizure activity while preserving as much normal brain tissue and
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function as possible. On the other hand, surgeons who treat patients with
gliomas are most interested in removing as many of the cancerous cells as they
can even at the sacrifice of normal tissue. Gliomas often have necrotic foci but
are not well-circumscribed tumors, so any technology that can help locate more
abnormal brain cells might benefit the care of these patients.
Another long-term goal of our laboratory is the development of brain
interface devices that would be chronically implanted to monitor and interact with
the intracranial environment. Once again, epileptics may be among the first
patients to experience this novel approach. Because extracellular Glu levels rise
immediately before seizure onset, it may be possible to use a chronically
implanted Glu recording microelectrode array to determine this critical period and
relay the information in real time. Upon notification, the patient or medical staff
could administer interventional treatment. A similar but more sophisticated
approach would require the development and use of small implantable
computers and drug delivery systems. In this case, the Glu recording would be
monitored by a simple computer that would control the release of medications in
response to fluctuations in Glu levels. These drugs could be delivered
intravenously or perhaps intraparenchymally, directly into the brain at the site of
abnormal activity. Obviously, these future clinical applications require appropriate
laboratory testing and clinical trials prior to federal approval; however, we have
made many of the first steps and are excited by the future potential benefits to
patient care that we envision.
Copyright © Brian Keith Day 2005

151

References

1. Albin,R.L., Young,A.B., and Penney,J.B. (1989). The functional anatomy
of basal ganglia disorders. Trends Neurosci. 12, 366-375.
2. Anderson,C.M. and Swanson,R.A. (2000). Astrocyte glutamate transport:
review of properties, regulation, and physiological functions. Glia 32, 1-14.
3. Baker,D.A., Xi,Z.X., Shen,H., Swanson,C.J., and Kalivas,P.W. (2002). The
origin and neuronal function of in vivo nonsynaptic glutamate. J.Neurosci.
22, 9134-9141.
4. Balaban,R.S., Nemoto,S., and Finkel,T. (2005). Mitochondria, oxidants,
and aging. Cell 120, 483-495.
5. Bamford,N.S., Robinson,S., Palmiter,R.D., Joyce,J.A., Moore,C., and
Meshul,C.K. (2004). Dopamine modulates release from corticostriatal
terminals. J.Neurosci. 24, 9541-9552.
6. Barbeito,L., Girault,J.A., Godeheu,G., Pittaluga,A., Glowinski,J., and
Cheramy,A. (1989). Activation of the bilateral corticostriatal glutamatergic
projection by infusion of GABA into thalamic motor nuclei in the cat: an in
vivo release study. Neuroscience 28, 365-374.
7. Behrens,P.F., Langemann,H., Strohschein,R., Draeger,J., and Hennig,J.
(2000). Extracellular glutamate and other metabolites in and around RG2
rat glioma: an intracerebral microdialysis study. J.Neurooncol. 47, 11-22.
8. Benazzouz,A. and Hallett,M. (2000). Mechanism of action of deep brain
stimulation. Neurology 55, S13-S16.
9. Bergman,H., Wichmann,T., and DeLong,M.R. (1990). Reversal of
experimental parkinsonism by lesions of the subthalamic nucleus. Science
249, 1436-1438.
152

10. Berners,M.O., Boutelle,M.G., and Fillenz,M. (1994). On-line measurement
of brain glutamate with an enzyme/polymer-coated tubular electrode.
Anal.Chem. 66, 2017-2021.
11. Bianchi,L., De Micheli,E., Bricolo,A., Ballini,C., Fattori,M., Venturi,C.,
Pedata,F., Tipton,K.F., and Della,C.L. (2004). Extracellular levels of amino
acids and choline in human high grade gliomas: an intraoperative
microdialysis study. Neurochem.Res. 29, 325-334.
12. Bortolotto,Z.A., Lauri,S., Isaac,J.T., and Collingridge,G.L. (2003). Kainate
receptors and the induction of mossy fibre long-term potentiation.
Philos.Trans.R.Soc.Lond B Biol.Sci. 358, 657-666.
13. Brewer,G.J. (2000). Neuronal plasticity and stressor toxicity during aging.
Exp.Gerontol. 35, 1165-1183.
14. Burkhart,K.K., Beard,D.C., Lehman,R.A., and Billingsley,M.L. (1998).
Alterations in tau phosphorylation in rat and human neocortical brain slices
following hypoxia and glucose deprivation. Exp.Neurol. 154, 464-472.
15. Burmeister,J.J., Moxon,K., and Gerhardt,G.A. (2000). Ceramic-based
multisite microelectrodes for electrochemical recordings. Analytical
Chemistry 72, 187-192.
16. Burmeister,J.J. and Gerhardt,G.A. (2001). Self referencing ceramic based
multisite microelectrodes for the detection and elimination of interferences
from the measurement of L-glutamate and other analytes. Analytical
Chemistry 73, 1037-1042.
17. Burmeister,J.J., Pomerleau,F., Palmer,M., Day,B.K., Huettl,P., and
Gerhardt,G.A. (2002). Improved ceramic-based multisite microelectrode
for rapid measurements of L-glutamate in the CNS. Journal of
Neuroscience Methods 119, 163-171.

153

18. Burmeister,J.J. and Gerhardt,G.A. (2003). Ceramic-based multisite
microelectrode arrays for in vivo electrochemical recordings of glutamate
and other neurochemicals. Trac-Trends in Analytical Chemistry 22, 498502.
19. Burmeister,J.J., Palmer,M., and Gerhardt,G.A. (2005). L-lactate measures
in

brain

tissue

with

ceramic-based

multisite

microelectrodes.

Biosens.Bioelectron. 20, 1772-1779.
20. Calabresi,P., Mercuri,N.B., Sancesario,G., and Bernardi,G. (1993).
Electrophysiology of dopamine-denervated striatal neurons. Implications
for Parkinson's disease. Brain 116 ( Pt 2), 433-452.
21. Calabresi,P., Pisani,A., Mercuri,N.B., and Bernardi,G. (1996). The
corticostriatal projection: from synaptic plasticity to dysfunctions of the
basal ganglia. Trends Neurosci. 19, 19-24.
22. Calabresi,P.,

Centonze,D.,

Gubellini,P.,

Marfia,G.A.,

Pisani,A.,

Sancesario,G., and Bernardi,G. (2000). Synaptic transmission in the
striatum: from plasticity to neurodegeneration. Prog.Neurobiol. 61, 231265.
23. Cartmell,J. and Schoepp,D.D. (2000). Regulation of neurotransmitter
release by metabotropic glutamate receptors. J.Neurochem. 75, 889-907.
24. Cass,W.A., Gerhardt,G.A., Zhang,Z., Ovadia,A., and Gash,D.M. (1995).
Increased dopamine clearance in the non-lesioned striatum of rhesus
monkeys

with

unilateral

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

(MPTP) striatal lesions. Neurosci.Lett. 185, 52-55.
25. Cavus,I.,

Kasoff,W.S.,

Cassaday,M.P.,

Jacob,R.,

Gueorguieva,R.,

Sherwin,R.S., Krystal,J.H., Spencer,D.D., and Abi-Saab,W.M. (2005).
Extracellular metabolites in the cortex and hippocampus of epileptic
patients. Ann.Neurol. 57, 226-235.

154

26. Centonze,D.,

Gubellini,P.,

Bernardi,G.,

and

Calabresi,P.

(1999).

Permissive role of interneurons in corticostriatal synaptic plasticity. Brain
Res.Brain Res.Rev. 31, 1-5.
27. Clapp-Lilly,K.L., Roberts,R.C., Duffy,L.K., Irons,K.P., Hu,Y., and Drew,K.L.
(1999). An ultrastructural analysis of tissue surrounding a microdialysis
probe. J.Neurosci.Methods 90, 129-142.
28. Cooper,J.R., Bloom,F.E., and Roth,R.H. (1996). The Biochemical Basis of
Neuropharmacology, 7th ed. Oxford University Press, New York.
29. Cui,G., Kim,S.J., Choi,S.H., Nam,H., Cha,G.S., and Paeng,K.J. (2000). A
disposable amperometric sensor screen printed on a nitrocellulose strip: a
glucose biosensor employing lead oxide as an interference-removing
agent. Anal.Chem. 72, 1925-1929.
30. Danbolt,N.C. (2001). Glutamate uptake. Prog.Neurobiol. 65, 1-105.
31. Deumens,R., Blokland,A., and Prickaerts,J. (2002). Modeling Parkinson's
disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal
pathway. Exp.Neurol. 175, 303-317.
32. Dingeldine,R.

and

McBain,C.J.

(1994).

Excitatory

Amino

Acid

Transmitters, in Basic Neurochemistry: Molecular, Cellular, and Medical
Aspects,

5th

ed.

(Siegel,G.J.,

Agranoff,B.W.,

Albers,R.W.,,

and

Molinoff,P.B., eds), 367-387. Raven Press, Ltd., New York.
33. Drew,K.L., Pehek,E.A., Rasley,B.T., Ma,Y.L., and Green,T.K. (2004).
Sampling glutamate and GABA with microdialysis: suggestions on how to
get the dialysis membrane closer to the synapse. J.Neurosci.Methods
140, 127-131.
34. During,M.J.

and

Spencer,D.D.

(1993).

Extracellular

hippocampal

glutamate and spontaneous seizure in the conscious human brain. Lancet
341, 1607-1610.
155

35. Engel,J., Jr. (1998). Research on the human brain in an epilepsy surgery
setting. Epilepsy Res. 32, 1-11.
36. Eskandar,E.N., Shinobu,L.A., Penney,J.B., Jr., Cosgrove,G.R., and
Counihan,T.J. (2000). Stereotactic pallidotomy performed without using
microelectrode guidance in patients with Parkinson's disease: surgical
technique and 2-year results. J.Neurosurg. 92, 375-383.
37. Feldman,R.S., Meyer,J.S., and Quenzer,L.F. (1997). The Amino Acid
Neurotransmitters

and

Neuropsychopharmacology,

Histamine,
391-454.

in

Principles

of

Sinauer

Associates,

Inc.,

Sunderland, MA.
38. Fillenz,M. (1995). Physiological release of excitatory amino acids.
Behav.Brain Res. 71, 51-67.
39. Foster,T.C. and Kumar,A. (2002). Calcium dysregulation in the aging
brain. Neuroscientist. 8, 297-301.
40. Fried,I., Wilson,C.L., Maidment,N.T., Engel,J., Jr., Behnke,E., Fields,T.A.,
MacDonald,K.A.,

Morrow,J.W.,

and

Ackerson,L.

(1999).

Cerebral

microdialysis combined with single-neuron and electroencephalographic
recording in neurosurgical patients. Technical note. J.Neurosurg. 91, 697705.
41. Friedemann,M.N. and Gerhardt,G.A. (1992). Regional effects of aging on
dopaminergic function in the Fischer-344 rat. Neurobiol.Aging 13, 325332.
42. Friedemann,M.N. and Gerhardt,G.A. (1996). In vivo electrochemical
studies of the dynamic effects of locally applied excitatory amino acids in
the striatum of the anesthetized rat. Exp.Neurol. 138, 53-63.

156

43. Gerhardt,G.A., Oke,A.F., Nagy,G., Moghaddam,B., and Adams,R.N.
(1984).

Nafion-coated

electrodes

with

high

selectivity

for

CNS

electrochemistry. Brain Res. 290, 390-395.
44. Gerhardt,G.A.,

Rose,G.M.,

and

Hoffer,B.J.

(1986).

Release

of

monoamines from striatum of rat and mouse evoked by local application of
potassium: evaluation of a new in vivo electrochemical technique.
J.Neurochem. 46, 842-850.
45. Gerhardt,G.A., Cass,W.A., Henson,M., Zhang,Z., Ovadia,A., Hoffer,B.J.,
and Gash,D.M. (1995). Age-related changes in potassium-evoked
overflow

of

dopamine

in

the

striatum

of

the

rhesus

monkey.

Neurobiol.Aging 16, 939-946.
46. Gerhardt,G.A. and Burmeister,J.J. (2000). In Vivo Voltammetry for
Chemical Analysis of the Nervous System, in Encyclopedia of Analytical
Chemistry: Instrumentation and Applications, (Meyers,R.A., ed), 710-731.
John Wiley & Sons, Ltd., Chichester.
47. Glowinski,J., Besson,M.J., and Cheramy,A. (1984). Role of the Thalamus
in the Bilateral Regulation of Dopaminergic and Gabaergic Neurons in the
Basal Ganglia. Ciba Foundation Symposia 107, 150-163.
48. Gorji,A., Hohling,J.M., Madeja,M., Straub,H., Kohling,R., Tuxhorn,I.,
Ebner,A., Wolf,P., Panneck,H.W., Behne,F., Lahl,R., and Speckmann,E.J.
(2002). Effect of levetiracetam on epileptiform discharges in human
neocortical slices. Epilepsia 43, 1480-1487.
49. Granholm,A.C., Mott,J.L., Bowenkamp,K., Eken,S., Henry,S., Hoffer,B.J.,
Lapchak,P.A., Palmer,M.R., van Horne,C., and Gerhardt,G.A. (1997). Glial
cell

line-derived

neurotrophic

factor

improves

survival

of

ventral

mesencephalic grafts to the 6-hydroxydopamine lesioned striatum.
Exp.Brain Res. 116, 29-38.

157

50. Greenamyre,J.T. (2001). Glutamatergic influences on the basal ganglia.
Clin.Neuropharmacol. 24, 65-70.
51. Guilbault,G.G. and Hrabankova,E. (1970). An electrode for determination
of amino acids. Anal.Chem. 42, 1779-1783.
52. Guridi,J., Rodriguez-Oroz,M.C., Lozano,A.M., Moro,E., Albanese,A.,
Nuttin,B., Gybels,J., Ramos,E., and Obeso,J.A. (2000). Targeting the
basal ganglia for deep brain stimulation in Parkinson's disease. Neurology
55, S21-S28.
53. Harman,D. (1956). Aging: a theory based on free radical and radiation
chemistry. J.Gerontol. 11, 298-300.
54. Herrera-Marschitz,M.,

You,Z.B.,

Goiny,M.,

Meana,J.J.,

Silveira,R.,

Godukhin,O.V., Chen,Y., Espinoza,S., Pettersson,E., Loidl,C.F., Lubec,G.,
Andersson,K., Nylander,I., Terenius,L., and Ungerstedt,U. (1996). On the
origin of extracellular glutamate levels monitored in the basal ganglia of
the rat by in vivo microdialysis. J.Neurochem. 66, 1726-1735.
55. Hu,Y., Mitchell,K.M., Albahadily,F.N., Michaelis,E.K., and Wilson,G.S.
(1994). Direct measurement of glutamate release in the brain using a dual
enzyme-based electrochemical sensor. Brain Res. 659, 117-125.
56. Hudson,J.L.,

van

Horne,C.G.,

Stromberg,I.,

Brock,S.,

Clayton,J.,

Masserano,J., Hoffer,B.J., and Gerhardt,G.A. (1993). Correlation of
apomorphine-

and

amphetamine-induced

turning

with

nigrostriatal

dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain
Res. 626, 167-174.
57. Hudspith,M.J. (1997). Glutamate: a role in normal brain function,
anaesthesia, analgesia and CNS injury. Br.J.Anaesth. 78, 731-747.
58. Kajihara,T. and Hagihara,B. (1966). [Serum glucose measurement by
oxygen electrode and glucose oxidase]. Rinsho Byori 14, 322-327.
158

59. Kennedy,R.T., Watson,C.J., Haskins,W.E., Powell,D.H., and Strecker,R.E.
(2002). In vivo neurochemical monitoring by microdialysis and capillary
separations. Curr.Opin.Chem.Biol. 6, 659-665.
60. Khan,S.H. and Shuaib,A. (2001). The technique of intracerebral
microdialysis. Methods 23, 3-9.
61. Kim,R. and Spencer,D. (1994). Surgery for Mesial Temporal Sclerosis, in
The Surgical Management of Epilepsy (Wyler,A.R. and Hermann,B.P.,
eds), 1436-1444. Butterworth-Heinemann, Boston.
62. Kish,L.J., Palmer,M.R., and Gerhardt,G.A. (1999). Multiple single-unit
recordings in the striatum of freely moving animals: effects of
apomorphine

and

D-amphetamine

in

normal

and

unilateral

6-

hydroxydopamine-lesioned rats. Brain Res. 833, 58-70.
63. Korenbrot,J.I., Perry,R., and Copenhagen,D.R. (1987). Development and
characterization of a polymer gel with an immobilized enzyme to measure
L-glutamate. Anal.Biochem. 161, 187-199.
64. Krack,P., Poepping,M., Weinert,D., Schrader,B., and Deuschl,G. (2000).
Thalamic, pallidal, or subthalamic surgery for Parkinson's disease?
J.Neurol. 247 Suppl 2, II122-II134.
65. Krauss,J.K. and Jankovic,J. (1996). Surgical treatment of Parkinson's
disease. Am.Fam.Physician 54, 1621-1629.
66. Kulagina,N.V., Shankar,L., and Michael,A.C. (1999). Monitoring glutamate
and

ascorbate

in

the

extracellular

space

of

brain

tissue

with

electrochemical microsensors. Anal.Chem. 71, 5093-5100.
67. Kusakabe,H., Midorikawa,Y., Fujishima,T., Kuninaka,A., and Yoshino,H.
(1983). Purification and Properties of A New Enzyme, L-Glutamate
Oxidase, from Streptomyces Sp X-119-6 Grown on Wheat Bran.
Agricultural and Biological Chemistry 47, 1323-1328.
159

68. Lada,M.W., Vickroy,T.W., and Kennedy,R.T. (1997). High temporal
resolution monitoring of glutamate and aspartate in vivo using
microdialysis on-line with capillary electrophoresis with laser-induced
fluorescence detection. Anal.Chem. 69, 4560-4565.
69. Lada,M.W., Vickroy,T.W., and Kennedy,R.T. (1998). Evidence for
neuronal origin and metabotropic receptor-mediated regulation of
extracellular glutamate and aspartate in rat striatum in vivo following
electrical stimulation of the prefrontal cortex. J.Neurochem. 70, 617-625.
70. Lancia,A.J.,

Williams,E.A.,

McKnight,L.V.,

and

Zahm,D.S.

(2004).

Vulnerabilities of ventral mesencephalic neurons projecting to the nucleus
accumbens following infusions of 6-hydroxydopamine into the medial
forebrain bundle in the rat. Brain Res. 997, 119-127.
71. Lang,A.E. and Lozano,A.M. (1998). Parkinson's disease. First of two
parts. N.Engl.J.Med. 339, 1044-1053.
72. Lei,W., Jiao,Y., Del Mar,N., and Reiner,A. (2004). Evidence for differential
cortical input to direct pathway versus indirect pathway striatal projection
neurons in rats. J.Neurosci. 24, 8289-8299.
73. Lindefors,N. and Ungerstedt,U. (1990). Bilateral regulation of glutamate
tissue and extracellular levels in caudate-putamen by midbrain dopamine
neurons. Neurosci.Lett. 115, 248-252.
74. Linnane,A.W.,

Marzuki,S.,

Ozawa,T.,

and

Tanaka,M.

(1989).

Mitochondrial DNA mutations as an important contributor to ageing and
degenerative diseases. Lancet 1, 642-645.
75. Liu,Z., Stafstrom,C.E., Sarkisian,M., Tandon,P., Yang,Y., Hori,A., and
Holmes,G.L. (1996). Age-dependent effects of glutamate toxicity in the
hippocampus. Brain Res.Dev.Brain Res. 97, 178-184.

160

76. Marino,M.J., Awad,H., Poisik,O., Wittmann,M., and Conn,P.J. (2002).
Localization and physiological roles of metabotropic glutamate receptors
in the direct and indirect pathways of the basal ganglia. Amino Acids 23,
185-191.
77. McCarthy,G., Spencer,D.D., and Riker,R.J. (1991). The Stereotaxic
Placement of Depth Electrodes in Epilepsy, in Epilepsy Surgery
(Luders,H., ed), 385-393. Raven Press, Ltd., New York.
78. Meldrum,B.S.,

Akbar,M.T.,

and

Chapman,A.G.

(1999).

Glutamate

receptors and transporters in genetic and acquired models of epilepsy.
Epilepsy Res. 36, 189-204.
79. Meldrum,B.S. (2000). Glutamate as a neurotransmitter in the brain:
Review of physiology and pathology. Journal of Nutrition 130, 1007S1015S.
80. Meshul,C.K., Emre,N., Nakamura,C.M., Allen,C., Donohue,M.K., and
Buckman,J.F. (1999). Time-dependent changes in striatal glutamate
synapses following a 6-hydroxydopamine lesion. Neuroscience 88 , 1-16.
81. Michaelis,E.K. (1998). Molecular biology of glutamate receptors in the
central nervous system and their role in excitotoxicity, oxidative stress and
aging. Progress in Neurobiology 54, 369-415.
82. Mitchell,I.J., Cooper,A.J., and Griffiths,M.R. (1999). The selective
vulnerability of striatopallidal neurons. Prog.Neurobiol. 59, 691-719.
83. Molina,H.,

Quinones-Molina,R.,

Munoz,J.,

Alvarez,L.,

Alaminos,A.,

Ortega,I., Ohye,C., Macias,R., Piedra,J., Gonzalez,C., and . (1994).
Neurotransplantation in Parkinson's disease: from open microsurgery to
bilateral stereotactic approach: first clinical trial using microelectrode
recording technique. Stereotact.Funct.Neurosurg. 62, 204-208.

161

84. Nakanishi,S. (1992). Molecular diversity of glutamate receptors and
implications for brain function. Science 258, 597-603.
85. Nickell,J., Pomerleau,F., Allen,J., and Gerhardt,G.A. (2005). Age-related
changes in the dynamics of potassium-evoked L-glutamate release in the
striatum of Fischer 344 rats. J.Neural Transm. 112, 87-96.
86. Nieoullon,A., Cheramy,A., and Glowinski,J. (1977). Interdependence of
the nigrostriatal dopaminergic systems on the two sides of the brain in the
cat. Science 198, 416-418.
87. Obrenovitch,T.P. and Zilkha,E. (2001). Microdialysis coupled to online
enzymatic assays. Methods 23, 63-71.
88. Olanow,C.W., Brin,M.F., and Obeso,J.A. (2000). The role of deep brain
stimulation as a surgical treatment for Parkinson's disease. Neurology 55,
S60-S66.
89. Olivier,A. and Boling,Jr.,W. (1994). Stereotactic Intracranial Recording
(Stereoelectroencephalography), in The Surgical Management of Epilepsy
(Wyler,A.R. and Hermann,B.P., eds), 1511-1528. Butterworth-Heinemann,
Boston.
90. Ozawa,T. (1997). Genetic and functional changes in mitochondria
associated with aging. Physiol Rev. 77, 425-464.
91. Paxinos,G. and Watson,C. (1986). The Rat Brain in Stereotaxic
Coordinates. Academic Press, San Diego.
92. Parikh,V.,

Pomerleau,F.,

Huettl,P.,

Gerhardt,G.A.,

Sarter,M.,

and

Bruno,J.P. (2004). Rapid assessment of in vivo cholinergic transmission
by amperometric detection of changes in extracellular choline levels.
Eur.J.Neurosci. 20, 1545-1554.

162

93. Perese,D.A., Ulman,J., Viola,J., Ewing,S.E., and Bankiewicz,K.S. (1989).
A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain
Res. 494, 285-293.
94. Pollak,P., Krack,P., Fraix,V., Mendes,A., Moro,E., Chabardes,S., and
Benabid,A.L. (2002). Intraoperative micro- and macrostimulation of the
subthalamic nucleus in Parkinson's disease. Mov Disord. 17 Suppl 3,
S155-S161.
95. Pomerleau,F., Day,B.K., Huettl,P., Burmeister,J.J., and Gerhardt,G.A.
(2003). Real time in vivo measures of L-glutamate in the rat central
nervous system using ceramic-based multisite microelectrode arrays.
Ann.N.Y.Acad.Sci. 1003, 454-457.
96. Qu,Y., Arckens,L., Vandenbussche,E., Geeraerts,S., and Vandesande,F.
(1998).

Simultaneous

determination

of

total

and

extracellular

concentrations of the amino acid neurotransmitters in cat visual cortex by
microbore

liquid

chromatography

and

electrochemical

detection.

J.Chromatogr.A 798, 19-26.
97. Qureshi,A.I.,

Ali,Z.,

Suri,M.F.,

Shuaib,A.,

Baker,G.,

Todd,K.,

Guterman,L.R., and Hopkins,L.N. (2003). Extracellular glutamate and
other amino acids in experimental intracerebral hemorrhage: an in vivo
microdialysis study. Crit Care Med. 31, 1482-1489.
98. Reader,T.A. and Dewar,K.M. (1999). Effects of denervation and
hyperinnervation on dopamine and serotonin systems in the rat
neostriatum: implications for human Parkinson's disease. Neurochem.Int.
34, 1-21.
99. Recht,L.D. and Bernstein,M. (1995). Low-grade gliomas. Neurol.Clin. 13,
847-859.

163

100. Reiner,A., Jiao,Y., Del Mar,N., Laverghetta,A.V., and Lei,W.L. (2003).
Differential morphology of pyramidal tract-type and intratelencephalically
projecting-type corticostriatal neurons and their intrastriatal terminals in
rats. J.Comp Neurol. 457, 420-440.
101. Riedel,G., Platt,B., and Micheau,J. (2003). Glutamate receptor function in
learning and memory. Behavioural Brain Research 140, 1-47.
102. Robinson,D.L., Venton,B.J., Heien,M.L., and Wightman,R.M. (2003).
Detecting subsecond dopamine release with fast-scan cyclic voltammetry
in vivo. Clin.Chem. 49, 1763-1773.
103. Ronne-Engstrom,E., Hillered,L., Flink,R., Spannare,B., Ungerstedt,U., and
Carlson,H. (1992). Intracerebral microdialysis of extracellular amino acids
in the human epileptic focus. J.Cereb.Blood Flow Metab 12, 873-876.
104. Roslin,M.,

Henriksson,R.,

Bergenheim,A.T.

(2003).

Bergstrom,P.,

Baseline

levels

Ungerstedt,U.,
of

glucose

and

metabolites,

glutamate and glycerol in malignant glioma assessed by stereotactic
microdialysis. J.Neurooncol. 61, 151-160.
105. Rossell,S., Gonzalez,L.E., and Hernandez,L. (2003). One-second time
resolution brain microdialysis in fully awake rats. Protocol for the
collection, separation and sorting of nanoliter dialysate volumes.
J.Chromatogr.B Analyt.Technol.Biomed.Life Sci. 784, 385-393.
106. Roth,G.S., Ingram,D.K., and Lane,M.A. (2001). Caloric restriction in
primates and relevance to humans. Ann.N.Y.Acad.Sci. 928, 305-315.
107. Rowley,H.L., Martin,K.F., and Marsden,C.A. (1995). Determination of in
vivo

amino

acid

chromatography

neurotransmitters
with

by

high-performance

o-phthalaldehyde-sulphite

J.Neurosci.Methods 57, 93-99.

164

liquid

derivatisation.

108. Schober,A. (2004). Classic toxin-induced animal models of Parkinson's
disease: 6-OHDA and MPTP. Cell Tissue Res. 318, 215-224.
109. Segovia,G., Porras,A., Del Arco,A., and Mora,F. (2001). Glutamatergic
neurotransmission in aging: a critical perspective. Mech.Ageing Dev. 122,
1-29.
110. Shigeri,Y., Shimamoto,K., Yasuda-Kamatani,Y., Seal,R.P., Yumoto,N.,
Nakajima,T.,

and

Amara,S.G.

(2001).

Effects

of

threo-beta-

hydroxyaspartate derivatives on excitatory amino acid transporters
(EAAT4 and EAAT5). J.Neurochem. 79, 297-302.
111. Shimamoto,K., Lebrun,B., Yasuda-Kamatani,Y., Sakaitani,M., Shigeri,Y.,
Yumoto,N., and Nakajima,T. (1998). DL-threo-beta-benzyloxyaspartate, a
potent blocker of excitatory amino acid transporters. Mol.Pharmacol. 53,
195-201.
112. Shiraishi,M., Kamiyama,Y., Huttemeier,P.C., and Benveniste,H. (1997).
Extracellular glutamate and dopamine measured by microdialysis in the
rat striatum during blockade of synaptic transmission in anesthetized and
awake rats. Brain Res. 759, 221-227.
113. Smolders,I., Sarre,S., Michotte,Y., and Ebinger,G. (1995). The analysis of
excitatory, inhibitory and other amino acids in rat brain microdialysates
using microbore liquid chromatography. J.Neurosci.Methods 57, 47-53.
114. Somjen,G.G. (2001). Mechanisms of spreading depression and hypoxic
spreading depression-like depolarization. Physiol Rev. 81, 1065-1096.
115. Spencer,D.D.,

Robbins,R.J.,

Naftolin,F.,

Marek,K.L.,

Vollmer,T.,

Leranth,C., Roth,R.H., Price,L.H., Gjedde,A., Bunney,B.S., and . (1992).
Unilateral transplantation of human fetal mesencephalic tissue into the
caudate nucleus of patients with Parkinson's disease. N.Engl.J.Med. 327,
1541-1548.

165

116. Sreenivas,G., Ang,S.S., Fritsch,I., Brown,W.D., Gerhardt,G.A., and
Woodward,D.J. (1996). Fabrication and characterization of sputteredcarbon microelectrode arrays. Analytical Chemistry 68, 1858-1864.
117. Starr,M.S. (1995). Glutamate/dopamine D1/D2 balance in the basal
ganglia and its relevance to Parkinson's disease. Synapse 19, 264-293.
118. Starr,P.A., Vitek,J.L., and Bakay,R.A. (1998). Ablative surgery and deep
brain stimulation for Parkinson's disease. Neurosurgery 43, 989-1013.
119. Tamiya,E. and Karube,I. (1992). Ultramicrobiosensors for monitoring of
neurotransmitters. Ann.N.Y.Acad.Sci. 672, 272-277.
120. Thomas,P.M., Phillips,J.P., Delanty,N., and O'Connor,W.T. (2003).
Elevated extracellular levels of glutamate, aspartate and gammaaminobutyric acid within the intraoperative, spontaneously epileptiform
human hippocampus. Epilepsy Res. 54, 73-79.
121. Timmerman,W. and Westerink,B.H. (1997). Brain microdialysis of GABA
and glutamate: what does it signify? Synapse 27, 242-261.
122. Tossman,U., Segovia,J., and Ungerstedt,U. (1986). Extracellular levels of
amino acids in striatum and globus pallidus of 6-hydroxydopaminelesioned rats measured with microdialysis. Acta Physiol Scand. 127, 547551.
123. Tucci,S., Rada,P., Sepulveda,M.J., and Hernandez,L. (1997). Glutamate
measured by 6-s resolution brain microdialysis: capillary electrophoretic
and laser-induced fluorescence detection application. J.Chromatogr.B
Biomed.Sci.Appl. 694, 343-349.
124. Unger,J.W. (1998). Glial reaction in aging and Alzheimer's disease.
Microsc.Res.Tech. 43, 24-28.

166

125. Updike,S.J. and Hicks,G.P. (1967). The enzyme electrode. Nature 214,
986-988.
126. Watkins,J.C. (2000). L-glutamate as a central neurotransmitter: looking
back. Biochem.Soc.Trans. 28, 297-309.
127. Wichmann,T. and DeLong,M.R. (2003). Pathophysiology of Parkinson's
disease:

the

MPTP

primate

model

of

the

human

disorder.

Ann.N.Y.Acad.Sci. 991, 199-213.
128. Wilson,C.L., Maidment,N.T., Shomer,M.H., Behnke,E.J., Ackerson,L.,
Fried,I., and Engel,J., Jr. (1996). Comparison of seizure related amino
acid release in human epileptic hippocampus versus a chronic, kainate rat
model of hippocampal epilepsy. Epilepsy Res. 26, 245-254.
129. Wyler,A.R. and Abson-Kraemer,D. (1994). Diagnostic Techniques in
Surgical Management of Epilepsy: Strip Electrodes, Grids, and Depth
Electrodes, in The Surgical Management of Epilepsy (Wyler,A.R. and
Hermann,B.P., eds), 1429-1435. Butterworth-Heinemann, Boston.
130. Zhang,S., Takeda,Y., Hagioka,S., Takata,K., Aoe,H., Nakatsuka,H.,
Yokoyama,M., and Morita,K. (2005). Measurement of GABA and
glutamate in vivo levels with high sensitivity and frequency. Brain
Res.Brain Res.Protoc. 14, 61-66.

167

VITA

Name:

Brian Keith Day

Birthdate:

07/19/1975

Birthplace:

Lexington, KY

Education
Fall 1999-

MD/PhD Candidate, University of Kentucky

Spring 2007

Lexington, KY 40536

Fall 2001-

Doctoral degree candidate

Summer 2005

Department of Anatomy and Neurobiology
The Graduate School at the University of Kentucky

Fall 1999-

Medical degree candidate

Spring 2007

University of Kentucky College of Medicine

1997

AB in Biology, Cum Laude, Harvard University
Cambridge, MA 02138

1993

Commonwealth Diploma, Boyle County High School
Danville, KY 40422

Professional Positions Held

168

1997-1999

Head Research Associate and Laboratory Coordinator;
Uniformed Services University, Bethesda, MD 20814
Geoffrey S. F. Ling, MD, PhD, Principal Investigator

1996-1997

Student researcher, Farlow Herbarium, Harvard University
Donald Pfister, PhD, Supervisor

1996

Summer research associate, Department of Entomology,
University of Kentucky
David Wise, PhD, Supervisor

Scholastic and Professional Honors
January 2005-

Graduate Student Representative, Program in Translational

June 2005

Neurosciences, Department of Anatomy and Neurobiology,
University of Kentucky
Don M. Gash, Ph.D., Chairman

July 2004-

Morris K. Udall Fellowship, University of Kentucky,

June 2005

Morris K. Udall Parkinson’s Disease Research Center of
Excellence
Greg A. Gerhardt, PhD, Director

October 2004

Invited speaker, Frontiers in Neuroscience Symposium,
University of Kentucky
“L-Glutamate Dynamics in the Young and Aged Brain”

March 2004

Graduate student poster award, Bluegrass Chapter, Society
for Neurosciences

169

July 2003-

Research Challenge Trust Fund Fellowship, University of

June 2004

Kentucky

March 2002

Graduate student poster award, Bluegrass Chapter, Society
for Neurosciences

August 2001-

Morris K. Udall Fellowship, University of Kentucky,

June 2003

Morris K. Udall Parkinson’s Disease Research Center of
Excellence

1999-2007

MD/PhD scholarship, University of Kentucky MD/PhD
Program, E. Charles Snow, PhD, Director

1993-1997

Parker Browne Francis Scholarship
Roy Goodman Scholarship
Harvard College Scholarship
Robert C. Byrd Scholarship
Brotherhood Relief and Compensation Fund Scholarship
WalMart Scholarship

Publications
Abstracts:

Day BK, Stephens ML, Quintero JE, Huettl P, Grondin R, Zhang Z, Luan L, Gash
DM, and Gerhardt GA. Second-by-second L-glutamate measurements in
cortical areas of young and aged rhesus monkeys. Annual Meeting, Society
for Neurosciences, Washingotn, DC. November 2005.

170

Day BK, Pomerleau F, Huettl P, and Gerhardt GA. Basal measurements of Lglutamate using microelectrode arrays in the anesthetized rat brain. Annual
Meeting, Society for Neurosciences, San Diego, CA. October 2004.
Day BK, Pomerleau F, Huettl P, and Gerhardt GA. Basal measurements of Lglutamate using microelectrode arrays in the anesthetized rat brain. Frontiers
in Neurosciences Symposium, University of Kentucky, Lexington, KY.
October 2004.
Day BK, Pomerleau FP, Huettl PF, Willis L, Granholm AC, and Gerhardt GA.
Potassium-evoked glutamate release is affected bilaterally in the striatum of
unilateral 6-OHDA-lesioned rats. National M.D./Ph.D. Student Conference,
Keystone, CO. July 2004.
Day BK, Pomerleau FP, Huettl PF, Willis L, Granholm AC, and Gerhardt GA.
Potassium-evoked glutamate release is affected bilaterally in the striatum of
unilateral 6-OHDA-lesioned rats. Spring Neurosciences Day, Bluegrass
Chapter, Society for Neurosciences, Lexington, KY. March 2004.
Day BK, Pomerleau FP, Huettl PF, Willis L, Granholm AC, and Gerhardt GA.
Potassium-evoked glutamate release is affected bilaterally in the striatum of
unilateral 6-OHDA-lesioned rats. Annual Meeting, Society for Neurosciences,
New Orleans, LA. November 2003.
Day BK, Pomerleau FP, Huettl PF, Burmeister JJ, and Gerhardt GA.
Pharmacological manipulation of baseline levels of L-glutamate in CNS
measured

using

ceramic-based

multisite

microelectrodes.

Spring

Neurosciences Day, Bluegrass Chapter, Society for Neurosciences. Spring
2003.

171

Day BK, Pomerleau FP, Huettl PF, Burmeister JJ, and Gerhardt GA.
Pharmacological manipulation of baseline levels of L-glutamate in CNS
measured using ceramic-based multisite microelectrodes. Annual Meeting of
the Society for Neurosciences, Orlando, FL. November 2002.

Day BK, Gerhardt GA, Huettl PF, Pomerleau FP, Palmer, MR and Burmeister JJ.
Rapid measures of the dynamics of glutamate release and uptake in the rat
CNS.

Spring

Neurosciences

Day,

Bluegrass

Chapter,

Society

for

Neurosciences, Lexington, KY. Spring 2002.

Manuscripts:
Day BK, Pomerleau F, Burmeister JJ, Huettl P, and Gerhardt GA. Microelectrode
array studies of basal and potassium-evoked release of L-glutamate in the
anesthetized rat brain. (submitted 2005).
Pomerleau F, Day BK, Huettl P, Burmeister JJ, and Gerhardt GA. Real time in
vivo measures of L-glutamate in the rat central nervous system using
ceramic-based multisite microelectrode arrays. Ann. N.Y. Acad. Sci.
1003:454-457, 2003.
Burmeister, JJ, Pomerleau F, Palmer M, Day BK, Huettl P and Gerhardt GA.
Improved ceramic-based multisite microelectrode for rapid measurements of
L-glutamate in the CNS. J Neurosci Meth 119(2):163-171, 2002.

Signed: Brian Keith Day

172

